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 Abstract 
G protein-gated inwardly-rectifying K+ (GIRK/Kir3) channels mediate the 
inhibitory effect of many neurotransmitters on excitable cells of the heart and brain. 
Dysregulation of GIRK signaling is known to underlie a number of disorders, including 
arrhythmia, epilepsy, depression, anxiety, schizophrenia, and drug addiction. GIRK 
channels are gated by inhibitory Gi/o proteins and temporally modulated by Regulators of 
G protein Signaling (RGS) proteins. GIRK channels are tetramers consisting of various 
combinations of four mammalian Girk subunits (GIRK1-4). This dissertation focuses on 
neuronal and cardiac GIRK signaling cascades as targets for new pharmacotherapies in 
the treatment of anxiety-related disorders and cardiac arrhythmias. 
Both robust GIRK channel activity and modulation by a new class of GIRK-
specific drugs depend on the GIRK1 subunit. The presence of GIRK1 in channel 
complexes is necessary for robust channel activity. We first sought to better understand 
the potentiating influence of GIRK1, using the GABAB receptor and GIRK1/GIRK2 
heteromer as a model system. We found residues in both the distal carboxyl-terminal 
domain and channel core that underlie the GIRK1-dependent potentiation of receptor-
dependent and receptor-independent heteromeric channel activity. Further, ML297, the 
prototypical member of a new family of small molecule GIRK channel modulators, 
selectively activates GIRK1-containing channels. We found that ML297 activates GIRK 
channels via a unique mechanism that requires two amino acids specific to the GIRK1 
subunit. In addition, ML297 reduces anxiety-related behavior in mice, in a GIRK1-
dependent manner, without triggering addiction-related behavior. Thus, ML297 is a new 
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tool for probing the therapeutic potential of GIRK channel modulation, which may 
benefit individuals with anxiety-related disorders. 
Cardiac GIRK signaling plays a role in the parasympathetic regulation of heart 
rate (HR). Parasympathetic activity decreases HR by inhibiting pacemaker cells in the 
sino-atrial node (SAN). RGS proteins are negative modulators of the parasympathetic 
regulation of HR and the prototypical M2 muscarinic receptor (M2R)-dependent signaling 
pathway in the SAN that involves the muscarinic-gated atrial K
+
 channel IKACh (a 
GIRK1/GIRK4 tetramer). We first identified RGS6 as a temporal regulator of cardiac 
M2R-IKACh signaling in atrial myocytes and SAN cells. Both RGS4 and RGS6 have been 
implicated in the negative modulation of the parasympathetic regulation of HR and the 
M2R-IKACh signaling pathway. We next looked at the contribution of RGS4 and RGS6 to 
the modulation of M2R-IKACh signaling. Ablation of Rgs6, but not Rgs4, correlated with 
decreased resting HR and a significant delay of M2R-IKACh deactivation rate. Thus, 
RGS6, and not RGS4, is the primary RGS modulator of cardiac M2R-IKACh. Taken 
together, these findings suggest that RGS6 is a potential pharmacotherapeutic target as 
the dysregulation of parasympathetic influence has been linked to sinus node dysfunction 
and arrhythmia. 
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I. CONTROL OF CELLULAR EXCITABILITY  
Nerve cells and muscle cells have a lipid-based plasma membrane that is 
responsive to electrical and chemical stimulation. These excitable cells use electrical 
signals generated by separating electrical charges across the plasma membrane to 
communicate with other cells or trigger muscle cell contraction. Control and maintenance 
of cellular excitability is a fundamental physiological process. Dysregulation of cell 
excitability is a major underlying factor of prevalent and debilitating diseases, including 
cardiac arrhythmias and neurological disorders, such as epilepsy, schizophrenia and 
depression. Cell excitability is regulated by many hormones and neurotransmitters that 
act through cell surface receptors coupled to heterotrimeric GTP-binding proteins (G 
proteins), leading to the modulation of enzymes and ion channels. G proteins are active in 
nearly every organ system and, thus, their surface receptors are considered to be one of 
the most important drug targets by the pharmaceutical industry. Currently, more than 
30% of all available therapies target G protein signaling [1]. These treatments target high 
blood pressure, arrhythmias, pain, anxiety, depression, attention-deficit disorder, epilepsy 
and other seizure-inducing conditions. Unfortunately, medications targeting G protein 
signaling often have adverse side effects, due in part to the widespread activity of these 
signaling cascades. The mechanisms underlying the functional and spatial organization of 
G protein signaling cascades are still poorly understood. However, by understanding the 
many facets of G protein signaling, it may be possible to improve current 
pharmacotherapies by making them more selective and efficacious, while reducing 
unwanted side effects.  
        Rgs regulation of cardiac muscarinic signaling 
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Heterotrimeric GTP-binding proteins  
 Heterotrimeric G proteins consist of an α, β, and γ subunit [2, 3]. There are 21 
human Gα subunits, 5 Gβ subunits, and 12 Gγ subunits [4-6]. There are different Gα 
subtypes, including Gαs, Gαq, Gαi/o, and Gα12, all of which contain a conserved GTPase 
domain and helical domain [7-9]. The GTPase domain is responsible for the hydrolysis of 
GTP and creating the binding surfaces for interactions with surface receptors, the Gβγ 
dimer, and downstream effector proteins [2]. This domain also has three small loops that 
undergo significant conformational changes between the inactive GDP-bound and active 
GTP-bound states [10-12]. The helical domain of the Gα acts to enclose the GDP/GTP 
binding site. Most Gα subunits are anchored to the plasma membrane through the post-
translational addition of a palmitoyl, and for Gαi/o, myristoyl moiety to the N-terminus 
[13, 14]. Gα subtypes differ in the identity of their downstream effectors. Gαs and Gαq 
promote excitatory effects within the cell, whereas Gαi/o promotes inhibitory changes [2]. 
 Gβ and Gγ subunits form a protein dimer and act together as a single functional 
unit. The Gβ subunit has an N-terminal α-helix while the remainder of the subunit forms 
a large seven-bladed β-propeller structure. The Gγ subunit is smaller and has an N-
terminal α-helix that forms a coiled-coil domain with the Gβ N-terminus [15]. 
Additionally, the small C-terminus of the Gγ subunit interacts with Gβ blades 5 and 6 
[15]. Together, these interactions are responsible for the Gβγ dimer formation, which 
only separates under denaturing conditions [3, 15, 16]. The Gβγ dimer, like Gα, is also 
anchored to the membrane via a farnesyl or geranylgeranyl moiety that is added to the Gγ 
C-terminus through a post-translational isoprenylation [17]. The Gβ subunit of the Gβγ 
        Rgs regulation of cardiac muscarinic signaling 
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dimer interacts with the Gα subunit. The Gβ binding site on the Gα subunit is a 
hydrophobic pocket formed by two of the flexible loops and the N-terminus [10, 16]. 
Both Gα and Gβγ go on to act on downstream effectors, making the heterotrimeric G 
protein a ubiquitous signaling protein.  
 
G protein-coupled receptors  
Surface receptors that couple to heterotrimeric G proteins are known as G protein-
coupled receptors, or GPCRs. The GPCR superfamily is made up of vast and diverse 
group of receptors that are encoded by nearly 800 human genes and interact with 
numerous hormones and neurotransmitters [18]. Common to all GPCRs is a seven 
transmembrane-spanning α-helix domain, an extracellular N-terminus, an intracellular C-
terminus, three extracellular inter-helical loops, and three intracellular inter-helical loops 
[2]. The GPCR superfamily can be phylogenically divided into 5 separate families: 
rhodopsin, secretin, glutamate, adhesion, and frizzled-taste-2 [19]. There is evidence that 
GPCR members of the rhodopsin and glutamate families can form homo- and 
heterodimers, yielding further diversity and complexity to this superfamily [20-25]. Yet, 
despite the vastness of this superfamily of receptors, GPCRs signal through a relatively 
small but important group of G protein subtypes.  
 
GPCR activation of G proteins  
Ligand binding often occurs at the extracellular N-terminal domain of GPCRs, 
resulting in a conformational change of the receptor’s membrane-spanning domains, 
which activates heterotrimeric G proteins [20]. There are two leading proposals regarding 
        Rgs regulation of cardiac muscarinic signaling 
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how inactive G proteins encounter GPCRs in their active state. The “collision-coupling” 
theory postulates that many inactive G proteins are free floating in the membrane where 
they collide with and become activated by ligand-bound GPCRs [26]. Alternatively, the 
“pre-coupling” or “preassembly” theory suggests that inactive G proteins are already 
associated with inactive GPCRs and become activated when GPCRs are activated [27]. 
While evidence is mounting for the latter, experiments to date have primarily been 
performed in vitro and thus mechanisms underlying G protein-GPCR encounters remain 
somewhat unclear [28-32].  
However they couple, heterotrimeric G proteins are activated by ligand-bound 
GPCRs. Upon ligand binding, the transmembrane regions and the intracellular loops of 
GPCRs shift causing the Gα subunit to release its bound GDP (reviewed in [2]). After it 
dissociates from GDP, Gα readily binds GTP due to its high intracellular concentration, 
causing a significant conformational change which results in the dissociation of Gα-GTP 
from both the receptor and the Gβγ dimer [2]. Active GTP-bound Gα and the released 
Gβγ are both free to act on many downstream effectors, including cyclases, lipases, and 
ion channels [9, 33, 34]. These signaling cascades are ultimately terminated by the 
hydrolysis of bound GTP back to GDP, prompting Gα to reassociate with the Gβγ dimer 
and a return to the initial heterotrimeric conformation for subsequent activation. 
 
Gi/o G proteins regulate cell excitability  
 Activation of GPCRs coupled to the Gαi/o family of G proteins promotes 
activation of signaling cascades that exert a hyperpolarizing influence that is critical for 
regulation of cell excitability.  The Gi/o protein family is made up of Gαi and Gαo 
        Rgs regulation of cardiac muscarinic signaling 
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isoforms: Gαi1, Gαi2, Gαi3, GαoA, and GαoB [4]. This family of Gi/o proteins is unique in 
their sensitivity to pertussis toxin (PTX), which is produced by the bacterium Bordetella 
pertussis. Specifically, PTX promotes ADP-ribosylation of the Gα subunit, which locks 
the Gα subunit into an inactive GDP-bound state and disrupts interactions with activated 
GPCRs [35-39].  
 Upon Gi/o activation, GTP-bound Gαi/o and free Gβγ act on downstream effectors 
that reduce cell excitability or inhibit excitatory processes. There are three main pathways 
in which this occurs: inhibition of adenylyl cyclase, inhibition of Ca
2+
 channels, and 
activation of K
+
 channels (Fig. 1.1). Active Gαi/o inhibits the activity of adenylyl cyclase 
(AC), which normally catalyzes the conversion of ATP to cAMP (3’-5’-cyclic adenosine 
monophosphate), a cofactor for the prominent Protein Kinase A (PKA) [40-42]. 
Alternatively, Gβγ can directly inhibit Ca2+ influx through certain types of voltage-gated 
Ca
2+
 channels and activate a specialized subset of inwardly-rectifying K
+
 channels that 
normally allow an efflux of K
+
 and hyperpolarize the cellular membrane [43-49]. These 
specialized K
+
 channels are G protein-gated inwardly-rectifying K
+
 ion (GIRK) channels. 
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Figure 1.1. Inhibitory Gi/o G protein signaling pathway. This diagram demonstrates 
the downstream effects of heteromeric Gi/o protein activation via GPCR activation. 1. 
GTP-bound Gαi/o inhibits adenylyl cyclase activity, preventing the conversion of ATP 
into second messenger cAMP. 2. Released Gβγ can inhibit certain types of voltage-gated 
calcium channels, inhibiting calcium influx. 3. Released Gβγ activates G protein-gated 
inwardly-rectifying potassium channels, or GIRK channels, causing an efflux of 
potassium ions and hyperpolarization of the cell membrane. An RGS protein is included, 
as these proteins catalyze the hydrolysis of GTP to GDP, returning the G protein to its 
inactive heterotrimeric state.   
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II. GIRK CHANNELS  
 GIRK channels play a key role in the maintenance of cellular excitability 
throughout the brain and heart, where they regulate synaptic transmission and heart rate, 
respectively [50, 51]. Under physiological conditions, the basal level of GIRK activity 
contributes in the maintenance of neuronal resting membrane potential [52]. Upon 
receptor activation of GIRK channels, the membrane becomes hyperpolarized, reducing 
cell excitability. GIRK channel activation can result in the direct suppression of neuron 
firing or can contribute to the inhibitory tone of a neuronal network [53-56]. 
Dysregulation of GIRK signaling is known to be an underlying factor in a number of 
disorders, including arrhythmia, epilepsy, depression, anxiety, schizophrenia, and drug 
addiction [57]. Thus, GIRK channels have been, and remain, an important topic of study 
for more than two decades. The work that lies herein has given novel insight into the 
function and regulation of these channels that will impact the field. 
 
Electrophysiological properties of GIRK channels  
GIRK channels are members of the inward-rectifier potassium channel family 
(KirX) [58]. This channel family is characterized by their strong inwardly-rectifying 
current-voltage relationships. The inward-rectification of GIRK channels has been linked 
to intracellular Mg
2+
 and polyamines [58, 59]. These positively charged molecules block 
outward current by occluding the pore at depolarized potentials, or potentials above the 
equilibrium potential for potassium (EK). [58-61]. Equilibrium potentials for ions can be 
calculated using the Nernst equation. The Nernst equation adapted for the calculation of 
the equilibrium potential of potassium (EK) is defined below:  
        Rgs regulation of cardiac muscarinic signaling 
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At physiological conditions, where [K
+
]out = 4 mM and [K
+
]in =155 mM, EK is -90 mV.  
However, many electrophysiology experiments, including those described in this work, 
are done in high extracellular K
+
 (e.g. [K
+
]out = 25 mM). This shifts the experimental EK 
to -40 mV. In the current-voltage relationship of GIRK channels, the current changes 
from negative to positive near -90 mV (or near -40 mV when [K
+
]out = 25 mM), making 
this the reversal potential. This relationship is true of all inward-rectifying potassium 
channels, including GIRK channels.  
 
Channel formation and trafficking  
GIRK channels are tetrameric complexes that form one channel pore at the 
plasma membrane with eight transmembrane domains [57, 62-66]. There are four 
mammalian GIRK subunits: GIRK1 (Kir3.1), GIRK2 (Kir3.2), GIRK3 (Kir3.3), and 
GIRK4 (Kir3.4), all of which are highly conserved in sequence and structure [67]. Each 
subunit is composed of a cytosolic N-terminus, two membrane-spanning domains, two 
extracellular loops, one pore domain, and a cytosolic C-terminus. Four GIRK subunits 
come together to form a tetrameric channel. The pore domain contains the selectivity 
filter that permits only the passage of K
+
 ions through the channel opening.   
The identity and location of their trafficking motifs differ across the GIRK 
subunits. GIRK2 and GIRK4 contain endoplasmic reticulum (ER) export motifs as well 
as post-Golgi surface-promoting signals that allow both subunits to form functional 
homotetrameric channels at the plasma membrane [68]. The ER export motifs are located 
        Rgs regulation of cardiac muscarinic signaling 
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on the N-terminus: GIRK2 residues 18-25 (DQDVESPV) and GIRK4 residues 10-17 
(NQDMEIGV) [68]. The post-Golgi surface-promoting signals are highly-acidic regions 
in the distal C-terminus of both subunits: GIRK2 residues 394-401 (ELETEEEE) and 
GIRK4 residues 391-408 (EAEKEAEAEHDEEEEPNG) [68]. Furthermore, the 
phosphorylation of GIRK2 residue T397 can potentially increase the surface expression 
of GIRK2 [68]. These motifs are not conserved in GIRK1 and GIRK3, thus GIRK1 and 
GIRK3 cannot be independently exported from the ER to form functional homomeric 
channels, but instead require interaction with GIRK2 or GIRK4 subunits for transport to 
the membrane [64, 68-70].  
 Interestingly, GIRK3 has been shown to decrease the surface expression of 
heteromeric channels containing GIRK2/GIRK3 or GIRK1/GIRK2/GIRK3 [68]. It has 
also been shown that the presence of GIRK3 can reduce currents produced by GIRK2 
homomeric or GIRK1/GIRK2 heteromeric channels [66, 71]. The negative effect of 
GIRK3 can be attributed to both the absence of any forward trafficking signals and the 
presence of a lysosomal targeting signal in the distal C-terminus: GIRK3 residues 351-
354 (YWSI) [68]. As another form of regulation, GIRK2 contains an endocytosis signal 
(also known as internalization motif) in the N-terminus that controls the surface 
expression of GIRK2 homomeric and GIRK1/GIRK2 heteromeric channels: GIRK2 
residues 11-12 (VL) [68]. 
 
GIRK splice variants  
 Alternative splicing can yield many protein variations from the same gene. 
Structural and functional differences between splice variants could be exploited as a 
        Rgs regulation of cardiac muscarinic signaling 
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therapeutic strategy. The murine Kcnj6 gene that encodes GIRK2 undergoes alternative 
splicing to yield four different GIRK2 isoforms: GIRK2A, GIRK2B, GIRK2C, and 
GIRK2D. GIRK2A-C are expressed in the brain, while GIRK2D is primarily expressed 
in the testes [57, 72-74]. GIRK2A contains all of the forward trafficking domains and 
internalization motif previously described [68, 72]. GIRK2C is identical to GIRK2A, 
with the exception of 11 additional amino acid residues at the end of the C-terminus, 
which contain a PDZ binding domain: GIRK2C residues 421-425 (ESKV) [73, 75]. 
Alternatively, GIRK2B is a lesser expressed truncated variant that lacks the last 96 
residues of the GIRK2A C-terminus (residues 318-414), and the C-terminal forward 
trafficking motif, ELETEEE [68, 74]. GIRK2D was the final isoform identified and is 
identical to GIRK2A minus the presence of the first 18 amino acid residues [76]. This 
lack of the N-terminal internalization motif promotes stronger surface expression and 
reduced intracellular protein levels compared to GIRK2A [68, 76]. 
GIRK1 C-terminal splice variants have also been isolated from brain and heart 
tissue, in addition to certain cancer cell lines, and are referred to as hGIRK1a,b,c,d,e [77-
79]. Unlike wild-type GIRK1, these isoforms are limited in their ability to form 
functional heteromeric channels. No isoforms of GIRK3 or GIRK4 have yet been 
reported [57]. 
 
GIRK subunit distribution  
Central Nervous System 
 GIRK1, GIRK2 and GIRK3 are broadly distributed in the central nervous system 
(CNS) [50]. GIRK4 does not demonstrate expression in the CNS, apart from expression 
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in the hypothalamus [50, 80, 81]. Within the CNS, GIRK1, GIRK2, and GIRK3 exhibit 
overlapping but distinct distribution patterns [50]. While most neuron populations 
express GIRK1, GIRK2, and GIRK3, biochemical and genetic approaches have 
demonstrated that the predominant CNS GIRK channel contains GIRK1 and GIRK2 [63]. 
Ablation of GIRK2 results in a near to complete loss of GIRK current in many brain 
regions including the hippocampus [52, 82], cerebellum [83], substantia nigra [82], locus 
coeruleus [84, 85], and ventral tegmental area (VTA) [86]. GIRK subunits also display 
cell-type specific distribution within brain regions. For example, the VTA of the midbrain 
is known for its two prominent cell types: dopaminergic and GABAergic neurons [87]. 
VTA GABA neurons express GIRK1, GIRK2, and GIRK3 whereas VTA dopamine 
neurons only express GIRK2 and GIRK3 [87]. Furthermore, dopamine neurons in the 
substantia nigra, also part of the midbrain, only express GIRK2A and GIRK2C-
containing channels [88].  
 
Distribution in cardiac tissue and other regions  
GIRK1 and GIRK4 are expressed in cardiac atrial tissue, where together they 
form the IKACh channel [69]. IKACh-dependent currents have been observed in the 
sinoatrial node, the AV node and atrial cardiomyocytes [51, 89]. GIRK channels play a 
role in other regions of the body as well, including the testes and the islet cells of the 
pancreas. All four GIRK subunits are expressed in mouse pancreas islet cells, where they 
are involved in epinephrine-mediated signaling and mediate in part the inhibition of 
insulin secretion [90]. GIRK2, specifically GIRK2D, is expressed in the testes, where it 
plays a role in sperm function during fertilization in both mice and boars [76, 91].   
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Cofactors of GIRK channel activation  
 In addition to the binding of the Gβγ subunit, GIRK channels require the presence 
of phosphatidylinositol-4,5-bisphosphate (PIP2) to open and hyperpolarize the cell 
membrane [92, 93]. PIP2 is a specialized phospholipid located on the inner leaflet of the 
plasma membrane where it is involved in both excitatory and inhibitory signaling 
cascades [94]. PIP2 is mostly thought of as an intermediate in the Gαq activation of 
Protein Kinase C (PKC) and Ca
2+
 influx. In this pathway, phospholipase C (PLC), 
activated by Gαq, breaks down PIP2 into two excitatory second messengers: diacyl 
glycerol (DAG) and inositol 1,4,5-triphospate (IP3). DAG goes on to activate PKC, while 
IP3 is released to the cytosol where it releases Ca
2+
 from the ER into the cytosol. 
Increased cytosolic Ca
2+
 concentration can result in a number of excitatory actions, 
including muscle cell contraction [95]. PIP2, when not broken down into its excitatory 
counterparts, plays an inhibitory role at the plasma membrane, where it interacts with 
several types of potassium channels and is required for their subsequent activation and 
efflux of K
+
 ions. Inwardly-rectifying potassium channels (Kir1-7) require PIP2 for their 
activation [96]. GIRK channels are unique from their other inward-rectifying 
counterparts in that, in addition to PIP2, they also require Gβγ for activation [92].  GIRK 
channels have a reduced binding affinity for PIP2 compared to other inward-rectifying K+ 
channels that are constitutively activated by PIP2 alone, but Gβγ increases the strength of 
the PIP2-GIRK interaction [94, 97]. 
Along with PIP2, it has also been found that intracellular Na
+
 is able to activate 
GIRK channels (EC50 30-40 mM) [73, 97-101]. Na
+ 
is not thought to be necessary for 
GIRK activation, but rather can activate GIRK channels as part of an excitatory feedback 
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mechanism. In this context, excitatory mechanisms that increase the intracellular Na
+
 
concentration above the normal range of 5-15 mM would cause an increased level of 
GIRK activity, which would return the cell to a hyperpolarized state [93]. In summary, 
GIRK channels require both Gβγ and PIP2 for channel activation whereas Na
+
 can further 
enhance basal and receptor-induced GIRK channel activity. 
 
GIRK channel gating: structural insights  
 Functional studies have shown that Gβγ and PIP2 are required for channel 
activation. Yet, until recently, it was unclear how these cofactors were physically 
influencing GIRK channel gating. X-ray crystallography and functional NMR studies 
revealed partial cytosolic structures and chimeric structures of inwardly-rectifying K
+
 
channels [102-105]. More recently, a complete crystal structure of the GIRK2 homomeric 
channel was resolved [93]. This study identified the exact binding sites of Na
+
 and PIP2. 
The crystal structure of the GIRK2-Gβγ interaction was resolved shortly after [106]. The 
GIRK2 structure, in the absence of cofactors, gives a detailed view of what is considered 
to be the closed state of the channel. The ‘closed’ structure suggests that there are two 
gates within the GIRK channel. The first gate—the inner helix gate—is formed by the 
four M2 helical domains, one from each subunit, as they are the inner helices that line the 
pore opening. The side chain of phenylalanine residue 190 on each M2 helix makes up 
the narrowest part of the pore. The second gate—the G loop gate—is formed by the G-
loop (the loop connecting the βH-βI sheets) located in the cytosolic domains just below 
the plasma membrane (Fig. 1.2).  
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The resolved crystal structure of GIRK2 revealed the Na
+
 binding site. Na
+
 binds 
in the cytosolic region of GIRK2, right underneath the βC-βD loop (Fig. 1.2, see also 
Fig. 3.10). GIRK2 residue D226 has been shown to be a critical determinant of Na
+
 
activation [93]. The loss of the negative charge provided by the aspartic acid residue (by 
mutating it to the uncharged asparagine residue) disrupts the binding, and subsequent 
activation, of Na
+ 
to the GIRK2 channel [97-99]. Along with D226, there are other 
residues thought to coordinate Na
+
 binding, including R228, N229, S230, along with 
some residues from the βE-βG loop, L273 and V274 (Fig. 1.2). 
The PIP2 binding site is at the interface of the transmembrane domains and the 
cytosolic domains (see Fig. 3.10). Many positively-charged GIRK2 residues in this area 
coordinate the interaction with the negatively-charged PIP2 molecule, including K62, 
K192, K197, and K198. PIP2 binding to GIRK2, in the absence of Gβγ or a constitutively 
active mutation, produced only a slight rotation of the inner M2 helices, a modest 
displacement of the interfacial helix, and a weakened electrostatic state of F190, the most 
constricted part of the pore. PIP2 alone does not open either channel gate, which is 
consistent with previous studies that show PIP2 alone cannot open GIRK channels in 
electrophysiology experiments [92, 97]. 
The Gβγ binding surface is a very large portion (700Å2) of the outward-facing 
plane of the cytosolic domains [106]. The Gβγ binding surface is made up of the βK, βL, 
βM, βN sheets from one subunit, and of the βD, βE sheets from the adjacent subunit (Fig. 
1.2, see also Fig. 3.10). All of these structures are conserved across the inward-rectifying 
family, but only GIRK channels are able to interact with Gβγ. There are residues unique 
to GIRK channels within these structures that are essential to this protein-protein 
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interaction. These include: Q246 and F252 on the βD-βE loop, L340, S341/T341, L342 
on the βL-βM loop (Fig. 1.2). Further, there are electrostatic interactions between several 
acidic residues (unique to GIRK channels) on the βL-βM loop and the electropositive 
surface of the Gβ subunit. 
Taken together with years of functional data on these channels, the new resolved 
structures of open and closed channels give a clear model of GIRK channel gating.  
Alone, Na
+
, PIP2, and Gβγ are able to evoke small amounts of GIRK current, but together 
they activate GIRK channels to a greater, and perhaps full, extent [106]. Upon Gβγ 
binding to GIRK2, which already is interacting with PIP2, the cytoplasmic domains rotate 
(4° counter-clockwise) with respect the transmembrane domains, causing a splaying of 
the inner M2 helices. This conformation is only partially open when compared to the 
PIP2-bound constitutively active GIRK2 mutant, in which the inner helices further splay 
open due to a greater rotation of the cytoplasmic domains (8° counter-clockwise) [106]. 
These differences in open conformation are likely attributable to the bursts of channel 
activity characterized in single-channel electrophysiology. This detailed structure-
function mechanism of GIRK channel gating is important to the investigation of inherent 
GIRK channel properties across subunits (Chapter 2) and to understanding how new 
GIRK agonists modulate GIRK channel gating mechanisms (Chapter 3). 
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Figure 1.2. GIRK subunit alignment and secondary structure. The four mammalian 
GIRK channel amino acid sequences are aligned to convey the conserved sequence 
homology shared by these subunits. Accession numbers: NM008426 (GIRK1), 
NM010606 (GIRK2), NM008429 (GIRK3), and NM017297 (GIRK4). The bolded 
residues in the pore helix, K
+
 filter, and distal C-terminus are residues studied in Chapters 
2 and 3. The light gray sequence at the end of GIRK2 represents the sequence unique to 
GIRK2C, while the rest of the GIRK2 sequence is shared by GIRK2A and GIRK2C. 
Secondary structure, adapted from [103], is overlayed onto sequences to map specific 
regions as they relate to cofactor interactions and gating. Spiral shapes represent α-helices 
and arrows represent β-sheets. The lines that connect these structures are loops.  
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Structural and functional differences among GIRK subunits 
PDZ binding motifs  
A PDZ binding motif is located at the end of the C-terminus of both GIRK2C and 
GIRK3 that is absent from GIRK1, GIRK4, and other GIRK2 isoforms. The presence of 
this PDZ binding motif seems to confer differences in expression and/or function. In 
terms of expression, GIRK2C forms more surface channels relative to GIRK2A [68]. On 
GIRK3, this PDZ binding motif is thought to negatively regulate the level of GIRK 
channels at the cell surface. The PDZ binding motif on GIRK3 has been shown to interact 
with Sorting Nexin 27 (SNX27), a protein that associates with the early endosome, 
causing GIRK3-containing channels to be internalized at a higher rate relative to non-
GIRK3-containing channels [107]. While GIRK2C has been shown to interact with 
SNX27, it is believed that internalization is specific to GIRK3, as the surface expression 
of GIRK2C is unaffected by SNX27 [107]. GIRK3 is thought to play more of a 
regulatory role, as the genetic ablation of Girk3 does not affect hippocampal GIRK 
currents [82]. The difference between the behavior of the PDZ binding motifs of 
GIRK2C and GIRK3 could be attributed to the strength of the forward trafficking motif 
of GIRK2C, and the presence of the lysosomal targeting signal in GIRK3. There is yet to 
be a function associated with the PDZ binding motif of GIRK2C, but a few binding 
partners have been suggested in the literature: PSD95, SNX27, and SAP97 [88, 107, 
108]. Some data suggest that there is a potential difference in trafficking or intracellular 
compartmentalization between GIRK2A and GIRK2C, but more studies are needed 
[109].  
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GIRK1-containing channels  
There are inherent differences in channels containing GIRK1, as compared to 
channels lacking GIRK1. First, single channel properties are altered. For example, 
heteromeric channels that contain GIRK1 exhibit relatively long mean open times of 1-2 
ms, whereas GIRK2 homomeric channels demonstrate short mean open times of <0.5 ms 
[66, 70, 73, 110]. Next, binding affinities for cofactors PIP2 and Na
+
 differ across 
subunits. GIRK1-containing channels have a higher binding affinity for PIP2 relative to 
GIRK2 homomers [111]. In addition, GIRK2 and GIRK4 subunits contain the residue 
needed for Na
+
 binding (GIRK2 D226; GIRK4 D223), where GIRK1 does not (GIRK1 
N217) [97-99]. Finally, GIRK1-containing channels demonstrate robust receptor-induced 
currents compared to their homomeric counterparts as observed in whole-cell patch-
clamp electrophysiology experiments [82]. The mechanisms underlying single-channel 
and whole-cell electrophysiological properties unique to GIRK1-containing channels are 
explored in the work described in Chapter 2.  
 
Chimeric and mutagenesis studies  
 Early structure-function studies of GIRK channels were successful in identifying 
regions essential for important channel interactions and inherent channel properties. For 
example, a chimeric study comparing different regions of GIRK1 to those of IRK1 
(Kir2.1) was used to identify the regions of GIRK channels required for their hallmark 
interaction with Gβγ long before crystallography was used to study channel gating [110]. 
This chimeric method was further used in exploring inherent structures of GIRK channels 
that lead to enhanced channel activity [112-115]. The success of these studies is what led 
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to the selection of this chimeric method for the work in Chapter 2, as the structural 
determinants for robust GIRK1-containing channel activity remained unclear. As such, 
this work used a chimeric strategy to exchange GIRK2 domains for homologous GIRK1 
domains to elucidate the important structures and mechanisms that underlie the robust 
activity of GIRK1-containing channels. 
 
Temporal regulation of G Protein signaling  
 The strength of G protein-dependent signaling can be regulated at the G protein 
level by multiple mechanisms.  The activation and deactivation kinetics associated with 
the opening of GIRK channels are dependent upon the binding efficiency of Gβγ to the 
channel and the inherent GTPase activity of Gαi/o which can release or sequester Gβγ 
depending on its state [116-118]. The Gα subunit can be modulated by proteins that 
accelerate GTPase activity, influence the nucleotide exchange of GDP to GTP, or 
interrupt protein-protein interactions between G protein subunits[119]. For example, 
Activators of G protein Signaling (AGS) proteins can promote guanine nucleotide 
exchange in a similar manner to GPCRs or compete with Gβγ to bind GDP-Gα causing 
free Gβγ without GPCR activation [120-122].  Regulators of G protein Signaling (RGS) 
proteins on the other hand, promote hydrolysis of the GTP bound to active Gα subunits 
[123, 124] (Fig. 1.1). These proteins have a highly-conserved RGS domain of about 120 
amino acid residues that has GTPase-Accelerating Protein (GAP) activity [125]. RGS 
proteins are divided into subfamilies based on the identity of their other functional 
domains, many of which may determine affinity or selectivity for different Gα isoforms 
[126, 127]. 
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 Subfamilies of RGS proteins  
 There are over 30 RGS proteins that are divided into four subfamilies (R4, R7, 
R12, RZ), some of which have other functional domains that mediate protein-protein 
interactions, subcellular localization, target specificity, and protein stability [128, 129]. 
Only the R4 and R7 subfamilies will be discussed here, as their members are key players 
in Chapters 4 and 5. Members of the large R4 RGS subfamily contain only the RGS 
domain and small N- and C-terminal regions. These proteins are often anchored to the 
membrane by their N-terminal domains, which contain an amphipathic helix that can 
directly interact with phospholipids [130]. Nearly all R4 RGS proteins can bind and have 
GAP activity for all Gαq and Gαi/o isoforms [124, 131]. Notably, RGS4 belongs to this 
family. 
 The R7 RGS family has four members: RGS6, RGS7, RGS9, and RGS11. In 
addition to an RGS domain, these proteins contain a G protein Gamma-like (GGL) 
domain, a Disheveled, Egl-10, Pleckstrin (DEP) domain, and a DEP helical extension 
(DHEX) domain [132]. The GGL domain very specifically binds one Gβ isoform: Gβ5 
[133, 134]. The coiled-coil interaction between an R7 RGS protein and Gβ5 is integral to 
the protein stability of R7 RGS proteins [135]. Without Gβ5, these proteins undergo 
proteolytic degradation [136]. The DEP domain and DHEX domain form a single 
functional domain that allows R7 RGS proteins to interact R7BP (R7 family Binding 
Protein) [137]. R7BP is anchored to the plasma membrane and functions to stabilize and 
localize R7 RGS proteins to the plasma membrane through their interaction with the 
DEP/DHEX domain [138]. 
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RGS proteins and GIRK channels  
 Kinetics of GIRK activation and deactivation are much slower in reconstituted 
systems compared to that of physiological systems [139]. By expressing RGS proteins in 
reconstituted systems, activation and deactivation kinetics of GIRK channels are restored 
to rates comparable to those observed in physiological conditions. This has been 
demonstrated with several members of the R4 RGS family, including RGS4 [140-144]. 
There is some evidence of protein-protein interactions between RGS proteins and GIRK 
channels. GIRK1 and GIRK4 have been co-immunoprecipitated with RGS4 [145]. 
RGS7/Gβ5 can be co-immunoprecipitated by GIRK1, GIRK2 and GIRK3 [146].  
 
Pharmacology of GIRK channels  
 GIRK channels can be manipulated indirectly by compounds that target GPCRs 
and Gi/o proteins, but often other cellular components are also affected. In order to study 
GIRK channels in a more direct and meaningful way, direct channel manipulation by 
pharmacological compounds is highly desirable. While several compounds can directly 
act on GIRK channels, they unfortunately can act on several other types of potassium 
channels as well. At the beginning of this work (in 2009), the pharmacological landscape 
of GIRK channels was not nearly as developed as it is today in 2014. The work described 
in Chapter 3 focuses on the characterization of a new class of selective GIRK activators 
and inhibitors, specifically the prototype of this drug class: ML297. 
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Girk channel blockers  
Barium and cesium block inwardly-rectifying potassium channels, including 
GIRK channels, by physically occluding the pore [62]. At higher concentrations, barium 
is able to block other types of potassium channels; however at 0.1-0.3 mM it is relatively 
selective for inward-rectifying K
+
 channels [62, 147]. Early studies also revealed that 
quinidine and quinine can fully block GIRK channels [148-150]. Quinine, an anti-
malarial compound, also has anti-pyretic, analgesic, and anti-inflammatory effects [151]. 
Quinidine, a stereoisomer of quinine, is an anti-arrhythmic agent and its main mechanism 
of action is to block fast inward sodium current in the heart, prolonging QT intervals 
[152]. While these compounds block GIRK channels, their promiscuity for other ion 
channels makes them a poor tool for the study of GIRK channels. More recently, 
Tertiapin, a peptide toxin found in bee venom, was demonstrated to block certain Kir 
channels, including those that contain GIRK1/GIRK4, as well as certain types of Ca
2+
-
gated K
+
 channels [153-155]. The synthetic form, rTertiapin-q, blocks the channel pore 
through an interaction with the amino acid sequence connecting M1 and M2 [156]. 
rTertiapin-q has been used in many electrophysiology studies of GIRK channels [155, 
157, 158].  
 Small molecule GIRK channel antagonists with a level of specificity for GIRK 
channels have also been identified. Blood-brain barrier impenetrable drugs that 
selectively activate or inhibit GIRK1/GIRK4 heterotetramers (the cardiac IKACh channel) 
could represent efficacious therapies for certain types of cardiac arrhythmias. NIP-142 
blocks GIRK1/GIRK4 channels expressed in HEK cells, and blocks HERG channels at 
higher concentrations [159]. Two drugs that can inhibit GIRK1/GIRK4 heteromers 
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(NTC-801 and NIP-151) showed promise in preclinical studies in the treatment of atrial 
fibrillation [160, 161]. NIP-151 potently blocks GIRK1/GIRK4 current in reconstituted 
systems [160]. NTC-801 is a novel, potent, and selective GIRK1/GIRK4 blocker and 
less-potent GIRK1/GIRK2 blocker [161]. However, there is still a lack of GIRK1/GIRK4 
channel activators for the treatment of cardiac disorders. 
 
GIRK channel activators   
Compounds that can directly activate GIRK channels include alcohols, naringin, 
and certain volatile anesthetics [162-165]. Alcohols with up to a 4-carbon length chain 
activate GIRK1/GIRK2 heteromeric channels; however, those with longer carbon chains 
act to inhibit GIRK channels [166]. The residues that form the cytosolic alcohol binding 
pocket observed in IRK1 and GIRK2 are also conserved in GIRK1 [162, 163, 167]. 
Halothane, a prototypical anesthetic, activates basal GIRK activity, but was shown to 
block GPCR-agonist-induced currents [165]. Naringin selectively activates GIRK1-
containing channels and the structural determinants of this selectivity are GIRK1 residues 
Y148 and Y150. These residues are located within the extracellular naringin binding site, 
which overlaps with the rTertiapin-q binding site [164]. The downside of naringin is that, 
while selective, it lacks in potency [164].  
Recently, a new drug class that can selectively activate GIRK channels was 
identified in a high-throughput screen [168]. These compounds showed selectivity for 
GIRK1-containing channels [169]. The prototype for this new drug class, named ML297, 
is not only selective for GIRK1-containing channels, but discerns between 
GIRK1/GIRK2 and GIRK1/GIRK4 channels [169]. In collaboration with another group, 
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much of the work identifying structures of GIRK1 shown in Chapter 2 served as a 
platform for investigating the mechanism of ML297 GIRK1 selectivity discussed in 
Chapter 3.  
 
GIRK channels and disease 
 There are subunit-specific constitutive knockout mice that have been studied 
extensively and have subsequently demonstrated a wide array of phenotypes that suggest 
roles for GIRK channels in many physiological processes [57, 170]. Because of these 
knockout studies, GIRK channels are thought to play a role in several disorders, 
including anxiety, neuropathic pain, epilepsy, addiction, obesity, and arrhythmias [170]. 
Furthermore, GIRK polymorphisms identified in the human population have been linked 
to disease states. There is a human polymorphism in GIRK2 that is associated with 
increased dosing requirements for opioid anti-nociception and another that is associated 
with ethanol intake and stress [171-173]. The human GIRK2 gene is located on 
chromosome 21 and is up-regulated by the trisomy of chromosome 21 that causes 
Down’s syndrome [174, 175]. Surprisingly, there was a significant decrease in contextual 
recall found in rodent models of a triploid GIRK2 mutation [176]. Recently, a human 
polymorphism in GIRK1 was shown to be genetically linked with schizophrenia [177]. In 
this study, lower GIRK1 expression levels were observed in post-mortem brains from 
schizophrenic and bipolar individuals, suggesting that altered GIRK1 expression is linked 
to schizophrenia and bipolar disorders. There are multiple mutations in the human GIRK1 
and GIRK4 genes that are associated with long QT syndrome and atrial fibrillation [178-
180]. Furthermore, identified mutations of GIRK4 were found to be associated with 
        Rgs regulation of cardiac muscarinic signaling 
  26 
hyperaldosteronism and hypertension [181, 182]. Taken together, GIRK channels are an 
important target for therapeutic intervention in a number of disorders associated with the 
brain and the heart.  
 
Neuronal and Cardiac GIRK signaling  
Inhibitory G protein signaling cascades through GIRK channels offer a great deal 
of diversity and complexity. GIRK channels interact with the 5 isoforms of Gi/o proteins 
which in turn interact with many different GPCRs. GIRK channels have been 
demonstrated to be downstream effectors for many GPCRs, including adenosine, 
serotonin, dopamine, opioid, glutamate, adrenergic, GABAergic, and muscarinic 
receptors [57]. Two well-studied signaling cascades are used in this work to study 
intrinsic and extrinsic factors that impact GIRK signaling: the neuronal GABABR-GIRK 
cascade and the cardiac M2R-IKACh cascade.  
 
Neuronal GABABR-GIRK  
 GABA, or γ-aminobutyric acid, is the main inhibitory neurotransmitter in the 
nervous system, and it acts on two different receptors: GABAA and GABAB. The 
GABAA receptor is a chloride ion channel and the GABAB receptor is a GPCR coupled 
to inhibitory Gi/o proteins [183, 184]. The GABAB receptor is a functional heterodimer of 
GABABR1 and GABABR2 subunits [185-188]. Both subunits have the seven 
transmembrane domain structure characteristic to GPCRs. GABABR1 contains the N-
terminal ligand-binding domain and a C-terminal α-helix that contains an ER retention 
motif [189, 190]. GABABR2 contains the Gi/o protein interaction site in its intracellular 
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loops, and also a C-terminal α-helix that forms a coiled-coil interaction with the 
GABABR1 C-terminal helix [188, 191, 192]. GABABR2 is responsible for membrane 
trafficking and G protein interaction, while GABABR1 is responsible for ligand binding, 
together making a functional receptor [190, 193]. 
 GIRK channels are known to act as downstream effectors of GABABRs in 
numerous brain regions, including the hippocampus, cerebellum, VTA and substantia 
nigra, thalamus, locus coeruleus and prefrontal cortex [83, 87, 194-198]. The first 
evidence of GIRK channels being downstream effectors of the GABABR was identified 
by electrophysiology in hippocampal slices in 1997 [52]. GIRK and GABABR are known 
to co-localize sub-cellularly within neurons, and evidence suggests that GABAB receptors 
and GIRK channels are localized in close proximity at the membrane, and in fact may be 
physically coupled either directly or indirectly through scaffolding proteins [195, 199-
201].  
 
Cardiac M2R-IKACh  
 Acetylcholine (ACh) functions within the peripheral and central nervous systems, 
through several cholinergic receptor subtypes. Nicotinic receptors are ion channels 
permeable to Na
+
, K
+
 and to a lesser extent Ca
2+
. On the other hand, muscarinic receptors 
are GPCRs that couple to both excitatory Gq proteins (M1, M3, and M5), and inhibitory 
Gi/o proteins (M2 and M4) [202, 203]. The M2 receptor is often referred to as the atrial 
muscarinic receptor as it plays a key role in the parasympathetic regulation of heart rate 
[51, 204].  Ligand binding at this receptor promotes activation of a tetrameric K
+ 
channel 
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formed by GIRK1 and GIRK4 subunits, also known as IKACh [69], which hyperpolarizes 
the cell, decreases excitability and ultimately reduces heart rate [205, 206]. 
 Temporal regulation of M2R-IKACh signaling is thought to be important to cardiac 
pacing, as vagal control of heart rate occurs rapidly [207]. The kinetics of the endogenous 
atrial M2R-IKACh signaling pathway are fast compared to those measured when the 
signaling pathway was reconstituted in CHO cells [140]. Interestingly, by co-expressing 
an RGS protein (RGS4) with M2R and IKACh in CHO cells, the kinetic profile was 
restored to that observed in atrial myocytes [140].   
 
III. SUMMARY 
The last five years have yielded novel structural and pharmacological insights into 
GIRK channels and their regulation, some of which have been enriched by the work 
described in this dissertation. The work discussed in Chapters 2 and 3 studies the 
structural elements in GIRK1 within the context of the GABABR-GIRK cascade in either 
transfected cells or in cultured hippocampal neurons. Chapter 2 is focused on the 
mechanism behind the robust channel activity of GIRK1 containing channels and 
identifying key structural determinants within GIRK1 responsible for it. Chapter 3 is 
focused on identifying the structural determinants of GIRK1 responsible for the 
selectivity of ML297 for GIRK1 containing channels. Furthermore, Chapter 3 focuses on 
the mechanism of ML297 activation of GIRK channels, the efficacy of the drug in 
cultured hippocampal neurons, and the anxiolytic properties of ML297 when 
administered in a rodent model.  
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The work in Chapters 4 and 5 is dedicated to characterizing the RGS proteins 
involved in the modulation of IKACh, and their subsequent effect on the parasympathetic 
regulation of heart rate. The work in Chapter 4 was done right as another study on the 
same topic was published. In 2008, it was demonstrated that RGS4 was expressed in the 
mouse sinoatrial node, that genetic disruption of RGS4 slowed down the deactivation 
kinetics associated with IKACh, and that it enhanced M2R-agonist induced bradycardia 
[89]. Chapter 4 offers up another RGS protein that regulates the kinetics of IKACh: RGS6. 
Subsequent work described in Chapter 5 addresses how both RGS4 and RGS6 work to 
alter the kinetics of M2R-IKACh signaling in the mouse sinoatrial node and the resultant 
effects on the parasympathetic regulation of heart rate.  
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Structural elements in the GIRK1 subunit that potentiate G protein-
gated potassium channel activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wydeven N, Young D, Mirkovic K, Wickman K.  Structural elements in the Girk1 
subunit that potentiate G protein-gated potassium channel activity. Proc. Natl. 
Acad. Sci. USA 2012: 109(52):21492-7 
 
 
        Rgs regulation of cardiac muscarinic signaling 
  31 
Introduction 
Many neurotransmitters inhibit neurons by activating receptors linked to 
heterotrimeric GTP binding proteins (G proteins). A prototypical effector in such 
signaling pathways is the G protein-gated inwardly-rectifying K
+
 (GIRK/KIR3) channel 
(reviewed in [57]). GIRK channels are tetramers, with each subunit possessing 
intracellular amino (N)- and carboxyl (C)-termini and a core domain containing two 
transmembrane segments, two short extracellular loops, and a hydrophobic domain (P-
loop) that contributes to the pore and K
+
 selectivity filter. Four mammalian Girk genes 
have been identified (Girk1-4). The classical mode of GIRK channel activation involves 
the direct binding of G subunits, which stabilizes a low-affinity interaction between the 
channel and phosphatidylinositol 4,5-bisphosphate (PIP2). 
GIRK2 plays a key role in neuronal GIRK channel formation (e.g., [52]). 
Overlapping expression patterns and the impact of Girk2 ablation on Girk1 expression, 
however, argue that most neuronal GIRK channels contain both GIRK1 and GIRK2 [50, 
208]. In support of this contention, Girk1 ablation yields a near-complete loss of GIRK-
dependent signaling in neurons that express GIRK1 (e.g., [82]). These findings are 
surprising because GIRK2 forms functional homomers in expression systems that exhibit 
G protein-dependent gating, K
+
 selectivity, and inward rectification [73]. Moreover, 
GIRK2 homomers have been identified in midbrain dopamine neurons [88]. 
Nevertheless, work in expression systems has shown clearly that GIRK1 potentiates 
receptor-dependent and receptor-independent currents when co-expressed with GIRK2 or 
GIRK4 [66, 69, 73, 209].  
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Many studies have provided insight into the structural basis of channel regulation 
by G proteins, PIP2, and Na
+
, as well as channel gating mechanisms [57]. Most of the 
relevant structural elements, however, are well-conserved across GIRK subunits and thus 
cannot explain how GIRK1 potentiates GIRK signaling. Here, we sought new insights 
into the structural elements unique to GIRK1 that potentiate GIRK channel activity, using 
mutagenesis approaches exploiting insights from previous biochemical and 
crystallography studies. 
 
Materials and Methods  
 
Animals—Studies adhered to the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals, and were granted approval by the Institutional Animal 
Care and Use Committee. The generation of Girk1
–/–
 mice was described previously 
[210]. 
Molecular biology—pcDNA3-based expression constructs containing rat GIRK1 
(GIRK1-AU5) and mouse GIRK2a (GIRK2-myc) coding sequences served as parent 
constructs. GIRK1 C-terminal deletion constructs were generated by polymerase chain 
reaction (PCR). GIRK1/GIRK2 chimeras were generated by overlap extension PCR. 
Point mutations were introduced using the Quickchange II XL kit (Agilent 
Technologies). All constructs were validated by DNA sequencing. Expression constructs 
for human Gβ1 (FLAG-Gβ1) and G2 (HA-Gγ2) were purchased from the Missouri S&T 
cDNA Resource Center.  
Cell culture and biochemistry—For biochemical assays, HEK293FT cells 
(Invitrogen
TM 
/Life Technologies) were transfected using the calcium phosphate 
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technique and collected for analysis 36-54 h later. For electrophysiological studies, 
HEK293 cells (ATCC) were transfected with Lipofectamine
TM
 LTX reagent 
(Invitrogen
TM
/Life Technologies); experiments were conducted 18-36 h later. Some cells 
were treated with pertussis toxin (Tocris Bioscience) for 12-18 h prior to 
electrophysiological characterization. Primary cultures of hippocampal neurons were 
prepared as described [146]. For quantitative reverse transcriptase PCR (qRT-PCR) and 
biotinylation studies, neurons were plated onto 3-cm petri dishes and kept in culture for 
10-12 days prior to experimentation. qRT-PCR conditions for GABABR1 and Girk2 were 
described previously [211]. 
Immunoblotting and HEK cell biotinylation experiments were performed as 
described [212]. Blots were probed with primary antibodies targeting c-myc 
(11667149001, 1:500; Hoffmann-La Roche), β-actin (ab6276, 1:10,000; Abcam), AU5 
(A190-227A, 1:1,000; Bethyl Laboratories), or GIRK2 (APC-006, 1:200; Alomone 
Labs), and either donkey anti-mouse (926-32212, 1:7,000; LI-COR Biosciences) or anti-
rabbit (926-68072, 1:7,000; LI-COR) secondary antibodies. Blots were developed and 
band intensities quantified using the Odyssey® Infrared imaging system (LI-COR). 
Electrophysiology—Conditions for measuring baclofen-induced whole-cell GIRK 
currents were described previously [146].  Receptor-independent (basal) GIRK current 
was determined by measuring the decrease in holding current in the high-K
+
 bath solution 
evoked by 0.3 mM Ba
2+
.  Measured and command potentials were not corrected for 
liquid junction potential. An Axopatch 200B patch clamp amplifier (Molecular Devices) 
was used for measurement of cell-attached, single-channel activity. Borosilicate patch 
pipettes (4-6 MΩ) were filled with (in mM): 150 KCl, 1 MgCl2, 5 EGTA/KOH, 5 
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HEPES/KOH, and 0.1 baclofen (pH 7.4). To zero the cell membrane potential, baclofen-
induced single channel activity was measured in a high-K
+
 (150 mM) bath solution (in 
mM): 150 KCl, 1.8 CaCl2, 0.5 MgCl2, 5.5 D-glucose, 5 HEPES/KOH (pH 7.4). Effective 
zeroing of the membrane potential using this approach was validated by measuring the 
reversal potential of the high-conductance, weakly-rectifying Trek1 K
+
 channel. 
Immediately after gigaseal formation, membrane potential was clamped at -75 mV, 
recordings were low-pass filtered at 2 kHz, sampled at 10 kHz, and stored on hard disk 
for analysis using pCLAMP v. 9.0 software. Analysis of single-channel conductance and 
mean open time was performed on 5-15 s recordings taken within the 30-s timeframe 
immediately following seal formation. 
Data analysis—Data are presented throughout as the mean±SEM. Statistical 
analyses were performed with Prism 5 (GraphPad Software). Group comparisons were 
typically made using Student’s t-test or one-way ANOVA followed by Tukey’s HSD post 
hoc test when appropriate. Open-state dwell-time data were analyzed using the 
Kolmogorov-Smirnoff test, while single channel amplitude data were analyzed with the 
Kruskal Wallis test, with pairwise comparisons made using Dunn’s Multiple Comparison 
test.  In all analyses, the level of significance was set at P<0.05. 
 
Results 
GIRK1-dependent potentiation of GABABR-GIRK signaling 
  HEK cells expressing the GABAB receptor (GABABR) subunits GABABR1 and 
GABABR2, along with epitope-tagged GIRK1 and GIRK2, exhibited large currents in 
response to a saturating concentration of the GABABR agonist baclofen, as well as 
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receptor-independent or basal (Ba
2+
-sensitive) whole-cell currents (Fig. 2.1A,B). In 
contrast, currents in cells expressing GABABR and GIRK2 were small. Consistent with 
previous observations [199, 213], pre-treatment of cells expressing the GIRK1/GIRK2 
heteromer with pertussis toxin, which uncouples Gi/o G proteins from activated receptors, 
eliminated the baclofen-induced but not basal current (Fig. 2.1B). Thus, GIRK1 
potentiates GIRK currents in both receptor-dependent and receptor-independent manners. 
GIRK2 levels at the cell surface measured using a biotinylation approach were not 
significantly different with or without GIRK1 present (Fig. 2.1C,D). Moreover, the ratio 
of surface-to-total GIRK2 protein was unaltered, indicating that GIRK1 does not impact 
the surface trafficking of GIRK2-containing channels. 
  We also examined the impact of Girk1 ablation on GABABR-GIRK signaling in 
mouse hippocampal cultures. Girk1 ablation yielded a dramatic reduction (~80%) in 
baclofen-induced currents in large pyramidal-shaped neurons (Fig. 2.2A). Interestingly, 
the small residual currents in neurons from Girk1
–/–
 mice correlated with a significant 
increase in GABABR1 and Girk2 expression (Fig. 2.2B). There was no difference, 
however, in total or surface GIRK2 protein levels in cultures from wild-type and Girk1
–/–
 
mice (Fig. 2.2C). Collectively, these data indicate that the potentiating effect of GIRK1 
on GIRK currents in heterologous and native systems is not due to increased protein 
levels or surface targeting of GIRK2. 
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Figure 2.1. The potentiating influence of GIRK1. A) Baclofen-induced and basal 
(Ba
2+
-sensitive) currents, measured in a high-K
+
 bath solution (25 mM) at a holding 
potential of -70 mV, in cells expressing GABABR and either GIRK1/GIRK2 or GIRK2 
alone. Bars denote the duration of baclofen (100 M) and Ba2+ (0.3 mM) applications. B) 
Summary of currents measured in cells expressing GIRK2 and GABABR, along with the 
subunit depicted on the left (n=15-61/group). GIRK2 homomeric currents were measured 
in cells transfected with double (2x) the amount of GIRK2 used in cells transfected with 
GIRK1 and GIRK2. A subset of cells expressing GIRK1/GIRK2 was pre-treated (24 h) 
with pertussis toxin (PTX, 0.1 ng/ml). A significant impact of group was observed for 
basal (F2,94=9.5, P<0.001) and baclofen-induced (F2,98=61.1, P<0.001) currents. Symbols: 
*** P<0.001, respectively, vs. GIRK1/GIRK2. C) Blot from a biotinylation experiment 
probing total and surface GIRK2 protein levels in cells transfected with GIRK1 and 
GIRK2 (GIRK1/2), GIRK2 alone (1x), and GIRK2 alone at twice the concentration (2x). 
D) Quantification of biotinylation data (n=3 separate experiments). No significant 
differences were detected between groups. 
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Figure 2.2. GIRK1-dependent potentiation of GABABR-GIRK currents in 
hippocampal neurons.  A) Representative currents induced by baclofen (100 M) in 
hippocampal neurons from wild-type (7.3±1.0 pA/pF, n=8) and Girk1
–/–
 (1.6±0.3 pA/pF, 
n=10; P<0.001) mice.  B) qRT-PCR analysis of GABABR1 and Girk2 expression in 
hippocampal cultures from wild-type and Girk1
–/–
 mice (n=3 separate cultures).  
Symbols: *,*** P<0.05 and 0.001 vs. wild-type.  C) Total and surface GIRK2 protein in 
hippocampal cultures from wild-type and Girk1
–/–
 mice (n=3 separate cultures). 
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Influence of the distal C-terminus 
Multiple intracellular domains have been implicated in the binding of G to 
GIRK subunits [57]. These elements are highly-conserved across GIRK subunits, 
however, and thus cannot explain the potentiating influence of GIRK1. While the unique 
distal C-terminal GIRK1 domain between residues 390-462 does not bind G directly, it 
has been shown to enhance the binding of the GIRK1 C-terminus to G [214]. As such, 
we used a targeted deletion strategy to probe the functional relevance of this and 
surrounding domains (Fig. 2.3). The deletion mutants were expressed at levels 
comparable to GIRK1 (Fig. 2.4A,B), and the protein levels and surface trafficking of 
GIRK2 was comparable in cells expressing GIRK1 or deletions (Fig. 2.4C-E).  
Basal and baclofen-induced currents were measured in cells transfected with 
GIRK1 deletion constructs, GIRK2, and GABABR (Fig. 2.3A). The first construct tested 
(GIRK1462) revealed that the last 39 amino acids of GIRK1 are not required for normal 
basal or GABABR-dependent GIRK currents. Basal current for GIRK1409/GIRK2 and 
GIRK1406/GIRK2 heteromers was, however, significantly lower than those measured 
for GIRK1/GIRK2, while GABABR-dependent GIRK currents were preserved. Further 
deletion (GIRK1399) correlated with a significant decrease in baclofen-induced GIRK 
currents. Thus, structures between residues 409 and 462 uniquely support robust basal 
activity, while residues 399-406 are important for robust GABABR-dependent GIRK 
currents. 
A sharp distinction in baclofen-induced currents was observed for 
GIRK1406/GIRK2 and GIRK1403/GIRK2 heteromers. Mutation of the pertinent 
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residues individually to alanine (Q404A, K405A, I406A), in the context of the 
GIRK1406 backbone, identified Q404 as a possible determinant of robust receptor-
induced current (Fig. 2.3B,C). Basal current observed with the GIRK1(Q404A) mutation 
was smaller than GIRK1406, though this difference was not statistically significant.  
 We next engineered the Q404A mutation into full-length GIRK1. While basal 
activity was not different in cells expressing GABABR, GIRK2, and either GIRK1 or 
GIRK1(Q404A), baclofen-induced currents were ~30% lower in cells expressing 
GIRK1(Q404A) (Fig. 2.5A). This difference was not related to reduced expression of 
GIRK1(Q404A) (Fig. 2.6A,B), or to a negative influence of GIRK1(Q404A) on the 
protein level or surface trafficking of GIRK2 (Fig. 2.6C,D). The EC50 for baclofen 
activation of GIRK1(Q404A)/GIRK2 heteromers (0.76 M; 0.52-1.11 M, 95% CI), 
measured by sequential application of increasing baclofen concentrations (0.01-300 M), 
was slightly but significantly greater (F1,42=4.3; P<0.05) than that measured for 
GIRK1/GIRK2 (0.47 M; 0.36-0.61 M, 95% CI). When co-expressed with GIRK2 and 
G (G1 and G2), GIRK1 and GIRK1(Q404A) supported robust and indistinguishable 
Ba
2+
-sensitive currents (Fig. 2.5B,C). Collectively, these data are consistent with a role 
for Q404 in enhancing the channel-G interaction. 
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Figure 2.3. Impact of the GIRK1 distal C-terminus. A) Basal and baclofen-induced 
currents in cells expressing GABABR, GIRK2, and the subunit depicted on the left 
(n=12-61/group). A significant impact of group was observed for basal (F5,137=8.4, 
P<0.001) and baclofen-induced (F5,141=6.7, P<0.001) currents. Symbols: *,*** P<0.05 
and 0.001, respectively, vs. GIRK1/GIRK2; 
##
 P<0.01 vs. GIRK1406/GIRK2. GIRK2 
homomeric basal and baclofen-induced currents are shown for comparison, but were not 
included in the analysis. B) Immunoblot of I406A, K405A, and Q404A point mutants, 
generated on the GIRK1406 backbone. C) Basal and baclofen-induced currents in cells 
expressing GABABR, GIRK2, and the construct depicted on the left (n=8-18/group). A 
significant impact of group was observed for baclofen-induced (F3,42=3.0, P<0.05) but 
not basal (F3,41=2.6, P=0.06) current. Symbols: * P<0.05 vs. GIRK1406/GIRK2. 
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Figure 2.4. Characterization of GIRK1 C-terminal deletion constructs.  A) 
Expression levels of AU5-tagged GIRK1 and GIRK1 deletion mutants were assessed by 
immunoblotting. B) The summed intensity of core and core-glycosylated forms of 
GIRK1 (doublet) was normalized to -actin (lower blot). All mutants expressed at or 
slightly above the level of GIRK1 (F6,20=1.4, P=0.3; n=3 separate transfections). C,D) 
Representative blots from a biotinylation experiment measuring total and surface myc-
tagged GIRK2 protein level in cells transfected with GIRK2 and either GIRK1 or GIRK1 
deletion mutant. E) Quantification of biotinylation data. No significant impact of group 
was found for total (F6,27=0.3, P=0.95) or surface (F6,27=2.3, P=0.1) GIRK2 protein (n=4 
separate experiments). 
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Figure 2.5. Impact of Q404. A) Basal and baclofen-induced currents in cells expressing 
GABABR, GIRK2, and the depicted construct (n=19-20/group). A significant difference 
between groups was observed for baclofen-induced (t37=2.8, P<0.01) but not basal 
(t35=0.2, P=0.9) current. Symbols: **P<0.01 vs. GIRK1. B) Ba
2+
-sensitive currents 
measured in high-K
+
 bath solution in cells expressing Gβ1γ2 and either GIRK1/GIRK2 
or GIRK1(Q404A)/GIRK2 (Vhold = -70 mV). Bars denote the duration of Ba
2+
 (0.3 mM) 
application. C) Summary of Ba
2+
-sensitive currents in cells transfected with Gβ1γ2 and 
empty vector (G only), GIRK1/GIRK2, or GIRK1(Q404A)/GIRK2. A significant 
impact of group was observed (F2,29=4.6, P<0.05). Symbols: * P<0.05, respectively, vs. 
GIRK1. 
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Figure 2.6. Characterization of GIRK1(Q404A) mutant. A,B) Expression of AU5-
tagged GIRK1 and GIRK1(Q404A) was assessed by quantitative immunoblotting, with 
the summed intensity of core and core-glycosylated forms of GIRK1 normalized to -
actin. Levels of GIRK1(Q404A) were not different from GIRK1 (t6=0.6, P=0.6; n=3). C) 
Blot from a biotinylation experiment measuring total and surface GIRK2 protein levels in 
cells transfected with GIRK1/GIRK2 or GIRK1(Q404A)/GIRK2. D) Quantification of 
biotinylation data. No differences were observed for total (t4=0.5, P=0.7) or surface 
(t4=0.4, P=0.7) GIRK2 protein levels (n=5). 
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Impact of the GIRK1 core 
  Baclofen-induced currents observed for GIRK1399/GIRK2 were significantly 
larger than those carried by GIRK2 homomers (t34=5.6, P<0.001), arguing that structures 
between residues 1-399 also contribute to the GIRK1-dependent potentiation of GIRK 
channel activity. Unfortunately, GIRK1 expression levels declined with more aggressive 
deletions (not shown). As such, we generated 3 chimeras incorporating N-terminal 
(GIRK1 residues 1-85), core (GIRK1 residues 86-180), or C-terminal (GIRK1 residues 
181-501) domains from GIRK1 within a GIRK2 backbone, and expressed them with 
GIRK2 and GABABR (Fig. 2.7). All three chimeras (NT, TM, CT) were expressed at 
higher levels than GIRK1 (Fig. 2.8A), but none significantly altered the surface 
trafficking of GIRK2 (Fig. 2.8B). Only the GIRK1 core domain (TM) conferred a partial 
but significant potentiation of basal and baclofen-induced currents (Fig. 2.7A).  
Single channel conductance and mean open time values are larger for GIRK1-
containing channels than GIRK1-lacking counterparts [69, 112]. Enhancement of these 
unitary properties should increase basal and receptor-induced whole-cell GIRK currents. 
Thus, we next measured single channel conductance and mean open times of baclofen-
activated GIRK channels in cells expressing GIRK1/GIRK2, GIRK2 alone, or 
TM/GIRK2. In cells expressing GIRK1 and GIRK2, most channel openings were 
reasonably well-resolved (Fig. 2.7B), exhibiting a prominent single-channel conductance 
of 35 pS (Table 2.1, Fig. 2.8C). The open-state dwell time data for GIRK1/GIRK2 
heteromers was modeled best with two terms (0.4 and 2.2 ms; Table 2.1, Fig. 2.8D). In 
cells expressing GIRK2 homomers, events were less well-resolved; analysis revealed a 
single channel conductance of 11 pS and a mean open time of 0.3 ms. Channels observed 
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in cells expressing TM and GIRK2 exhibited an intermediate conductance (21 pS) and 
mean open times (0.4 and 1.7 ms), values significantly different from those of both 
GIRK1/GIRK2 heteromers and GIRK2 homomers (Table 2.1). These data suggest that 
larger whole-cell currents seen in cells expressing TM/GIRK2 as compared to GIRK2 
homomers can be attributed, at least in part, to an enhancement of single-channel 
conductance and mean open time.  
  A second set of chimeras with overlapping GIRK1 content was generated to better 
resolve potentiating elements within the 95-residue domain (Fig. 2.9). The 3 chimeras 
(M1-P, P, P-M2) were expressed at levels comparable to the TM chimera (Fig. 2.10A,B). 
Single channel conductance and open times were significantly lower for all 3 chimeras 
relative to TM, but significantly greater than those for GIRK2 homomers (Table 2.1). All 
3 chimeras supported basal currents comparable to those measured for the TM chimera 
(Fig. 2.9B), implicating the GIRK1 P-loop as a key potentiating influence on basal 
channel activity. Interestingly, baclofen-induced currents supported by the M1-P and P 
(but not P-M2) chimeras were significantly larger than those measured for the TM 
chimera, indicating that the GIRK1 P-loop also enhances GABABR-GIRK current, and 
that this influence is tempered by structural content between GIRK1 residues 150 and 
180.  
  Six residues differ between GIRK1 and GIRK2 within this region, and all are 
found within the M2 domain (Fig. 2.9A). To identify the structural basis for the 
inhibitory influence of the M2 domain, we introduced GIRK1-specific residues into the 
M2 domain of the P chimera, focusing on three substitutions predicted to exert the most 
significant structural impact (L173F, I175F, N184D). While cells expressing GABABR, 
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GIRK2, and either P(I175F) or P(N184D) exhibited basal and baclofen-induced currents 
comparable to or greater than cells expressing the TM chimera, currents supported by the 
P(L173F) mutant were indistinguishable from those seen in cells expressing TM. 
Moreover, baclofen-induced currents in cells expressing P(L173F) were significantly 
lower than currents measured in cells expressing the P chimera (Fig. 2.9C). The single 
channel conductance (but not mean open time) measured in cells co-expressing GIRK2 
and P(L173F) was also significantly lower than that measured for the P chimera (Table 
2.1). Collectively, these data suggest that residue F162 in the GIRK1 M2 domain is a 
selective inhibitory influence on the receptor-dependent gating of heteromeric GIRK 
channels. 
Only four residues differ between GIRK1 and GIRK2 within the P-loop (Fig. 
2.11A). To determine which residue(s) confer potentiation of basal and baclofen-induced 
currents, we generated GIRK2 point mutants containing one or more GIRK1 residues at 
the analogous positions. No enhancement of basal activity was observed when the single 
mutants were co-expressed with GIRK2 (Fig. 2.11C). GIRK2(S148F) did tend to support 
larger baclofen-induced currents, despite the fact that total protein levels for this mutant 
were significantly lower than GIRK2 (Fig. 2.12). Mean open-time for channels in cells 
expressing GIRK2(S148F) and GIRK2, however, was significantly longer than that of a 
GIRK2 homomer, suggesting that the mutant was expressed and available to influence 
the unitary properties of the expressed channel.  
We next evaluated the GIRK2(S148F/T153A) double mutant, or FA mutant, 
reasoning that this dual substitution would promote a redistribution of intra-subunit 
interactions. T153 in GIRK2 is located at the junction between the K
+
 selectivity filter 
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and pore helix (Fig. 2.11B), and it participates in an intra-subunit interaction with W106. 
Introduction of the GIRK1-specific alanine at this position should preclude this 
interaction and foster an intra-subunit interaction between W106 and the GIRK1-specific 
phenylalanine incorporated at position 148. Total expression levels of the FA mutant 
were, like GIRK2(S148F), significantly lower than GIRK2 (Fig. 2.12). Basal activity and 
unitary channel properties measured in cells expressing FA and GIRK2 was comparable 
to those seen in cells expressing GIRK2(S148F), and while baclofen-induced currents 
were larger than those measured in cells expressing GIRK2(S148F), the difference was 
not significant (Fig. 2.11C).  
V142P and V161Y substitutions were next introduced independently to the FA 
mutant to generate PFA and FAY triple mutants. Introduction of the proline at position 
142 should cause a premature termination of the pore helix, while the V161Y substitution 
should strengthen inter-subunit interactions by promoting aromatic stacking with Y159 
(conserved in all GIRK subunits) in the adjacent GIRK subunit (Fig. 2.11B). PFA protein 
levels were low in whole-cell extracts from transfected cells (Fig. 2.12), and PFA/GIRK2 
co-expression yielded basal and baclofen-induced responses comparable to those of 
GIRK2 homomers. In contrast, total protein levels for FAY were notably higher than 
those of the PFA, FA, and S148F mutants (Fig. 2.12), and FAY/GIRK2 co-expression 
recapitulated the enhanced basal and baclofen-induced currents seen with the P chimera 
(referred to as PFAY in Fig. 2.11C).  
Importantly, reversal potentials for the baclofen-induced currents measured in the 
high-K
+
 recording solution were similar (F2,16=2.6, P=0.1) for cells expressing 
GIRK1/GIRK2 (-42±1 mV, n=5), P/GIRK2 (-33±5 mV, n=5), and FAY/GIRK2 (-36±1 
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mV, n=7), and were close to the K
+
 equilibrium potential (-43 mV). Thus, the 
potentiation of basal and baclofen-induced currents observed with P chimera and FAY 
mutant was not attributable to marked alterations in channel selectivity. Moreover, 
channels measured in cells expressing GIRK2 and FAY or P chimera exhibited 
significantly longer mean open times and slightly larger single-channel conductances 
than GIRK2 homomers, arguing that the potentiating influence of these P-loop residues 
on basal and baclofen-induced currents is mediated, at least in part, by an enhancement of 
unitary channel properties. 
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Figure 2.7. Impact of the GIRK1 core. A) Basal and baclofen-induced currents in cells 
expressing GABABR, GIRK2, and the depicted construct (n=10-34/group). A significant 
impact of group was observed for basal (F5,105=10.3, P<0.001) and baclofen-induced 
(F5,110=10.9, P<0.001) currents. Symbols: *,*** P<0.05 and 0.001, respectively, vs. 
GIRK2 homomer; 
### 
P<0.001 vs. GIRK1/GIRK2. B) Representative segments (300 ms) 
of cell-attached recordings (Vhold = -75 mV), measured with 100 M baclofen in the 
high-K
+
 (150 mM) pipette solution, from cells expressing GABABR, GIRK2, and either 
GIRK1 (top), TM chimera (middle), or GIRK2 (bottom). A patch with higher activity 
(and at least 2 channels) is shown for TM to emphasize the profile overlap with 
GIRK1/GIRK2 heteromers and GIRK2 homomers. 
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Figure 2.8. Characterization of GIRK1/GIRK2 NT, TM, and CT chimeras. A) 
Summary of expression of AU5-tagged GIRK1 and GIRK1 chimeras, as assessed by 
quantitative immunoblotting (n=3 separate transfections). A significant impact of group 
was observed (F3,15=4.5, P<0.05). Symbols: * P<0.05 vs. GIRK1. B) Ratio of surface-to-
total GIRK2 protein measured in cells transfected with GIRK2 and either GIRK1 or 
chimera (n=3 separate transfections); no significant impact of group was observed 
(F3,11=0.3, P=0.8). C,D) Amplitude and open-state dwell time histograms for channels 
observed in cells expressing GABABR, GIRK2, and either GIRK1, GIRK2, or TM 
chimera. Single channel conductance and mean open times were extracted from Gaussian 
or log exponential fits, respectively, of these data, and are summarized in Table 2.1. 
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Figure 2.9. Impact of the GIRK1 P-loop and M2 domain.  A) Sequence alignment of 
GIRK1 and GIRK2 core domains, with key structural elements highlighted. The 
arrowheads denote 3 residues tested for their influence on the M2-dependent inhibition of 
baclofen-induced currents. B) Basal and baclofen-induced currents in cells expressing 
GABABR, GIRK2, and the depicted chimera (n=12-22 per group). A significant impact 
of group was observed for baclofen-induced (F3,54=7.6, P<0.001) but not basal (F3,55=1.0, 
P=0.4) current. Symbols: **,*** P<0.01 and 0.001, respectively, vs. TM. Basal and 
baclofen-induced currents for GIRK1/GIRK2 are presented for comparison, but were not 
included in the statistical analysis. C) Basal and baclofen-induced currents in cells 
expressing GABABR, GIRK2, and the depicted construct (n=7-22/group). A significant 
impact of group was observed for baclofen-induced (F4,55=15.6, P<0.001) and basal 
(F4,54=9.8, P<0.001) currents. Symbols: *,** P<0.05 and P<0.01, respectively, vs. TM; 
#
 
P<0.05 vs. P. 
  
        Rgs regulation of cardiac muscarinic signaling 
  52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. Characterization of GIRK1 core chimeras. A,B) Quantitative 
immunoblotting of the AU5-tagged GIRK1 core chimeras TM, M1-P, P, and P-M2. The 
intensity of TM and mutant bands was normalized to -actin (lower blot). No significant 
impact of group was observed (F3,11=3.4, P=0.07; n=3 separate transfections). C) 
Modeling of the GIRK2 homomer (PBD 3SYQ) in the open conformation, with one 
subunit (facing the viewer) removed for clarity. The three remaining subunits are 
displayed in different colors: light, medium, and dark gray. The model highlights residues 
L173 in the M2 (inner helix) domain of the dark gray subunit and I155 in the selectivity 
filter of the adjacent (medium gray) subunit. 
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Figure 2.11. Impact of GIRK1 P-loop residues. A) Alignment of GIRK1 and GIRK2 
P-loop domains. The arrowheads denote the four amino acid differences between GIRK1 
and GIRK2 in this domain. B) Modeling of the GIRK2 homomer (PBD 3SYQ) in the 
open conformation, with one subunit (facing the viewer) removed for clarity. The three 
remaining subunits are displayed in different colors: light, medium, and dark gray. The 
right inset shows detailed structures within the pore, with the M2 domain (inner helix) of 
the dark gray subunit removed for clarity. C) Basal and baclofen-induced currents in cells 
expressing GABABR, GIRK2, and the depicted construct (n=6-17/group). A significant 
impact of group was observed for basal (F8,83=9.8, P<0.001) and baclofen-induced 
(F8,81=14.1; P<0.001) currents. Symbols: *** P<0.001 vs. GIRK2 homomer; 
##,### 
P<0.01 and P<0.001, respectively, vs. GIRK1/GIRK2 heteromer (only select 
comparisons shown). 
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Figure 2.12. Characterization of GIRK2 P-loop point mutants. A) Expression of myc-
tagged GIRK2 and P-loop mutants (upper blot), as assessed by quantitative 
immunoblotting (n=3 separate transfections). B) The intensity of GIRK2 and mutants 
was normalized to -actin (lower blot in A). A significant impact of group was observed 
(F7,23=11.9, P<0.001).  Symbols: * P<0.05 vs. GIRK2.  
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Subunit Conductance (pS) Open time (ms) 
GIRK1 35 ± 1 0.4 ± 0.5 (54%) 
22 ± 2 2.2 ± 0.4 (46%) 
TM 21 ± 1*
,†
 0.4 ± 0.5 (49%)*
,†
 
1.7 ± 0.3 (51%) 
M1-P 18 ± 1*
,†,‡
 0.2 ± 0.5 (56%)*
,†,‡
 
1.2 ± 0.3 (44%) 
P 17 ± 1*
,†,‡
 0.5 ± 0.3 (64%)*
,†,‡
 
2.4 ± 0.5 (36%) 
P-M2 17 ± 1*
,†,‡
 1.1 ± 0.1*
,†,‡,§
 
P(L173F) 13 ± 1*
,‡,§
 0.9 ± 0.1*
,†,‡
 
FAY 16 ± 1*
,†,‡
 0.2 ± 0.4 (60%)*
,†,‡
 
1.5 ± 0.3 (40%) 
FA 13 ± 1*
,‡,§
 0.7 ± 0.2*
,†,‡,§
 
S148F 14 ± 1*
,‡,§
 0.8 ± 0.1*
,†,‡,§
 
T153A 14 ± 1*
,‡,§
 0.8 ± 0.2*
,†,‡,§
 
V161Y 18 ± 1*
,†
 0.6 ± 0.1*
,†,‡,§
 
GIRK2 11 ± 1* 0.3 ± 0.2*
,‡
 
 
 
 
 
 
Table 2.1.  Summary of single-channel data. Single-channel conductance and open 
times derived from channel events (n = 250–892) measured in three to five cells 
expressing GIRK2 and the subunit listed on the left. Amplitude data were binned in a 
conventional histogram (0.2-pA bin width; 0.4- to 4.4-pA constraints), normalized, and 
fit using a Gaussian function. Models with different term number were compared 
automatically, and results from the optimal fit are listed here. Open-state dwell-time data 
were binned in a logarithmic histogram (15 bins per decade; 0.3- to 10-ms constraints). 
Square roots of bin counts were determined, and resultant histograms were fit using an 
exponential (log-probability) function. Optimal fits were determined for each channel. 
For two-term fits, the influence of each term is listed as a percentage. The 
GIRK2(V142P) mutant was not evaluated because of low-level whole-cell activity. *P < 
0.001 vs. GIRK1/GIRK2; 
†
P < 0.05 vs. GIRK2; 
‡
P < 0.05 vs. TM; 
§
P < 0.05 vs. P. 
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Discussion 
Previous chimeric studies explored the influence of intracellular and core domains 
of GIRK1 on channel function [110, 112, 113, 115], leading to the identification of N- 
and multiple C-terminal domains critical for promoting direct interactions with G, 
including the “L-M sheet” (residues 331-340) and L333 [57]. These structures form a 
binding pocket that maps onto the external face of an extended cytosolic ion permeation 
pathway [102]. Given the conservation of these and other critical domains across GIRK 
subunits, they cannot explain the potentiating influence of GIRK1 on GIRK currents. 
Moreover, while the distal C-terminal domain of GIRK1 (residues 325-501) can confer 
enhanced G–dependent activation to a heteromeric channel consisting of GIRK4 and 
an IRK1/GIRK1 chimera, robust receptor-induced currents required the GIRK1 core 
domain [110]. Thus, structural features of GIRK1 might enhance receptor-dependent 
GIRK signaling via mechanisms that do not involve G binding. 
Structural insights into the unique distal C-terminal domain of GIRK1 are limited 
as published crystal structures were derived from recombinant proteins lacking the distal 
regions of the N- and C-terminal domains. While this domain alone does not bind G, 
its presence significantly strengthened binding of G to the GIRK1 C-terminus [214]. 
Thus, the potentiating effect of GIRK1 on GIRK-dependent signaling might reflect in 
part the presence of distal C-terminal domain that confers a stronger association between 
the channel and G. Here, we identified a single residue within this domain (Q404) that 
selectively influences receptor-induced GIRK channel activity. Available evidence is 
consistent with the possibility that this residue strengthens the channel-G interaction. It 
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is also possible, however, that Q404 strengthens the allosteric coupling that translates 
G binding to an increase in channel gating. 
Three amino acids (F137, A142, Y150) in the P-loop were found to collaborate to 
enhance heteromeric channel activity, probably via the redistribution of intra-subunit 
interactions and strengthening of inter-subunit interactions that leads to enhanced single 
channel conductance and mean open time, and perhaps enhanced gating. F137 was 
identified previously as an enhancer of basal and receptor-dependent currents carried by 
the GIRK1/GIRK4 heteromer [114]. While the precise structural impact of the 
phenylalanine substitution is unknown, manipulations at this site influence diverse 
channel properties. Indeed, an S148T substitution in GIRK2 yields highly-active 
homomeric channels [215]. Perhaps more surprisingly, GIRK1(F137S) homomers reach 
the cell surface and are functional, despite the lack of an ER export signal that precludes 
surface trafficking of GIRK1 [68]. 
Our data show that the positive collective influence of F137, A142, Y150 on basal 
and receptor-induced GIRK currents is tempered by F162 in the GIRK1 M2 domain. 
Using the structure of the GIRK2 homomer as a template, one would predict that 
replacing L173 (the analogous position in GIRK2) with the relatively bulky 
phenylalanine would result in a Van der Waals interaction with I155 of the adjacent 
GIRK subunit, pushing I155 toward the K
+
 permeation pathway (Fig. 2.10C). In support 
of this contention, the unitary conductance of channels formed with P(L173F) was lower 
than that of the P chimera, and the longer mean open times (2.4 ms) observed with the P 
chimera were not seen for P(L173F). The relatively selective influence of this residue on 
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receptor-dependent current argues that it is involved in conformational changes in the 
channel triggered by G binding. 
While pore-related structures that enhance unitary properties should increase 
basal (and receptor-dependent) whole-cell current, we found that the domain between 
409-462 in the distal C-terminus is a significant and selective determinant of receptor-
independent channel activity. The impact of the distal C-terminus of GIRK1 on basal 
activity might relate to channel interactions with G subunits. Gi3 was found to interact 
with the distal GIRK1 C-terminus, leading to a reduction in basal activity and increased 
G–dependent activation of GIRK1(F137S) homomers [216]. In contrast, basal activity 
of GIRK2 homomers was insensitive to Gi3-dependent modulation. In light of the 
substantial basal activity of GIRK channels seen in neurons (e.g., [158]), refinement of 
the impact of the distal GIRK1 C-terminal domain on basal activity is warranted.  
The single-channel conductance and mean open time of GIRK1-containing 
channels are both larger than those of GIRK1-lacking channels. Our data reveal that 
GIRK1 core domain accounts for much of the influence of GIRK1 on mean open time, 
and some of its influence on unitary conductance. Presumably, structures in the proximal 
N- and/or C-terminal domains of GIRK1 that contribute to the cytoplasmic pore 
participate in modulating these unitary channel properties. Given the robust influence of 
GIRK1 on GIRK channel activity, it seems likely that GIRK1 also enhances other aspects 
of channel function, including gating. In addition to an inner helix gate formed by the 2
nd
 
transmembrane segments, GIRK channels possess a G-loop gate found near the interface 
of the cytoplasmic domain and membrane [93]. Binding of G to GIRK2 homomers 
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opens the G-loop gate in the absence of PIP2, and both G-loop and inner helix gates in the 
presence of PIP2 [93]. While these gates are conserved across GIRK subunits, GIRK1 
and GIRK2 do differ with regard to PIP2 affinity [111]. Subunit-dependent differences in 
channel modulation by Na
+
 also support the contention that subtle differences associated 
with GIRK channel gates may translate into significant differences in channel activity 
[98]. 
The existence of four GIRK subunit genes, and their overlapping but distinct 
expression patterns, suggests that subunit composition influences GIRK channel function 
in tangible ways. Given the critical contributions made by GIRK channels to complex 
behavior and organ physiology [57], a detailed understanding of intrinsic and extrinsic 
factors that influence channel function is warranted. Here, we explored the structural 
underpinnings of the clearest GIRK subunit-dependent functional difference described to 
date. These efforts have refined the map of features influencing receptor-dependent and 
independent activity of GIRK1-containing channels, the dominant GIRK channel type in 
the brain and heart. 
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CHAPTER 3 
 
Mechanisms underlying the activation of G protein-gated inwardly-
rectifying K
+
 (GIRK) channels by the novel anxiolytic drug, ML297 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wydeven N, Marron E, Du Y, Bennyworth M, Hearing M, Fischer R, Thomas M, 
Herring C, Weaver CD, Wickman K. Structural elements conferring selectivity of a 
novel anxiolytic compound (ML297) for G protein-gated inwardly-rectifying K+ 
(GIRK) channels containing GIRK1. Proc. Natl. Acad. Sci. USA 2014: Under Review. 
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Introduction 
Signal transduction involving inhibitory (Gi/o) G proteins titrates the excitability 
of neurons, cardiac myocytes, and endocrine cells, influencing behavior, cardiac output, 
and energy homeostasis [170]. G protein-gated inwardly-rectifying potassium (K
+
) 
(GIRK/Kir3) channels are a common effector for Gi/o-dependent signaling pathways in 
the heart and nervous system [57, 217]. Polymorphisms and mutations in human GIRK 
channels have been linked to arrhythmias, hyperaldosteronism (and associated 
hypertension), schizophrenia, sensitivity to analgesics, and alcohol dependence [170]. 
GIRK channels are activated by binding of the G protein G subunit [57, 170, 
217]. G binding strengthens channel affinity for phosphatidylinositol-4,5-bisphosphate 
(PIP2), a co-factor for channel gating [92, 101]. GIRK channels are also activated in a G 
protein-independent manner by ethanol [162, 163], volatile anesthetics [165, 218], and 
the flavonoid naringin [164]. Many psychoactive and clinically-relevant compounds with 
other primary molecular targets inhibit GIRK channels, albeit at relatively high doses 
[170, 219]. The lack of selective GIRK channel modulators, and in particular, drugs that 
discriminate among GIRK channel subtypes, has hampered investigation into their 
physiological relevance and therapeutic potential. 
GIRK channels are homo- and heterotetramers formed by GIRK1, GIRK2, 
GIRK3, and GIRK4 subunits [57, 217]. GIRK subunits exhibit overlapping but distinct 
cellular expression patterns, yielding multiple channel subtypes [170]. Though it cannot 
form functional homomers [68], GIRK1 is an integral subunit of the cardiac GIRK 
channel and most neuronal GIRK channels [63, 69]. GIRK1 confers robust basal and 
receptor-dependent activity to GIRK heteromers, attributable in part to unique residues in 
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the pore and second transmembrane domain [110, 114, 220]. The intracellular C-terminal 
domain also contributes to the potentiating influence of GIRK1 on channel activity, likely 
due to the presence of unique structures that modify the interaction between the channel 
and G, G, and PIP2, and render the channel susceptible to phosphoregulation [57, 170, 
217].  
Recently, we identified a new class of small molecule GIRK channel modulators 
[169]. The prototype (ML297) is a potent agonist selective for GIRK1-containing 
channels. At present, however, the selectivity of ML297 in vivo is untested and 
mechanisms underlying its selective activation of GIRK1-containing channels are 
unclear. The goals of this study were to identify the structural basis of ML297 efficacy 
and selectivity for GIRK1-containing channels, explore the mechanisms underlying 
channel activation, and probe further its therapeutic potential. We report that ML297 
activates GIRK1-containing channels in unique fashion, requiring only two amino acids 
unique to GIRK1, and suggest that ML297 or derivatives might represent a new class of 
anxiolytic compounds with limited sedative and addictive liabilities. 
 
Materials and Methods 
Animals—Animal experiments were approved by the Institutional Animal Care 
and Use Committee at the University of Minnesota. Male C57BL/6J mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME) for some behavioral studies. 
Wild-type and Girk1
–/–
 mice generated on-site from crosses of Girk1
+/–
 mice were used 
for other behavioral studies and for establishing hippocampal cultures. Generation of 
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Girk1
–/–
 mice was described previously [210]. The Girk1 null mutation was backcrossed 
against the C57BL/6J strain for >20 rounds prior to establishing the crosses in this study.  
Plasmids/DNA—Expression constructs for GABABR1, GABABR2, and Dr-VSP 
were kindly provided by Dr. Paul Slesinger; Dr-VSP was provided with the permission of 
Dr. Yasushi Okamura. Plasmids containing rat GIRK1 (GIRK1-AU5) and mouse 
GIRK2A (GIRK2-myc) coding sequences served as parent constructs for mutagenesis. 
GIRK1/GIRK2 chimeras were generated by overlap extension PCR [220], and point 
mutations were introduced using the QuikChange II XL site-directed mutagenesis kit 
(Agilent Technologies, Inc.; Santa Clara, CA). 
Whole-cell experiments—ML297 was synthesized in the Vanderbilt Institute of 
Chemical Biology Chemical Synthesis Core and Vanderbilt MLPCN Specialized 
Chemistry Center. Hippocampal cultures were prepared as described [146], and kept in 
culture for 10-14 d prior to electrophysiological analysis. HEK293 cells were maintained 
according to ATCC recommendations and were transfected using the calcium phosphate 
technique; electrophysiological studies were carried out 16-24 h later. Conditions for 
measuring and analyzing whole-cell drug-induced GIRK currents were described 
previously [220]. 
Data analysis—Data are presented as mean±SEM. Statistical analyses were done 
with Prism 5 (GraphPad Software, Inc.; La Jolla, CA) and SigmaPlot 11 (Systat 
Software, Inc.; San Jose, CA). The least squares fitting method was used for non-linear 
fitting of dose-response data, Hill co-efficient analysis, and EC50 analysis. Behavioral 
data were analyzed by one-way ANOVA or two-way ANOVA; Dunnett’s post hoc 
testing was used for pairwise comparisons, as appropriate. 
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Outside-out recordings—HEK293 cells stably expressing GIRK1/GIRK2 or 
GIRK2 alone were used for single-channel recordings [169]. For some experiments, cells 
were transfected with GABABR1 and GABABR2 using the calcium phosphate technique, 
and electrophysiological experiments were carried out 16-24 h later [220]. Borosilicate 
patch pipettes (3.5-4.5 MΩ) coated with HIPEC® R6101 elastomer (Dow Corning Corp.; 
Midland, MI) were filled with (in mM): 150 KCl, 1 MgCl2, 5 EGTA/KOH, 5 
HEPES/KOH (pH=7.4). The bath solution contained (in mM): 150 KCl, 1.8 CaCl2, 0.5 
MgCl2, 15 D-glucose, 5 HEPES/KOH (pH 7.4). To measure the impact of baclofen on 
unitary GIRK currents, Na2-ATP (2 mM) and Na-GTP (0.3 mM) were added to the 
pipette solution. After adopting the outside-out configuration, the holding potential was 
set to -70 mV. Bath solution containing ML297 (0.1, 0.25, and 1 M) or baclofen (100 
M) was applied to the chamber by gravity flow. Currents were recorded using an 
Axopatch 200B patch clamp amplifier (Molecular Devices), low-pass filtered at 2-5 kHz, 
sampled at 10 kHz, and stored on hard disk for analysis using pCLAMP v. 9.2 software.  
Analysis of single-channel parameters was performed on 10 s recordings taken 
before and after vehicle or drug application. To calculate channel mean open time, dwell-
time data were binned in a logarithmic histogram (15 bins/decade) using min/max 
constraints for amplitude (0.4-4.4 pA) and dwell-time (0.3-10 ms). Square roots of bin 
counts were determined and resultant histograms were fit using a standard exponential 
(log probability) function, with variable metric search method and maximum likelihood 
minimization method. Single-channel amplitude data were binned in a conventional 
histogram (0.2 pA bin width) using min/max constraints for amplitude (0.4-4.4 pA). 
Histograms were normalized and fit using a Gaussian function, with Levenberg-
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Marquardt search method and sum of squared errors minimization method. Models with 
different numbers of terms were compared automatically. Optimal model parameters for 
each channel type were determined. Open-state dwell-time data were analyzed using the 
Kolmogorov-Smirnoff test. Conductance of the channel was calculated plotting the 
amplitude values against different potential ranging from -50 to -100 mV and fitting the 
results to a linear regression. 
Thallium flux assays—Expression constructs used in the thallium flux assay were 
prepared from human GIRK expression plasmids described previously [169], using the 
GENEART site-directed mutagenesis system (Life Technologies; Carlsbad, CA); PCR 
reactions were conducted using AccuPrime Pfx DNA polymerase (Life Technologies). 
Amplified constructs were transformed into DH5-T1R cells (Life Technologies). DNA 
from selected colonies was obtained from liquid cultures and purified using the QIAprep 
Spin kit (Qiagen; Germantown, MD). 
HEK-293 cells (ATCC; Manassas, VA) were maintained in T75 flasks at 37°C 
and 5% CO2 in Minimal Essential Medium (Mediatech; Manassas, VA) containing 10% 
(v/v) fetal bovine serum (Sigma-Aldrich; Saint Louis, MO) and 1x Glutagro (Mediatech), 
referred to henceforth as cell culture medium. Cells were dislodged from 90% confluent 
T75 flasks (Corning) using TrypLE Express (Life Technologies). HEK cells in 
suspension (2 mL) in cell culture medium were added to 6-well plates to achieve ~60% 
confluence after one night of incubation at 37°C and 5% CO2. Transfections were 
performed using FuGENE® 6 (Promega; Madison, WI), according to manufacturer 
specifications. In brief, FuGENE® 6 was mixed with Opti-MEM (Life Technologies) and 
incubated for 5 min at room temperature. Subsequently, the mixture was combined by 
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gentle pipetting with expression plasmids. Following the 15 min incubation, the 
FuGENE/DNA mixture was added drop-wise to a well of a 6-well plate and mixed with a 
gentle side-to-side motion. Once the desired number of wells had been treated, the 6-well 
plates were returned to the cell culture incubator (37°C and 5% CO2) overnight. The next 
day, cells were lifted using TrypLE-Express, resuspended in cell culture medium (~500 
cells/L), and transferred to a total of 48 wells of an amine-coated, black-walled, clear-
bottom, 384-well plate (Beckton-Dickinson; Franklin Lakes, NJ). Additional 
transfections from the 6-well plate were added to the other wells of the 384-well plate 
with each plate always containing 48 wells of mock-transfected HEK-293 cells. Thus, 
each 384-well plate contained one set of mock-transfected controls and up to 7 
transfection conditions. 
Transiently-transfected cells in 384-well plates were incubated overnight at 37
o
 C 
and 5% CO2. The next day, cell culture medium was removed and replaced with 20 
L/well of a dye loading solution containing 0.4 M Thallos (TEFlabs, Austin, TX) in 
assay buffer (Hanks Balanced Salt Solution plus 20 mM HEPES, pH 7.3) and 0.04% 
(w/v) Pluronic F-127 (Sigma-Aldrich, St. Louis, MO). Following a 1-h incubation, the 
dye loading solution was replaced with assay buffer (20 L/well) and the plates were 
loaded into a Hamamatsu FDSS 6000 (Bridgewater, NJ). Data were acquired at 1 Hz 
(excitation 470±20 nm, emission 540±30 nm) for 10 s prior to the addition of assay 
buffer (20 L/well), a concentration series of ML297, or a single concentration of the 
non-selective GIRK inhibitor SCH23390 (Sigma-Aldrich). After 4 min, “5x” thallium 
stimulus buffer (10 L/well) was added and data collection continued for an additional 2 
min. The thallium stimulus buffer contained (in mM): 125 NaHCO3, 1.8 CaSO4, 1 
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MgSO4, 5 glucose, 2.4 Tl2SO4, 10 HEPES (pH 7.4). As a positive control, 4 
wells/transfection were tested with thallium stimulus buffer containing a 5% (v/v) 
solution (final concentration of 78 mM) of the non-selective GIRK channel activator 
methyl pentanediol (MPD; Sigma).  
     ML297 was dissolved in DMSO to concentrations of 10 mM, diluted by hand in 
7 x 3-fold steps in DMSO, and then further diluted in assay buffer (1:500) to achieve 
“2x” solutions. Diluted samples were used within 1 h of dilution. Final DMSO 
concentrations in all studies were 0.1%. Changes in thallium flux induced by either 
ML297 or MPD were analyzed as described
1
; in brief, each point in each wave was 
divided by the first point in that wave (F/F0). Then, the average wave arising from 
vehicle-control wells for each transfected construct was subtracted from waves measured 
in ML297- or MPD-treated wells. The slopes of these vehicle control-subtracted waves 
were calculated from 10 data points beginning 2 s after thallium stimulus addition. The 
choice to use slope values instead of amplitudes helped prevent shifts in potency that can 
result from indicator dye or detector saturation due to large increases in channel activity. 
For each wild-type and mutant construct tested, the slope values obtained from a 
maximally-effective concentration of ML297 (10 M) were divided by the slope values 
obtained in 78 mM MPD, and thus the efficacy of ML297 for each wild-type and mutant 
construct is expressed as a percentage of MPD efficacy for that same construct.  
Behavioral assays—For the motor activity study, mice were injected with ML297 
(3, 10, 30, or 60 mg/kg i.p.) or vehicle (saline + 10% Tween-80), placed into a novel 
open-field environment (22x42 cm), and activity was monitored by video camera for 60 
min. Distance traveled was determined by video analysis software (ANY-maze
TM
 v4.96; 
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Stoelting Co., Wood Dale, IL). Anxiety-related behavior was measured using an elevated 
plus maze (EPM, Med-Associates, Inc.; St. Albans, VT). Thirty minutes prior to testing, 
mice were injected with ML297 (3, 10, or 30 mg/kg i.p.) or vehicle (0.5% hydroxypropyl 
cellulose/4% DMSO); these dosing conditions were used for subsequent tests as well. 
Mice were placed in the center of the EPM, and the time spent within the open and closed 
arms, along with total distance traveled, was recorded for 5 min. Anxiety-like behavior 
was determined by the proportion of arm exploration in the open arm (open arm 
time/(open arm + closed arm time)). For the stress-induced hyperthermia (SIH) test, mice 
were injected with ML297 or vehicle 30 min prior to testing. Subsequently, an initial 
rectal temperature was determined using a RET-3 rectal probe (Physitemp Instruments, 
Inc.; Clifton, NJ); the probe was dipped into silicon oil, inserted ~1.5 cm into the rectum, 
and held there until a stable rectal temperature was observed (~20 s). Mice were then 
returned to their home cage for 10 min, followed by second rectal temperature 
measurement. The difference between the second and first temperature measurements 
was determined and evaluated across treatment groups. The forced swim test (FST) was 
conducted with clear cylinders (18-cm diameter x 25 cm tall) filled up to 13 cm with 
25°C water. Animals were placed in the water and movement was tracked from the side 
by a video camera. Immobility in the last 4 min of a 6-min session was determined using 
ANY-maze
TM
 software. 
The conditioned place preference (CPP) test spanned 12 d and was conducted in 
an apparatus (22x45x20 cm) divided into two compartments by an opaque wall with 
guillotine-style door. The floor of one compartment consisted of an array of 2.3 mm 
stainless steel rods, centered every 6.4 mm (grid). The floor of the other compartment 
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consisted thin chicken wire with openings of 2.5x2.5 mm (mesh). All data were acquired 
by video camera and movements analyzed with ANY-maze
TM
 software. Prior to 
beginning the study, mice were habituated to experimenter by 5 d of handling. During the 
pre-conditioning test, mice were placed in the apparatus and allowed free exploration for 
20 min; time spent in the “grid” and “mesh” chambers was recorded. Any mice 
displaying a severe preference (>800 s) for any one side were excluded from further 
testing.  Mice were then assigned to drug treatment (3, 10, or 30 mg/kg ML297) or 
vehicle (0.5% hydroxypropyl cellulose and 4% DMSO in water) treatment groups, and 
paired with either the “grid” or “mesh” compartment (CS+). The other chamber (CS-) 
was paired with a saline treatment. Assignments were counterbalanced based upon pre-
conditioning test performance. During the conditioning trials, subjects were injected with 
either drug or vehicle, and after a 15-min delay were confined for 30 min in the 
corresponding CS+ chamber. A total of 4 drug/vehicle and 4 saline trials were performed 
in alternating fashion, with only one trial performed per day. Side preferences were 
evaluated twice, first on the day following the 4
th
 conditioning session, and again on the 
day after the final conditioning session. Place preference was determined by calculating 
the difference in time spent in the CS+ and CS- chambers during the test sessions; 
“Preference” is defined as CS+ - CS- within a given test session. 
 
Results 
We began by comparing whole-cell currents evoked by ML297 and the GABAB 
receptor (GABABR) agonist baclofen in transfected HEK293 cells. ML297 evoked 
concentration-dependent inward currents in cells expressing GABABR and the 
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prototypical neuronal GIRK channel (GIRK1/GIRK2; Fig. 3.1A). The EC50 for ML297-
induced activation of GIRK1/GIRK2 channels was 233±38 nM; 10 μM ML297 evoked a 
maximal response (Fig. 3.1B). Activation and deactivation kinetics of the ML297-
induced current were concentration-dependent, increasing and decreasing, respectively, 
with higher ML297 concentrations (Fig. 3.1C). Maximal ML297-induced currents were 
larger than those evoked by a saturating concentration of baclofen (100 M; Fig. 3.1D). 
Reversal potentials measured for basal, baclofen-induced, and ML297-induced GIRK 
currents were comparable and close to the predicted value for a K
+
-selective channel 
(EK= -43 mV; Fig. 3.1E). Inward rectification, however, was markedly stronger for basal 
and baclofen-induced currents than for ML297-induced current (Fig. 3.1E,F). 
We next measured the effect of ML297 on GIRK1/GIRK2 channels in outside-out 
patches from transfected cells (Fig. 3.2). ML297 evoked a concentration-dependent 
increase in activity (NPo) of GIRK1/GIRK2 channels (Fig. 3.2A,B), but had no effect on 
GIRK2 homomers (Fig. 3.2B). At the highest ML297 concentration tested (1 M), 
GIRK1/GIRK2 channel activity was enhanced 8-fold over basal levels, complicating 
extraction of unitary channel properties. At lower concentrations (100 nM), ML297 
promoted the occurrence of longer opening events without altering single channel 
conductance (29.30.5 pS before vs. 31.31.5 pS after; P=0.3) (Fig. 3.2A,C). Baclofen 
(100 M) also increased channel activity without altering single-channel conductance 
(29.30.5 pS before vs. 29.11.6 pS after; P=0.9). In contrast to ML297, however, 
baclofen primarily increased the frequency of shorter-lived events (Fig. 3.2D). 
Collectively, data from whole-cell and single-channel experiments suggested that 
baclofen and ML297 activate GIRK channels in distinct manners.   
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We next examined the impact of the Danio rerio voltage-sensitive phosphatase 
(Dr-VSP) on baclofen- and ML297-induced GIRK currents (Fig. 3.3). Dr-VSP is 
activated by strong depolarization, leading to depletion of membrane-bound PIP2 [221]. 
GIRK currents induced by baclofen and ML297 were recorded twice in each cell, once 
prior to and once after Dr-VSP activation (Fig. 3.3A). GIRK currents induced by 
baclofen and ML297 were strongly attenuated following Dr-VSP activation (Fig. 
3.3A,B). In contrast, no attenuation of GIRK currents was seen in cells lacking Dr-VSP 
(Fig. 3.3C). Thus, ML297-induced activation of GIRK1-containing channels, like other 
modes of GIRK channel activation, requires PIP2. 
To test whether the potency, efficacy, and selectivity of ML297 for GIRK1-
containing channels are retained in cells that normally express GIRK channels, we next 
measured ML297-induced currents in cultured hippocampal neurons, which express 
GIRK1, GIRK2, and GIRK3 [109]. ML297 evoked a concentration-dependent inward 
current (Vhold = -70 mV) in pyramidal-shaped hippocampal neurons from wild-type mice 
(Fig. 3.4A,B). The EC50 (377±70 nM) was comparable to that measured with 
recombinant GIRK1/GIRK2 channels (233±38 nM; Fig. 3.1B), and ML297-induced 
current kinetics in hippocampal neurons showed a concentration dependence comparable 
to that seen in transfected cells (Fig. 2.4C). Currents evoked by application of 10 M 
ML297 were comparable in magnitude to those evoked by a saturating concentration of 
baclofen (100 M; Fig. 3.5A,B). Unlike baclofen-induced responses, however, ML297-
induced currents showed little acute desensitization (Fig. 3.5C), and the kinetics were 
slower than those measured for baclofen (Fig. 3.5D). Importantly, while ML297 and 
vehicle had negligible effects on holding current in neurons from Girk1
–/–
 mice, baclofen 
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evoked reliable (albeit small) currents in these neurons (Fig. 3.5A,B), likely attributable 
to activation of residual GIRK1-lacking channels [220].  
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Figure 3.1. ML297- and baclofen-induced GIRK currents: whole-cell. (A) Trace 
showing the effect of increasing concentrations of ML297 on holding current (Vhold = -70 
mV) in a cell expressing GABABR, GIRK1, and GIRK2. Horizontal bars above the trace 
denote the duration of ML297 application. (B) Concentration-response of ML297-evoked 
currents in transfected cells. Steady-state currents at each concentration were normalized 
to the response measured with 10 µM ML297 (n=6 recordings/concentration). (C) 
Activation and deactivation kinetics (, time constant) for the ML297-induced current in 
transfected cells. A significant effect of concentration was observed for both activation 
(F3,21=10.2; P<0.001) and deactivation (F3,21=4.8; P<0.05) rate. *,***P<0.05 and 0.001, 
respectively, vs. 30 M ML297. (D) Peak currents evoked by vehicle (V, 0.1% DMSO), 
baclofen (B, 100 M), or ML297 (M, 10 M) in cells expressing GABABR, GIRK1, and 
GIRK2 (F2,26=12.2; P<0.001, n=4-15/condition) or GABABR and GIRK2 alone (t10=3.1; 
P<0.05, n=6 recordings/group). *,**P<0.05 and 0.01, respectively. (E) I-V plot for basal 
GIRK current (measured in 25 mM K
+
, circles), together with plots for GIRK currents 
evoked by baclofen (100 μM; squares) or ML297 (10 μM; triangles) (n=3 
recordings/group). (F) Rectification index (ratio of current measured at 0 mV and -80 
mV) for basal GIRK current (‘Basal’), or GIRK currents evoked by baclofen (B, 100 μM) 
or ML297 (M, 10 μM). A significant impact of group on rectification index was observed 
(F2,11=5.5; P<0.05). *P<0.05 vs. basal and baclofen groups. 
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Figure 3.2. ML297- and baclofen-induced GIRK currents: single-channel. (a) 
Representative traces showing the effect of 100 nM and 1 M ML297 on the activity of 
recombinant GIRK1/GIRK2 channels measured in the outside-out configuration. 
Segments of the recording made prior to and after application of 100 nM ML297 are 
shown below on an expanded time scale. (b) Summary of the impact of ML297 (0, 0.1, 
0.25, 1 M) on the activity (NPo) of recombinant GIRK1/GIRK2 heteromeric (filled 
bars) and GIRK2 homomeric (open bar) channels. NPo data were normalized to channel 
activity (basal) measured prior to drug application. A significant effect of concentration 
was seen for experiments involving GIRK1/GIRK2 channels (F3,13=29.7; P<0.001). 
**,***P<0.01 and 0.001, respectively, vs. basal activity (0 M). (c) Open time 
histograms and curve fits for GIRK1/GIRK2 channel activity measured before (gray) and 
after (black) application of ML297 (100 nM). Histograms were fit best with a double 
exponential; pre-application values were 0.30.2 ms and 1.00.4 ms. After ML297 
application, corresponding values were 0.40.1 ms and 1.80.2 ms (pre vs. post 
comparison; K-S statistic = 0.047, 19759 events; P<0.001). (d) Open time histograms 
and curve fits for GIRK1/GIRK2 channel activity measured before (gray) and after 
(black) the application of baclofen (100 M, left). Histograms were fit best with a double 
exponential function; pre-baclofen open time values were 0.30.2 ms and 1.00.2 ms. 
After baclofen, the corresponding values were 0.20.3 ms and 0.70.2 ms (pre vs. post 
comparison; K-S statistic = 0.105, 58196 events; P<0.001).  
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Figure 3.3. ML297- and baclofen-induced GIRK currents: PIP2 dependence. (A) 
Traces showing the effect of PIP2 depletion on currents evoked by baclofen- (B, 100 M) 
and ML297- (M, 10 M). Black dashes denote the cell being held at -70 mV, keeping Dr-
VSP in an inactive state. Step symbols (
┌┐┌┐
) denote the Dr-VSP activation protocol, 
which involved alternating 500 ms voltage steps between -70 and +100 mV; at least 120 
steps to +100 mV were made prior to the 2
nd
 application of baclofen and ML297. (B) 
Summary of responses evoked by baclofen (B, 100 M) and ML297 (M, 10 M) in cells 
expressing GABABR, GIRK1, GIRK2, and Dr-VSP. Peak amplitudes of the 2
nd
 
responses were normalized to the amplitude of the first response. Dr-VSP activation 
significantly decreased baclofen- (t16=4.6; P<0.001) and ML297- (t16=2.3; P<0.05) 
induced currents (n=9 recordings/condition). *,***P<0.05 and 0.001, respectively. (C) 
Summary of responses evoked by baclofen (B, 100 M) and ML297 (M, 10 M) in cells 
expressing GABABR, GIRK1, GIRK2, and empty vector (no Dr-VSP). No significant 
difference in peak current was observed between 1
st
 and 2
nd
 applications of either 
baclofen (t6=0.7; P=0.5) or ML297 (t6=0.1; P=0.9) groups (n=4 recordings/condition). 
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Figure 3.4. ML297- and baclofen-induced GIRK currents in hippocampal neurons. 
(A) Trace showing the effect of increasing concentrations of ML297 on holding current 
(Vhold = -70 mV) in a wild-type hippocampal neuron. (B) Concentration-response 
analysis of ML297-evoked currents in hippocampal neurons from wild-type mice. 
Steady-state currents at each concentration were normalized to the response measured 
with 10 M ML297 (n=5-6 recordings/concentration). (C) Activation (F2,16=30.0; 
P<0.001) and deactivation (F2,16=5.0; P<0.05) kinetics for the ML297-induced current in 
hippocampal neurons. *,***P<0.05 and 0.001, respectively, vs. 30 M ML297. 
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Figure 3.5. ML297- and baclofen-induced GIRK currents in hippocampal neurons. 
(A) Traces showing the relative effects of vehicle (V, 0.1% DMSO), baclofen (B, 100 
µM), and ML297 (M, 10 µM) on holding currents in neurons from wild-type (upper 
trace) and Girk1
–/–
 (lower trace) mice. (B) Summary of peak currents evoked by vehicle 
(0.1% DMSO), baclofen (100 M), and ML297 (10 M) in neurons from wild-type (wt) 
and Girk1
–/–
 (G1
–/–
) mice; a significant genotype x drug interaction was observed 
(F2,43=16.4; P<0.001). ***P<0.001 (within drug); 
###
P<0.001 vs. ML297 (within 
genotype). (C) Acute desensitization of currents induced by baclofen (100 M) and 
ML297 (10 M), measured by comparing peak currents with currents measured 20 s after 
drug application. Baclofen-induced currents showed modest acute desensitization (20%), 
while ML297-induced currents did not (t12=4.2, P<0.01). **P<0.01. (D) Activation 
(t8=12.8, P<0.001) and deactivation (t8=6.5, P<0.001) kinetics of currents induced by 
baclofen (B, 100 M) and ML297 (M, 10 M) in hippocampal neurons from wild-type 
mice. ***P<0.001. 
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  To identify structural elements in GIRK1 required for ML297-induced channel 
activation, we used a thallium flux assay to compare responses induced by ML297 and 
the short-chain alcohol methyl pentanediol (MPD, a non-selective GIRK channel agonist) 
in cells co-expressing GIRK2 and either GIRK1 or a chimera harboring discrete GIRK1 
sub-domains on a GIRK2 backbone (Fig. 3.6). We demonstrated previously that these 
GIRK1/GIRK2 chimeras interact with wild-type GIRK2 and promote levels of GIRK2-
containing channels on the cell surface comparable to wild-type GIRK1 [220]. Using this 
approach, we found that while the non-selective GIRK agonist MPD was efficacious for 
all constructs evaluated, the P-M2 domain in GIRK1, which contains the pore helix/K
+
 
selectivity filter and second membrane-spanning domain, was critical for ML297 efficacy 
(Fig. 3.6A,B).  
  Based on the sequence alignment between GIRK1 and GIRK2 within the P-M2 
domain (Fig. 3.7A), we next mutated residues in GIRK1 to match the corresponding 
residues in GIRK2 in an effort to identify specific amino acids required for the ML297-
induced activation of GIRK1-containing channels. Two GIRK1 residues (F137 and 
D173) were identified using this approach (Fig. 3.6B). In cells expressing GIRK2 and 
either GIRK1
F137S
 or GIRK1
D173N
, ML297-induced channel activation was virtually 
absent, while activation by MPD was preserved. Introduction of either of these GIRK1 
residues individually into GIRK2 (S148F or N184D) failed to restore ML297 sensitivity. 
In cells expressing GIRK2 and the GIRK2 mutant harboring both GIRK1 residues 
(GIRK2
F/D
), ML297-induced channel activation was restored. 
To extend these findings, ML297-induced whole-cell currents were compared in 
cells expressing GIRK2 and either GIRK1, GIRK1
F137S
, GIRK1
D173N
, GIRK1
S/N
, 
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GIRK2
S148F
, GIRK2
N184D
, or GIRK2
F/D
 (Fig. 3.7B,C). Similar to the thallium flux results, 
ML297-induced whole-cell currents were strongly-attenuated or undetectable in cells 
expressing GIRK2 and either GIRK1
F137S
, GIRK1
D173N
, GIRK1
S/N
, GIRK2
S148F
, or 
GIRK2
N184D
 (Fig. 3.7C). ML297-induced currents were normal, however, in cells 
expressing GIRK2 and GIRK2
F/D 
(Fig. 3.7B,C). ML297-induced current kinetics were 
slower for GIRK2
F/D
/GIRK2 channels as compared to GIRK1/GIRK2 channels (Fig. 
3.7D,E). Finally, the I-V profiles of basal, ML297-induced, and baclofen-induced 
currents carried by GIRK2
F/D
/GIRK2 channels were comparable to those observed for 
GIRK1/GIRK2 channels, with ML297 significantly weakening channel inward 
rectification (Fig. 3.8A,B). Thus, GIRK1 residues F137 and D173 are necessary for the 
ML297-induced activation of GIRK1/GIRK2 channels, and are sufficient to confer 
ML297 sensitivity to GIRK2.  
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Figure 3.6. Structural elements of GIRK1 required for ML297 activation. (A) 
Schematic depiction of the GIRK1/GIRK2 chimeras used to localize structural elements 
required for the ML297-induced activation of GIRK1-containing channels. Residues 
differing between GIRK1 and GIRK2 in the P-M2 region are highlighted, including the 
two residues required for ML297-induced channel activation. (B) Thallium flux induced 
by 10 M ML297 in cells expressing GIRK2 and the construct designated below the X-
axis, expressed as a percentage of the response of the same cells to MPD (%MPD). 
Constructs depicted in panel (A) are presented on the left side of the plot, with more 
selective point mutations introduced into the Pore (P), P-M2, GIRK1, and GIRK2 
backbones on the right.  
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Figure 3.7. Structural elements in GIRK1 required for ML297 activation. (A) 
Alignment of core domains of GIRK1 and GIRK2: M1 (1
st
 membrane-spanning domain), 
x1 (1
st
 extracellular loop), pore helix, K
+
-selectivity filter, x2 (2
nd
 extracellular domain), 
M2 (2
nd
 transmembrane spanning domain). Arrowheads identify the GIRK1 residues 
required for ML297 activation. (B) Traces showing currents evoked by ML297 (10 M) 
in cells expressing GABABR and either GIRK1/GIRK2 or GIRK2
FD
/GIRK2. (C) 
Summary of ML297-induced peak currents measured in cells expressing GABABR, 
GIRK2, and either GIRK1, GIRK2, or GIRK mutant (n=4-6/group). A significant impact 
of group was found for ML297-induced currents for the GIRK1 mutant series 
(upper/black, F3,20=18.9; P<0.001), and for the ML297-induced peak currents for the 
GIRK2 mutant series (lower/gray, F3,19=45.4; P<0.001). **P<0.01 vs. GIRK1; 
++
P<0.01 
vs. GIRK2. Significant differences were found for (D) activation (t12=4.3, P<0.01) and 
(E) deactivation kinetics (t10=3.6, P<0.01) of ML297-induced currents carried by cells 
expressing GIRK2 and either GIRK1 or GIRK2
F/D
 (n=6-8/group). **P<0.01. 
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Figure 3.8. Structural elements in GIRK1 required for ML297 activation. (A) I-V 
plots for basal GIRK currents (circles), together with plots for GIRK currents evoked by 
baclofen (100 M, squares) or ML297 (10 M, triangles), in cells expressing GIRK2 and 
GIRK2
F/D
 (n=3 recordings/condition). (B) Rectification index for basal GIRK currents 
(‘Basal’) and GIRK currents evoked by baclofen (B, 100 M) or ML297 (M, 10 M) in 
cells expressing GABABR, GIRK2, and GIRK2
F/D
. A significant impact of group on 
rectification index was observed (F2,8=45.6; P<0.02). *P<0.05 vs. basal and baclofen 
groups. 
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Previously, we reported that ML297 was protective in rat epilepsy models [169]. 
To further investigate the behavioral effects of ML297, we probed its efficacy in tests of 
motor activity, reward, depression, and anxiety. We began with an open-field motor 
activity test involving wild-type C57BL/6J mice. We found that at the highest dose tested 
(60 mg/kg, the dose used in the seizure studies; [169]), ML297 suppressed motor activity 
(Fig. 3.9A). Lower doses (3, 10, and 30 mg/kg), however, had no impact on motor 
activity. Thus, to avoid the potentially confounding effect of ML297 on motor activity, 
30 mg/kg was selected as the maximum dose used in subsequent behavioral tests. 
ML297 did not exhibit significant reinforcing effects in wild-type mice as 
measured using a conditioned place preference (CPP) test (Fig. 3.9B), nor did it exhibit 
anti-depressant efficacy in the forced swim test (FST, Fig. 3.9C,D). ML297 did evoke a 
dose-dependent decrease in anxiety-related behavior in the elevated plus maze (EPM) 
test, increasing time spent in the open arms of the maze (Fig. 3.9E). Similarly, ML297 
produced a dose-dependent suppression of stress-induced hyperthermia (SIH; Fig. 3.9F), 
a motor activity-independent physiological stress response blunted by anxiolytic drugs 
[222].  
We repeated EPM and SIH tests using a cohort of wild-type and Girk1
–/–
 siblings. 
Consistent with published data for Girk2
–/–
 mice [223, 224], Girk1
–/–
 mice exhibited less 
anxiety-related behavior than wild-type controls in the EPM test (Fig. 3.9G). No 
additional anxiolytic effect of ML297 was observed in Girk1
–/–
 mice, however, ML297 
increased time spent in the open arm in the wild-type group. Similarly, no anxiolytic 
effect of ML297 was observed in Girk1
–/–
 mice during the SIH test (Fig. 3.9H). 
Collectively, these results argue that the anxiolytic effect of ML297 observed in wild-
        Rgs regulation of cardiac muscarinic signaling 
  84 
type mice is primarily, if not exclusively, attributable to activation of GIRK1-containing 
channels.   
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Figure 3.9. Behavioral impact of ML297. (A) Total distance traveled (m) by C57BL/6J 
mice in 1 h in a novel open-field following injection of ML297 (0/vehicle, 3, 10, 30, 60 
mg/kg i.p.; n=11-12 mice/dose). A significant effect of dose was observed (F4,58=3.2; 
P<0.05). **P<0.01 vs. 0/vehicle. (B) Difference in time spent by C57BL/6J mice in the 
drug-paired and unpaired sides of a CPP chamber, measured on the first day of testing 
(pre-test, white bars), and after 4 conditioning sessions with ML297 (0/vehicle, 3, 10, or 
30 mg/kg i.p.; n=12-13 mice/dose). No significant effect of group was observed for either 
the pre-test (F3,48=0.5; P=0.65) or test day (F3,48=1.5; P=0.24). C,D) Total immobility 
time (C, F3,43=0.5; P=0.70) and latency to first immobility period (D, F3,43=0.9; P=0.46) 
measured for C57BL/6J mice during a 6-min forced swim test 30 min following injection 
of ML297 (0/vehicle, 3, 10, or 30 mg/kg i.p.; n=11 mice/dose). E) Percent time spent in 
the open arms (F3,43=3.8; P<0.05) by C57BL/6J mice in a 5-min elevated plus maze test 
performed 30 min after injection of ML297 (0/vehicle, 3, 10, or 30 mg/kg i.p.; n=10-12 
mice/dose). **P<0.01 vs. 0/vehicle. (F) Effect of ML297 on stress-induced hyperthermia 
response in C57BL/6J mice. Change in temperature (ΔT, in °C) from the point of stress 
(T1) taken 30 min after injection of ML297 (0/vehicle, 3, 10, or 30 mg/kg i.p.; n=12 
mice/dose) to 10 min after stress (T2). A significant effect of dose was detected 
(F3,47=4.9; P<0.01). *,** P<0.05, 0.01, respectively, vs. 0/vehicle. (G) Percent time spent 
in the open arms by wild-type and congenic Girk1
–/–
 mice in a 5-min elevated plus maze 
test performed 30 min after injection of ML297 (0/vehicle or 30 mg/kg i.p.; n=11-16 
mice/group). A significant drug x genotype interaction (F1,52=7.0; P<0.01) was observed. 
Note the decreased baseline (vehicle group) anxiety-related behavior in Girk1
–/–
 mice. 
*P<0.05 vs. 0/vehicle (within genotype); 
###
P<0.001 vs. wild-type (within-dose). (H) 
Effect of ML297 (0/vehicle or 30 mg/kg i.p.; n=11-16 mice/group) on stress-induced 
hyperthermia response in wild-type and congenic Girk
–/–
 mice. A significant drug x 
genotype interaction (F1,36=4.2; P<0.05) was observed.  **P<0.01 vs. 0/vehicle (within 
genotype).  
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Discussion 
The classical mode of GIRK channel activation involves the receptor-induced 
activation of Gi/o G proteins, which facilitates an interaction between channel and G. 
Several lines of evidence argue that ML297-induced activation of GIRK channels differs 
mechanistically from this mode of channel activation. For example, ML297 activation of 
GIRK1-containing channels is not impacted by pertussis toxin, an inhibitor of Gi/o G 
proteins [169]. In addition, ML297 selectively activates GIRK1-containing channels, 
whereas G activates both GIRK1-containing and GIRK1-lacking channels (e.g.,
 
[64]).  
Clear resolution of the channel-G interaction was obtained with the co-
crystallization of G and a GIRK2 homomer [106]. G binds to an outward-facing 
surface created by two adjacent GIRK cytoplasmic domains (the K, L, M, and N 
sheets from one subunit, and the D and E sheets from the adjacent subunit; Fig. 
3.10A). GIRK2 residues mediating the GIRK-G interaction include Q248 and F254 in 
D-E, and L342-T343-L344 in L-M. The GIRK-G interaction is electrostatic, 
facilitated by negatively-charged glutamic and aspartic acid residues found in the L-M 
loop that attract the electropositive binding face on G. Importantly, key elements of this 
interaction interface are conserved across all GIRK subunits, including GIRK1. 
ML297-induced activation of GIRK channels also differs from channel 
modulation by other known channel activators. Intracellular Na
+
 (EC50 30-40 mM) 
activates neuronal and cardiac GIRK channels in a manner dependent on an aspartic acid 
residue found in the βC-βD loop of GIRK2 and GIRK4, respectively [98, 100]. This 
residue, which contributes to the binding site for Na
+
 [93], is not found in GIRK1. 
Ethanol activates both GIRK1-containing and lacking channels in a G protein-
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independent manner, without altering the strong rectification profile [162, 163]. The 
hydrophobic alcohol-binding pocket in GIRK2 homomers is formed by a residue in the 
N-terminus (Y58) and two residues in the βL-βM sheet from one subunit (L342 and 
Y349), together with three residues in the βD-βE sheet from the adjacent subunit (I244, 
P256, L257) [167]. As is the case for structures involved in mediating channel 
interactions with G and Na
+
, the structures mediating channel-alcohol interactions are 
largely conserved in GIRK1 [162, 163]. Furthermore, we show here that we can eliminate 
ML297-induced activation of GIRK channels without altering their sensitivity to MPD. 
While GIRK channel activation via G, ethanol, and Na
+
 involves unique 
structural determinants, these agents (and ML297) require membrane-bound PIP2 to 
activate GIRK channels. PIP2 interacts with lysine residues found at the interface 
between the transmembrane and cytoplasmic domains of GIRK subunits. Binding of G, 
ethanol, and Na
+
 to GIRK channels strengthens channel affinity for PIP2 [92, 97, 166]. 
PIP2 binding triggers a rotation of the inner transmembrane helices, displacing the inner 
helical gate found at the junction of the transmembrane and cytoplasmic domains. With 
PIP2 present, GIRK channels are ‘primed’ for activation. Indeed, Gβγ binding (in the 
presence of PIP2) leads to opening of the inner-helical gate and the G-loop gate, which is 
formed by the inner face of the cytosolic domains; G in the absence of PIP2 can only 
open the G-loop gate [93, 106]. We propose that ML297, like other channel agonists, 
ultimately activates GIRK channels by opening inner-helical and G loop gates. 
Our data argue that ML297 interacts directly with GIRK1-containing channels. 
Indeed, the observations that one of the GIRK1 residues (D173) required for ML297 
agonism has been linked to inward rectification [225] and that ML297 weakens the 
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inward rectification of the channel are difficult to reconcile with an indirect mechanism 
of action for ML297. Moreover, the relatively close spatial proximity of the two GIRK1 
residues necessary and sufficient for ML297 agonism suggests the possibility that ML297 
binds within a pocket formed by one or both residues [93] (Fig. 3.10B). We cannot 
exclude the possibility, however, that ML297 binds to other domains of GIRK1 or to 
domain(s) conserved across all GIRK subunits. ML297 may bind to both GIRK1/GIRK2 
heteromers and GIRK2 homomers, for example, but residues F137 and D173 in GIRK1 
translate ML297 binding to enhanced channel activity better than their counterparts in 
GIRK2. Indeed, these residues were implicated previously in studies aimed at identifying 
structures in GIRK1 that potentiate basal and receptor-induced activity of heteromeric 
GIRK channels [114, 220]. Moreover, we show that the deactivation rate of ML297-
induced current carried by GIRK2
F/D
/GIRK2 heteromers was substantially slower than 
that observed for GIRK1/GIRK2 heteromers. Since deactivation rate for a direct-acting 
channel agonist should largely reflect agonist-channel affinity, these findings support the 
contention that structures in GIRK2 influence the ML297-GIRK channel interaction. This 
contention is further supported by the observation that some ML297 derivatives show 
differential selectivity for GIRK1/GIRK2 and GIRK1/GIRK4 channels [226]. 
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Figure 3.10. Structural elements involved in GIRK channel activation by G, PIP2, 
Na
+
, and ML297. (A) Crystal structure of the GIRK2 homomer bound to G (Protein 
Data Bank (PDB) ID code 4KFM), with regions critical for binding PIP2, alcohol, and 
Na
+
 denoted by arrows. Note that only 2 bound G complexes are displayed, in the 
interest of clarity. The extracellular, transmembrane, and intracellular domains of the four 
GIRK2 subunits are shown. Specific locations of residues forming binding sites for PIP2 
[93, 106], alcohol [167], and Na
+
 [93] are shaded and denoted by arrows. (B) An 
expanded view of the transmembrane domain depicting the predicted locations of the 
GIRK1 residues (F137 and D173, shown by arrows) identified as necessary and sufficient 
for conferring ML297 sensitivity to GIRK channels. The locations of the pore helix 
(which contains F137) and 2
nd
 membrane-spanning domain (which contains D173) are 
highlighted. Three K
+
 ions are shown (spheres) to identify the location of the 
transmembrane permeation pathway. 
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ML297 reduced anxiety-related behavior in mice in a GIRK1-dependent manner, 
without displaying rewarding or sedative effects. Interestingly, genetic ablation of Girk1 
(this study) or Girk2 also correlated with reduced anxiety-related behavior in mice [223, 
224]. The similarity in behavioral outcome for Girk ablation and acute systemic 
pharmacologic GIRK activation is likely attributable to molecular and/or developmental 
compensation occurring secondary to constitutive gene ablation in knockout studies. 
Indeed, altered glutamatergic signaling has been documented in multiple neuron 
populations in Girk1
–/–
 and Girk2
–/–
 mice [227, 228].    
The sensitivity of GIRK channels to ethanol suggests that GIRK channels are 
relevant molecular targets for alcohol [162, 163]. In support of this contention, wild-type 
but not Girk2
–/–
 mice, developed a conditioned place preference to ethanol [229]. Thus, 
GIRK channel activation might underlie in part the rewarding effect of ethanol. ML297, 
however, did not evoke a conditioned place preference in wild-type mice. A possible 
explanation for the differential reward liability of ethanol and ML297 is that the reward-
related, GIRK-dependent effects of ethanol are mediated by GIRK channels lacking 
GIRK1. In this context, it is noteworthy that dopamine neurons in the ventral tegmental 
area, a key anatomic substrate of addictive drugs, express GIRK2/GIRK3 heteromers 
[87].     
The lack of potent and selective pharmacologic tools for studying GIRK channels has 
limited progress on understanding their physiological and pathophysiological relevance. 
Translational benefits associated with inhibiting or enhancing GIRK signaling are 
unlikely to be achieved without an ability to manipulate GIRK signaling in a region 
and/or subunit-selective manner. Here, we show that ML297 selectively activates native 
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GIRK1-containing channels, decreasing anxiety-related behavior at doses without 
associated reward or motor liabilities. Thus, ML297 – or perhaps its next-generation 
derivatives – represents an important step toward realizing the full therapeutic potential 
of GIRK channel manipulation.  
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CHAPTER 4 
 
RGS6/G5 complex accelerates IKACh gating kinetics in atrial myocytes 
and modulates parasympathetic regulation of heart rate  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Posokhova E, Wydeven N, Allen KL, Wickman K*, Martemyanov KA*. RGS6/G5 
complex accelerates IKACh gating kinetics in atrial myocytes and modulates 
parasympathetic regulation of heart rate. Circ. Res. 2010; 107:1350-4 
  
        Rgs regulation of cardiac muscarinic signaling 
  93 
Introduction 
  Cardiac output is shaped to a great extent by sympathetic and parasympathetic 
influences. Parasympathetic input tempers heart rate (HR) and counteracts the pro-
arrhythmic effects of sympathetic activation, and is mediated by acetylcholine (ACh) 
[204]. ACh is released from post-ganglionic parasympathetic neurons and binds to M2 
muscarinic receptors (M2R) on pacemaker cells and atrial myocytes, triggering activation 
of pertussis toxin-sensitive (Gi/o) heterotrimeric G proteins [51]. Once activated, G 
proteins dissociate into G-GTP and G subunits, leading to modulation of adenylyl 
cyclase and multiple ion channels. Central among these reactions is the binding of G to 
the atrial potassium channel IKACh, a heterotetramer composed of GIRK1 and GIRK4 
subunits [230]. Binding of G to IKACh enhances its gating which leads to cell 
hyperpolarization and ultimately, decreased HR [205].  
The duration of  G protein signaling is controlled by members of the Regulator of 
G protein Signaling (RGS) family [231]. RGS proteins stimulate inactivation of G-GTP, 
facilitating its re-assembly with G. RGS proteins play a critical role in shaping 
bradycardic effects of M2R receptor activation [89, 232, 233]. Indeed, eliminating RGS 
influence by expressing G subunits insensitive to RGS action results in a substantial 
enhancement of IKACh regulation by M2R signaling, via both Go and Gi2 pathways 
[232, 233]. Although more than 30 RGS proteins have been identified, the involvement 
of specific RGS proteins in the regulation of parasympathetic input is not fully-
understood.  Here, we report an unexpected role of the RGS6/G5 complex, previously 
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thought to be neuron-specific regulator, in the temporal regulation of M2R-IKACh 
signaling.  
 
Materials and Methods  
Littermate mice were used for all experiments in this study. All procedures were 
carried out in accordance with NIH guidelines and were approved by the Institutional 
Animal Care and Use Committee of the University of Minnesota. 
Antibodies, Recombinant Proteins, DNA Constructs—Sheep anti-RGS6 antibodies 
(-RGS6-FL) were generated against recombinant fragment containing amino acids 263-
472 of mouse RGS6 that was expressed and purified from E.coli as described [234]. 
Antibodies were affinity-purified on the epitope-conjugated column and stored in PBS 
buffer containing 50% glycerol. Rabbit anti-G5 (SGS) and rabbit anti-R7BP (TRS) 
antibodies were a generous gift from Dr. William Simonds, NIDDK. Rabbit polyclonal 
anti-AU1 tag (GenScript, Piscataway, NJ), mouse monoclonal anti-AU5 (MMS-135R; 
Covance, Princeton, NJ),  goat polyclonal anti-RGS4 (Santa Cruz Biotechnology, Santa 
Cruz, CA), rabbit polyclonal anti-Gi1/2 (Thermo Fisher Scientific, Rochford, IL) and 
rabbit polyclonal anti-Go (K20; Santa Cruz Biotechnology, Santa Cruz, CA) were 
purchased. All general chemicals were purchased from Sigma Aldrich (St. Louis, MO).  
Cloning of full-length mouse Gβ5S and RGS6 was described previously [235, 
236]. The open reading frame of G5S was subcloned into pcDNA3.1/TOPO 
(Invitrogen) mammalian expression vector, and RGS6 was cloned into pcDNA3.1NT-
GFP-TOPO (Invitrogen) creating an N-terminal fusion with GFP. Cloning of GIRK1-
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AU5 and GIRK4-AU1 into mammalian expression vectors has been described [237]. All 
constructs were propagated using an E.coli Top-10 strain (Invitrogen), isolated using 
Nucleobond kits, (Macherey-Nagel; Bethlehem, PA) and sequenced. 
Mouse Strains—The generation of R7bp–/– [137], G5–/–[238], and Girk4–/– [205] 
mice has been described previously. G5–/– mice were generously provided by Dr. Jason 
Chen (Virginia Commonwealth University). These three strains of mice were out-bred 
onto the C57BL/6 background for at least 5 generations. Rgs6
–/– 
mice were generated by 
Lexicon Pharmaceuticals using 129SvEvBrd embryonic stem cells. Chimeric offspring 
were mated with C57BL/6 strain and the resulting heterozygous progeny were inbred to 
generate null mutant and wild-type littermates. Mice were housed in groups on a 12h 
light/dark cycle with food and water available ad libitum. All procedures were carried out 
in accordance with the National Institute of Health guidelines and were granted formal 
approval by the Institutional Animal Care and Use Committee of the University of 
Minnesota. All efforts were made to minimize the use of animals in this study, as well as 
their suffering. All animals used in this study were bred on-site.  
Cell culture and transfections—HEK293FT cells were obtained from Invitrogen 
(Carlsbad, CA) and cultured at 37°C
 
and 5% CO2 in DMEM (Dulbecco’s Modified Eagle 
Medium; GIBCO) supplemented with 100 units of penicillin and 100 mg of 
streptomycin, 10% FBS, 1x MEM non-essential amino acids (GIBCO; Carlsbad, CA), 1 
mM sodium pyruvate and
 
4 mM L-glutamine. Cells were transfected at ~70% 
confluency, using Lipofectamine LTX (Invitrogen) according to the manufacturer’s 
protocol. The ratio of Lipofectamine to DNA used was 6.25 l : 2.5 g per 10 cm2 cell 
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surface. Cells were grown for 24-48 hours post-transfection. Equal amounts of each 
construct were transfected, balanced when necessary by empty pcDNA3.1 vector.  
Immunoprecipitation assays and Western blotting—Cellular and tissue lysates 
were prepared in immunoprecipitation (IP) buffer (1XPBS (Fisher Scientific), 150 mM 
NaCl, 1% Triton X-100, protease inhibitors (Roche; Indianapolis, IN) and centrifuged for 
15 min at 14,000 x g. Protein concentration was determined in the resulting extracts using 
BSA assay (Pierce; Rockford, IL) and equal amounts of protein were incubated with 3 g 
of antibodies and 10 l of protein G beads (GE Healthcare; Waukesha, WI) for 1 h at 
4
0
C. After 3 washes with ice-cold IP buffer proteins bound to the beads were eluted with 
SDS-sample buffer. Eluates were resolved on 12.5% SDS-PAGE gel, transferred onto 
PVDF membrane (Millipore (Billerica, MA)) and subjected to Western blot analysis 
using HRP conjugated secondary antibodies and an ECL West Pico (Pierce) detection 
system.  For quantification, samples were analyzed by infrared Western blotting using 
IRDye680 and IRDye800 labeled secondary antibodies (Li-Cor Biosciences; Lincoln, 
NE) according to the manufacturer's protocol. Detection and quantification of specific 
bands was performed on an Odyssey Infrared Imaging System (Li-Cor Biosciences). The 
integrated intensity of each band of interest was measured in a corresponding channel 
with a top-bottom background setting.  
Whole-cell electrophysiology—Primary cultures of atrial myocytes were 
generated from neonatal mice (P2-4) as described [210, 239], using the Neonatal 
Cardiomyocyte Isolation System (Worthington Biochemical Corp., Lakewood, NJ).  
Atrial myocytes were used for electrophysiological analysis after 1-3 d in culture.  
Sinoatrial nodal cells were isolated from adult mice (3 months) as described [89], and 
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used within 8 h of isolation.  In brief, hearts were excised into Tyrode’s solution (in mM): 
140 NaCl, 5.4 KCl, 1.2 KH2PO4, 1.0 MgCl2, 1.8 CaCl2, 5.5 glucose, 5 HEPES, pH 7.4 
with NaOH.  The sinoatrial node (SAN) was identified as the narrow band of tissue 
located on the inner wall of the right atrium, medial to the crista terminalis and between 
the superior and inferior vena cava.  Two incisions were made to the superficial side of 
the superior and inferior vena cava, followed by a longer cut along the outer atrial wall, to 
expose the SAN region.  SAN-containing tissue was excised into a modified Tyrode’s 
solution containing (in mM): 140 NaCl, 5.4 KCl, 1.2 KH2PO4, 0.2 CaCl2, 50 taurine, 18.5 
glucose, 5 HEPES, 0.1% BSA, pH 6.9 with NaOH, with elastase (0.3 mg/ml; 
Worthington Biochemical Corp.) and collagenase II (0.21 mg/ml; Worthington 
Biochemical Corp.).  SAN tissue was digested at 37°C for 30 min, with occasional 
inversion, and then washed three times in a solution containing (in mM): 100 L-glutamic 
acid/potassium salt, 10 L-aspartic acid/potassium salt, 25 KCl, 10 KH2PO4, 2 MgSO4, 20 
taurine, 5 creatine, 0.5 EGTA, 20 glucose, 5 HEPES, 0.1% BSA, pH 7.2 with KOH.  
SAN tissue was then triturated in the wash solution and plated onto poly-L-lysine coated 
coverslips for electrophysiological studies.  
Coverslips containing atrial myocytes or SAN cells were transferred to a chamber 
containing a low-K
+
 bath solution (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 2 MgCl2, 10 D-
glucose, 10 HEPES/NaOH (pH 7.4).  Cardiac cells were visualized using an Olympus IX-
70 microscope.  The dominant population of atrial myocytes with spherical shape (typical 
capacitance, 10-20 pF) was targeted for this study.  SAN cells were identified as the thin 
striated cells exhibiting spontaneous contractions (typical capacitance, 25-40 pF) (see 
Fig. 4.6A, inset).  Membrane potentials and whole-cell currents were measured with 
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hardware (Axopatch-200B amplifier, Digidata 1320) and software (pCLAMP v. 9.2) 
from Molecular Devices (Sunnyvale, CA).  Borosilicate patch pipettes (3-5 MΩ) were 
filled with (in mM): 130 gluconate, 2 MgCl2, 1.1 EGTA/KOH (pH 7.2), 5 HEPES/KOH 
(pH 7.2), 2 Na2ATP, 5 phosphocreatine, 0.3 Na-GTP. 
Upon achieving whole-cell access, input resistance, capacitance, and resting 
membrane potentials were measured.  Neonatal atrial myocytes and SAN cells from wild-
type and knockout mice did not differ with respect to these parameters.  CCh-induced 
currents were measured at a holding potential of -70 mV using a high-K
+
 bath solution 
(in mM): 120 NaCl, 25 KCl, 2 CaCl2, 2 MgCl2, 10 D-glucose, 10 HEPES/NaOH (pH 
7.4).  The high-K
+
 bath solution (+/-CCh) was applied with an SF-77B rapid perfusion 
system (Warner Instruments, Inc.; Hamden, CT).  In pilot studies, we found no difference 
in current amplitudes evoked by 10 and 100 M CCh, irrespective of genotype or cell 
type.  As such, 10 M CCh was taken as the saturating CCh concentration for these 
studies.  All currents were low-pass filtered at 1 kHz, sampled at 2 kHz, and stored on 
computer hard disk for analysis.  Steady-state current amplitudes were measured for each 
experiment by subtracting the baseline current from the current measured just prior to the 
return to drug-free solution.  Activation and deactivation time constants were extracted 
from appropriate regions of current traces, which were fit with a 1-term Boltzmann 
equation using the Levenberg-Marquardt search method, sum of squared errors 
minimization method, and no weighting (Fig. 4.1).  Only those experiments for which the 
access resistances were stable and low (<15 MΩ) were included in the final analysis. 
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Figure 4.1. Depiction of measured parameters for the whole-cell CCh-induced 
current studies.  A typical response of a wild-type neonatal atrial myocyte to 10 M 
CCh is shown, with the horizontal line showing the duration of CCh application.  Current 
amplitude and density determinations involved steady-state currents, measured relative to 
baseline just prior to the removal of CCh.  Shaded rectangles identify the regions of the 
trace used for determination of current activation and deactivation kinetics.  The fit 
curves, derived from a 1-term standard Boltzmann equation, are shown overlayed on the 
expanded parts of the trace (bottom).   
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Telemetry—Wild-type (n=5) and Rgs6–/– (n=5) littermates aged 4-5 months were 
used for in vivo ECG monitoring. Biopotential telemetry transmitters ETA-F10 (Data 
Sciences International; Saint Paul, MN) were implanted intraperitoneally under 
ketamine/xylazine anesthesia (60 and 12 mg/kg correspondently). ECG leads were 
externalized and abdominal wall was closed with Prolene 5-0 (Ethicon; Somerville, NJ) 
incorporating suture rib of the transmitter into the closure. ECG leads were tunneled 
under the skin into lead II position and sutured to the abdominal wall by Prolene 5-0. 
Skin incisions were closed using Vicryl 5-0 (Ethicon). Upon termination of anesthesia, 
animals received a single intraperitoneal injection of ketoprofen (5 mg/kg), followed by 
administration of ibuprofen and amoxicillin in drinking water during recovery period 
(days 1-10). Upon recovery, recordings were performed in a scheduled manner, for 20 s 
each min, following 1-h acclimation using Dataquest ART 4.2 acquisition software (Data 
Sciences International). On day 11, 6 h of baseline ECG data were recorded. On day 12, 
after 30 min of baseline recording, animals were injected i.p. with 0.9% saline solution 
(10 ml/kg) as a vehicle control. Atropine sulfate was injected 2 h later (1 mg/kg, i.p.; 
Hospira, Lake Forest, IL), followed by 3 h of recording. On day 13, following 30 min of 
baseline recording, animals were injected first with 0.9% saline solution and 2 h later 
with CCh (0.1 mg/kg, i.p.; Acros Organics, Geel, Belgium). Recording proceeded for 3 h, 
after which animals were sacrificed by CO2 inhalation. Transmitters were explanted, 
cleaned with 1% Tergazyme enzymatic detergent (Alconox; White Plains, NY), sterilized 
with Cidex activated dialdehyde solution (Ethicon), and reused.  
Statistical Analysis—Statistical analyses were performed using Prism (GraphPad 
Software, Inc.; La Jolla, CA) and SigmaPlot 11 (Systat Software Inc; San Jose, CA). 
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EC50 values were calculated with the Hill coefficient set to 1. The impact of genotype on 
CCh-induced current responses (steady-state current density and kinetics) was evaluated 
using one-way (single-saturating concentration study) and two-way (concentration-
response study) ANOVA. The impact of genotype on CCh- and atropine-induced heart 
rate response was evaluated using two-way (time-response study) ANOVA. Tukey’s 
Multiple Comparison (one-way ANOVA) and Bonferroni (two-way ANOVA) post hoc 
tests were used as appropriate.  For all analyses, the level of significance was set at P < 
0.05. 
 
Results  
  Profiling RGS6 protein expression across mouse tissues revealed its readily 
detectable levels in the heart in addition to abundant presence in the brain (Fig. 4.2A and 
Fig. 4.3). RGS6 protein was enriched in atria, where it was found predominantly in 
myocytes (Fig. 4.4), consistent with a recent report [240], and similar to the distribution 
of GIRK1, an integral subunit of IKACh (Fig. 4.2B).  To begin exploring the role of Rgs6 
in cardiac physiology, we obtained Rgs6
–/–
 mice where exons 5 to 7 encoding the critical 
N-terminal portion of the protein were eliminated (Fig. 4.2C,D). Immunoblotting verified 
the complete absence of RGS6 protein in the hearts of Rgs6
–/–
 mice (Fig. 4.2E). 
  RGS6 interacts with the type 5 G protein  subunit (G5) and the R7 binding 
protein (R7BP) in the CNS [132] (Fig. 4.2F). In the mouse heart, however, only G5 is 
available for the interaction with RGS6 (Fig. 4.2E). RGS6 was undetectable in hearts 
from G5–/– mice, indicating that the physical association with G5 is critical for the 
        Rgs regulation of cardiac muscarinic signaling 
  102 
expression and/or stability of RGS6 (Fig. 4.2G). Similarly, G5 levels were dramatically 
reduced in the Rgs6
–/–
 heart but not brain, indicating that in the heart RGS6 is the 
predominant RGS bound to G5. No effect on RGS6 or G5 levels was observed upon 
elimination of R7BP or GIRK4. Notably, we detected no compensatory changes in either 
Gi/o proteins or RGS4, a protein previously implicated in regulation of the M2R-IKACh 
signaling [89]. 
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Figure 4.2. RGS6 protein level and complex formation in the mouse heart. A, RGS6 
protein levels across mouse tissues as analyzed by Western blotting. Equal amounts of 
total protein (20 g) were loaded in each lane. Coomasie staining (CBB) was used as a 
loading control. B, RGS6 is co-enriched with GIRK1 in the atria. Atrial (ATR) and 
ventricular (VEN) lysates were analyzed by Western blotting (upper panels). CBB 
staining confirms equal protein loading. Graph: Quantification of RGS6 and GIRK1 
band densities. C, Strategy for Rgs6 ablation by homologous recombination. D, 
Structural organization of Rgs6. Frames designate the deleted region () and recognition 
site of the RGS6 FL antibody (RGS6 FL Ab) used throughout the study. Boxes 
designate known structural domains. E, Co-immunoprecipitation of RGS6 with G5 and 
R7BP from heart and brain tissues. F, Co-dependence of RGS6 and G5 expression in 
the heart and brain as analyzed by Western blotting. 
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Figure 4.3. Quantitative analysis of RGS6 distribution across tissues. RGS6 band 
densities from Western blot experiment presented in Figure 1A have been determined by 
densitometry using Image J software and normalized to the total protein content 
determined from CBB stained gel (Figure 1A). Resulting values representing relative 
abundance of RGS6 proteins across tissues are plotted as a bar graph. 
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Figure 4.4. RGS6 is present in isolated atrial cardiomyocytes. Cardiomyocytes were 
isolated from adult mice as described in the Materials and Methods section above. 
Following lysis in SDS sample buffer, 25 µg of total protein was loaded on the gel. RGS6 
expression was detected by Western blotting with specific anti-RGS6-FL antibodies. 
Brain tissue was used as a control. The absence of the immunoreactivity for the neuronal 
specific marker PSD95 in isolated cardiomyocyte fraction (CM) demonstrate that RGS6 
is predominantly expressed in the myocytes. Protein loading was verified by Coomasie 
Brilliant Blue (CBB) following separation on SDS-PAGE gel. Densitometric analysis of 
the total protein content quantified from the CBB-stained gel is presented in the lower 
panel.   
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  Given the coenrichment of RGS6 and IKACh in atria and the role of R7 RGS/Gβ5 
complexes in G protein–coupled receptor–GIRK signaling in the CNS [146], we next 
measured the impact of Rgs6 ablation on M2R-IKACh signaling in neonatal atrial 
myocytes, which exhibit robust inward current triggered by the nonselective muscarinic 
agonist carbachol (CCh). Whereas CCh evoked currents with comparable potency in 
atrial myocytes from wild-type mice, current deactivation kinetics were notably slower 
across all CCh concentrations tested in myocytes from Rgs6
−/−
 mice (Fig. 4.5). Current 
activation kinetics were also delayed in Rgs6
−/−
 myocytes, although only for the lower 
CCh concentrations tested. 
 We next compared CCh-induced currents in sinoatrial node (SAN) cells, the key 
anatomic substrate for parasympathetic control of heart rate (Fig. 4.6). Although some 
differences in the density and kinetics of CCh-induced responses between adult SAN 
cells and neonatal atrial myocytes were evident, Rgs6 ablation correlated with 
significantly delayed deactivation rates in both cell types. Under the same conditions, no 
differences in CCh-induced steady-state current density or activation kinetics were 
observed between genotypes in either atrial myocytes or SAN cells (Fig. 4.6). 
Furthermore, deletion of Gβ5 replicated prolonged deactivation kinetics seen in Rgs6−/− 
myocytes (Fig. 4.6E), indicating that regulation of the M2R-IKACh signaling in heart atria 
is mediated by the RGS6/Gβ5 complex rather than RGS6 by itself. 
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Figure 4.5.  Impact of Rgs6 ablation on M2R-IKACh signaling in atrial myocytes.  A, 
Inward currents evoked by CCh (0.1-10 mol/L) in atrial myocytes from wild-type and 
Rgs6
–/–
 mice.  Scale bars: 15 s/100 pA.  Evoked currents developed gradually at 0.1 
mol/L CCh and saturated at 10 mol/L CCh (responses to 10 mol/L CCh are not 
shown).  Steady-state current densities did not differ between Rgs6
–/–
 (-36±4 pA/pF at 10 
mol/L CCh, n=7) and wild-type (-42±6 pA/pF, n=7) myocytes.  B, Summary of M2R-
IKACh activation kinetics in atrial myocytes from wild-type and Rgs6
-/-
 mice.  Main effects 
of concentration (F3,43=25.5; P<0.001) and genotype (F1,43=13.3; P<0.001) were 
observed, as well as a concentration x genotype interaction (F3,43=4.1; P<0.05).  
Symbols: *** P<0.001 vs. wild-type (within dose).  C, Summary of M2R-IKACh 
deactivation kinetics in atrial myocytes from wild-type and Rgs6
-/-
 mice.  Main effects of 
concentration (F3,44=5.5; P<0.01) and genotype (F1,44=58.9; P<0.001) were observed, and 
there was no concentration x genotype interaction (F3,44=1.7; P=0.17).  Symbols: *
,
** 
P<0.05 and 0.01, respectively, vs. wild-type (within dose).   
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Figure 4.6. Impact of Rgs6 ablation on M2R-IKACh signaling in atrial myocytes and 
SAN cells. A, Inward currents evoked by CCh (10 µmol/L) in atrial myocytes from wild-
type and Rgs6
-/-
 mice.  Scale bars: 5 s/200 pA.  B, Inward currents evoked by CCh (10 
µmol/L) in SAN cells from wild-type and Rgs6
-/-
 mice.  Scale bars: 5 s/400 pA.  Inset: 
image of the wild-type SAN cell evaluated in the adjacent trace.  Summary of steady-
state CCh-induced current density (C), activation kinetics (D), and deactivation kinetics 
(E) in wild-type, Rgs6
-/-
, and G5-/- atrial myocytes (n=5-11 per group), and in wild-type 
and Rgs6
-/-
 SAN cells (n=10-12 per genotype).  Genotype did not impact current density 
(atrial myocytes: F2,21=1.9, P=0.18; SAN cells: t(20)=0.13, P=0.90) or activation kinetics 
(atrial myocytes: F2,21=1.0, P=0.38; SAN cells: t(20)=1.69, P=0.11), but did influence 
deactivation kinetics (atrial myocytes: F2,21=24.8,  P<0.001; SAN cells: t(20)=3.71, 
P<0.01).  Symbols: **
,
 *** P<0.01 and 0.001, respectively, vs. wild-type (within cell 
type).    
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 The striking impact of Rgs6 ablation on M2R-IKACh signaling kinetics in atrial 
myocytes and SAN cells prompted us to test whether RGS6/Gβ5 can physically associate 
with the IKACh channel. In transfected HEK293 cells, we detected robust 
coimmunoprecipitation of the RGS6/Gβ5 complex with GIRK4 but not GIRK1 by both 
forward and reverse precipitation strategies (Fig. 4.7). Thus, the involvement of 
RGS6/Gβ5 in M2R-IKACh signaling is likely aided by a direct protein–protein interaction 
mediated by the cardiac-specific GIRK subunit GIRK4. 
 The delay in IKACh deactivation kinetics triggered by RGS6/Gβ5 elimination is 
expected to enhance M2R-IKACh signaling because the channel would stay open longer, 
which would potentiate the parasympathetic regulation of HR. We addressed this 
possibility by analyzing cardiac function in mice using ECG telemetry, at baseline and 
following pharmacological manipulation. Analysis of ECG traces did not reveal gross 
abnormalities in cardiac physiology in Rgs6
−/−
 mice (Fig. 4.8A and Fig. 4.9). Rgs6
−/−
 
mice did, however, display a mild resting bradycardia (511±13 versus 476±4 bpm, 
P<0.05), consistent with the effect of RGS6/Gβ5 ablation on M2R-dependent signaling in 
atrial myocytes (Fig. 4.8B). Although CCh administration (0.1 mg/kg, IP) triggered a 
rapid decrease in HR in wild-type and Rgs6
−/−
 animals, the effect was significantly larger 
and persisted longer in Rgs6
−/−
 mice (Fig. 4.8C). Similarly, parasympathetic blockade 
with atropine (1 mg/kg, IP) had a positive chronotropic effect in both groups, with a 
significantly larger effect seen in Rgs6
−/−
 mice (Fig. 4.8D). Importantly, there was no 
difference in HR immediately following atropine administration, indicating that the 
bradycardia seen in Rgs6
−/−
 mice results from enhanced intrinsic M2R signaling. 
  
        Rgs regulation of cardiac muscarinic signaling 
  110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. RGS6/G5 forms a complex with GIRK4. RGS6 and G5 were co-
expressed with either AU1-tagged GIRK4 or AU5-tagged GIRK1 in HEK293 cells. 
Forward and reciprocal co-immunoprecipitation assays were performed as described in 
the Methods using indicated antibodies. Eluates were analyzed using Western blotting.  
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Figure 4.8. Effect of Rgs6 ablation on resting HR and muscarinic regulation. A, 
Baseline ECG recorded during light phase from conscious, unrestrained wild-type (WT, 
n=5) and Rgs6
–/– 
mice (n=5). B, Average HR as determined from the analysis of the ECG 
recordings (6hr).  Symbols: * P<0.05 vs. wild-type. C, Effect of CCh (10 mg/kg, i.p.) on 
HR, analyzed and plotted as simple moving average with a period of 10 min in wild-type 
(closed circles) and Rgs6
−/−
 mice (open circles). HR at 0 min corresponds to the 30-min 
average baseline HR on the day of the experiment. Two-way ANOVA analysis (genotype 
and time) of the 120-min post-injection interval revealed main effects of genotype 
(F1,104=21.6; P<0.001). D, Effect of atropine (1 mg/kg, i.p.) on HR, analyzed and plotted 
as simple moving averages with a period of 10 min in wild-type (closed circles) and 
Rgs6
−/−
 mice (open circles). No significant difference in HR was observed during the 60-
min post-injection interval (F1,56=0.02; P=0.89).  
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Figure 4.9. Quantitative analysis of ECG intervals in Rgs6
–/–
 mice. A, Representative 
ECG trace obtained from Rgs6
–/–
 mice. Peaks and intervals used for the quantitative 
analysis are annotated. B, Quantitative analysis of the ECG traces. Data derived from the 
analysis of total 500 representative traces from 3 to 5 mice of each genotype. Values were 
averaged separately for each animal. Group sizes were defined as a number of unique 
animals used for the analysis (n=3-5). Errors are s.e.m. values.   
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Discussion 
Here, we report that RGS6/Gβ5 negatively regulates M2R-IKACh signaling in atrial 
myocytes by accelerating IKACh deactivation kinetics. These observations, together with 
the effect of Rgs6 ablation on HR and responses to pharmacological manipulation, 
indicate that RGS6/Gβ5 represents a key node of regulation in the parasympathetic 
control of cardiac output. Because dysregulation of the parasympathetic tone by 
deficiencies in IKACh function is increasingly accepted as a major factor in the 
pathogenesis of the atrial fibrillation [204], our study introduces RGS6/Gβ5 complex as 
an attractive candidate for better understanding of cardiac pathophysiology and 
development of corrective therapies. 
RGS6 belongs to the R7 family of RGS proteins, members of which were thought 
to be expressed exclusively in the nervous system, where they play roles in nociception, 
vision, reward behavior and locomotion [132]. Although RGS6 expression was reported 
previously in the heart [135, 240, 241], our study documents for the first time the 
functional relevance of RGS6 to cardiac physiology. In the CNS, RGS6 forms complexes 
with 2 proteins, Gβ5 and R7BP, that specify its stability, subcellular distribution, and 
activity [132]. Here, we show that cardiac RGS6 forms a complex with Gβ5, but not with 
R7BP which is undetectable in the heart. The obligate and functionally relevant nature of 
the RGS6/Gβ5 interaction was underscored by the mutual dependence of RGS6 and Gβ5 
levels on their coexpression and the phenotypic similarities in M2R-IKACh signaling in 
myocytes from Rgs6
−/−
 and Gβ5−/− mice. In neurons, Gβ5 recruits R7 RGS proteins to 
GIRK channels, resulting in accelerated channel kinetics associated with GABAB 
receptor activation [146]. Thus, the present work reveals the conservation of this 
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compartmentalization mechanism by showing that RGS6/Gβ5 can likewise regulate 
M2R-IKACh signaling. 
Previous work has identified RGS4 as a critical regulator of M2R-IKACh signaling 
in sinoatrial nodal cells [89]. Indeed, the deficiencies in M2R-IKACh signaling linked to 
Rgs6 ablation reported herein are reminiscent of those reported in Rgs4
−/−
 mice [89]. 
Therefore, murine sinoatrial nodal cells may use parallel approaches involving RGS4 and 
RGS6/Gβ5 to regulate M2R-IKACh signaling. It is possible, for example, that RGS4 and 
RGS6/Gβ5 selectively regulate different G protein subtypes involved in IKACh gating. 
Indeed, studies with knock-in mice expressing RGS-insensitive G proteins reveal a 
differential contribution of Gαi2 and Gαo to M2R-dependent actions [232, 233]. 
Furthermore, RGS6/Gβ5 shows selectivity toward Gαo over Gαi2 in vitro [242]. However, 
whereas the role of Gαi2 in mediating M2R-IKACh coupling is well established [233], the 
involvement of Gαo in this process is less certain. Moreover, it remains possible that 
other proteins of the more than 30-member RGS family also play roles in this regulation. 
Delineating the mechanisms of the functional involvement of RGS proteins in controlling 
M2R-IKACh signaling in the mouse models and their relevance to human physiology will 
serve as an exciting direction for future research. 
 
 
 
 
 
 
 
 
 
 
 
        Rgs regulation of cardiac muscarinic signaling 
  115 
 
 
 
 
 
 
CHAPTER 5 
 
RGS6, but not RGS4, is the dominant regulator of G protein signaling 
(RGS) modulator of the parasympathetic regulation of mouse heart rate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wydeven N, Posokhova E, Xia Z, Martemyanov K, Wickman K. RGS6, but not 
RGS4, is the dominant regulator of G protein signaling (RGS) modulator of the 
parasympathetic regulation of mouse heart rate. J. Biol. Chem. 2014: 289(4):2440-9.  
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Introduction  
  Cardiac output reflects a balance between input from the parasympathetic and 
sympathetic branches of the autonomic nervous system. Parasympathetic tone is 
dominant under resting conditions, slowing heart rate (HR) by decreasing spontaneous 
pacemaker activity of the sino-atrial node (SAN) [243, 244]. Excessive parasympathetic 
influence can lead to atrioventricular block, and dysregulation of parasympathetic activity 
has been linked to sinus node dysfunction and arrhythmia [232, 245, 246]. The 
importance of parasympathetic regulation to cardiac physiology and pathophysiology has 
prompted much interest in characterizing the molecular basis of parasympathetic actions 
in the heart.  
  The negative chronotropic effect of acetylcholine (ACh) is largely mediated by 
activation of M2 muscarinic receptors (M2R) and inhibitory (Gi/o-dependent) G protein 
signaling in SAN cells [243, 244]. Activated Gi/o G proteins inhibit adenylyl cyclase, 
leading to suppression of hyperpolarization-activated cyclic nucleotide gated cation 
channels and L-type Ca
2+
 channels, while activating the muscarinic-gated atrial K
+
 
channel IKACh [243, 244]. IKACh is a tetramer formed by GIRK1/Kir3.1 and GIRK4/Kir3.4 
subunits [69], and is found in SAN cells, atrial myocytes, and atrioventricular node cells 
[243]. IKACh activation accounts for a substantial fraction of the negative chronotropic 
influence of parasympathetic stimulation on HR in mice [205]. Moreover, loss of this 
signaling pathway correlates with elevated resting HR, a decrease in heart rate variability 
(HRV), resistance to pacing-induced arrhythmia, and protracted recovery times from 
stress, physical activity, and direct sympathetic stimulation [205, 210, 247, 248]. 
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  The parasympathetic regulation of HR, and M2R-IKACh signaling in cardiac 
myocytes, is negatively-modulated by Regulator of G protein Signaling (RGS) proteins 
[232, 233, 249, 250]. RGS6, in complex with the atypical G subunit G5 (RGS6/G5), 
has been implicated in the parasympathetic regulation of HR [251, 252]. Indeed, Rgs6
–/–
 
mice exhibited slower resting HR, enhanced sensitivity to M2R-dependent bradycardia, 
elevated HRV, and enhanced M2R-IKACh signaling characterized primarily by a prominent 
slowing of current deactivation [251-253]. Moreover, a loss-of-function mutation in the 
human RGS6 gene correlated with elevated HRV [253], and an RGS6 polymorphism 
correlated with altered HR recovery after exercise [254]. 
  Interestingly, RGS4 was the first RGS protein implicated in the parasympathetic 
regulation of HR and modulation of M2R-IKACh signaling in SAN cells [89, 207]. Indeed, 
the isolated heart and SAN cell phenotypes reported in Rgs4
–/–
 and Rgs6
–/–
 mice related to 
parasympathetic HR regulation and M2R-IKACh signaling were virtually identical [251, 
252], suggesting the possibility that SAN cells employ parallel RGS4- and RGS6/G5-
dependent mechanisms to modulate the parasympathetic regulation of HR. To test this 
hypothesis, we generated mice lacking both RGS4 and RGS6, and evaluated the impact 
of single or dual RGS ablation on parasympathetic HR regulation and M2R-IKACh 
signaling in SAN cells. Our findings argue that RGS6/G5 provides the dominant RGS 
influence on parasympathetic regulation of HR in the mouse. 
 
Materials and Methods 
Animals––Rgs4–/– mice (B6;129P2-Rgs4tm1Dgen/J) were purchased from Jackson 
Labs (Bar Harbor, ME). The generation of Rgs6
–/– 
mice was described previously [252]. 
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Mice were housed in groups on a 12-h light/dark cycle with food and water available ad 
libitum. All procedures were approved by Institutional Animal Care and Use Committees 
of the University of Minnesota and The Scripps Research Institute. 
qRT-PCR––RGS4 expression in the SAN and hippocampus from wild-type and 
Rgs4
–/–
 mice was compared using quantitative RT-PCR. Intact hippocampi were 
extracted from freshly-isolated brain tissue, and total RNA was isolated using Trizol, 
according to manufacturer’s recommendations (Invitrogen; Carlsbad, CA), and treated 
with recombinant DNase I (Roche; Indianapolis, IN). Total RNA from mouse heart (SAN 
and left atria) was isolated using RNeasy Fibrous Tissue Mini Kit (Qiagen; Germantown, 
Maryland). Reverse transcription was performed using iScript™ cDNA Synthesis Kit 
(Bio-Rad Laboratories; Hercules, CA). The qPCR was performed on a LightCycler® 480 
II in a final volume of 20 L, with LightCycler® 480 SYBR Green I Master kit (Roche 
Applied Science; Indianapolis, IN). After pre-incubation at 95°C for 5 min, amplification 
consisted of 45 cycles of 10 s denaturation at 95°C, followed by annealing (30 s) at 60°C 
and extension (10 s) at 72°C. Intron-spanning RGS4 primer sets were as follows: set A 
(A+: 5’-gtcggaatacagcgaggagaac-3’, A-: 5’-ggaag gattggtcaggtcaagatag-3’), set B (B+: 
5’-ttcaccatgaa tgtggactggca-3’, B-: 5’-gtccaggttcacctcttttgttgc-3’). All samples were 
tested in triplicate; the average of replicates was used in the data analysis. GAPDH 
(Mm_Gapd_2_SG QuantiTect primers; Qiagen) was used as internal control in each test. 
Quantitative immunoblotting––Preparation of hippocampal neuron cultures was 
described previously [220]. After 10 days, cultures were treated with vehicle (DMSO) or 
50 M MG132 (American Peptide Company; Sunnyvale, CA) for 6 h. Neurons were 
lysed in RIPA buffer containing protease inhibitors (10 mg/mL pepstatin A, 10 mg/mL 
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aprotinin, 10 mg/mL PMSF, 1 mg/mL leupeptin, and 50 M MG132) and incubated on 
ice for 20 min. Lysates were centrifuged for 15 min at 16,000 x g at 4°C. The supernatant 
was mixed with 4X SDS sample buffer, heated to 75°C, and then stored at 4°C. DTT was 
added to each sample to a final concentration of 0.2 M. Samples were then heated at 75°C 
for 10 min, loaded onto 12% Bis-Tris gels, and run in a Tris-glycine buffer. Samples 
were transferred to nitrocellulose membranes and blocked in 5% milk for 1 h. Primary 
antibodies against RGS4 (EMD Millipore; Billerica, MA) and β-actin (Abcam; 
Cambridge, MA) were diluted in 5% milk to 1:200 and 1:10,000, respectively, and then 
incubated overnight at 4°C with shaking. Blots were washed 3X with PBS+0.1% Tween-
20 and then incubated with IRDye 680CW donkey anti-rabbit and IRDye 800CW donkey 
anti-mouse secondary antibodies (Li-Cor Biosciences; Lincoln, NE), diluted 1:2000 and 
1:5000 in 5% milk, respectively, for 1 h at room temperature with shaking. After 3 more 
washes in PBS+0.1% Tween-20, blots were developed using an Odyssey Infrared 
Imaging System (Li-Cor Biosciences); integral band intensities were measured using Li-
Cor Odyssey software.  
Ex vivo cardiac physiology––Mice (8-12 wks) were heparinized (100 IU) and 
anesthetized using isoflurane (Halocarbon; River Edge, NJ). Hearts were rapidly excised 
and immediately cannulated for retrograde aortic perfusion in a constant pressure mode 
(60 mmHg) with modified Krebs-Henseleit buffer containing (in mM): 118.5 NaCl, 25 
NaHCO3, 4.7 KCl, 1.2 KH2PO4, 11 D-glucose, 1.2 MgSO4, 1.8 CaCl2, 2 sodium 
pyruvate. The buffer solution was filtered (0.22 m) and saturated with 95% O2-5% CO2 
at 38C. Hearts were allowed to stabilize for 30 min, and were excluded from 
pharmacological experiments and HRV analysis if any of the following was present: (i) 
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persistent arrhythmia >5 min, (ii) HR below 250 bpm, (iii) stable steady-state HR not 
attained within the first 20 min. Hearts with signs of ischemia upon dismounting from the 
apparatus were also excluded. Ex vivo data were acquired using the PowerLab data 
acquisition system (ADInstruments; Colorado Springs, CO) and digitized at a sampling 
rate of 2 kHz. LabChart Pro v.7 software with HRV and dose-response plug-ins 
(ADInstruments) was used for all data analysis. Basal HRs were quantified within a 10 
min window using the HRV plug-in of LabChart Pro v7 as described below. The HR 
response to various doses of CCh was measured as the 7-min average following the 
beginning of drug application. Effect of CCh in isoproterenol (Iso)-treated hearts was 
evaluated in a similar manner. After stabilizing the hearts with Krebs-Henseleit buffer 
perfusion they were treated with 50 nM Iso alone (to establish the appropriate baseline) 
or in combination with increasing doses of CCh. All drugs were added to the perfusate 
immediately prior to the start of the treatment to minimize effects on stability and 
concentration. The HR response was measured as the 7-min average following the 
beginning of drug application (CCh+Iso) or the beginning of the response plateau (Iso 
alone). 
HRV analysis––A “maximum after threshold” algorithm was used for R peak 
detection. Noisy data segments and ectopic beats were manually excluded from analysis. 
Signal pre-processing, threshold and retrigger delay values were altered when necessary 
to ensure all the peaks within the selected window were labeled correctly. All HRV 
parameters were analyzed in the 5-min interval preceding drug treatment for isolated 
hearts, or over a 5 min total of appended consecutive intervals of telemetry recording 
(baseline), or within the last 5-min window of drug application for isolated hearts. For 
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time domain analysis, the following parameters were calculated: mean normal-to-normal 
interval (NN, ms), standard deviation of all NN intervals (SDNN, ms), and square root of 
the mean square of successive differences between adjacent NN intervals (RMSSD, ms). 
Frequency domain analysis was done with FFT (Fast Fourier Transformation) size of 
1024 and a Welch window with half overlap. Frequency bands were defined as follows: 
0.4-1.5 Hz, low frequency (LF); 1.5-5 Hz, high frequency (HF). Power in each band and 
total power (TP, 0.0-10 Hz; ms
2
) were calculated. LF and HF were also expressed in 
normalized units (nu; (LF or HF)x100/(TP-VLF)), and LF/HF ratio was determined.    
SAN preparation and electrophysiology––SAN cells were isolated from adult 
mice (2-3 months) as described [89], and used within 8 h of isolation. In brief, hearts 
were excised into Tyrode’s solution (in mM): 140 NaCl, 5.4 KCl, 1.2 KH2PO4, 1.0 
MgCl2, 1.8 CaCl2, 5.5 glucose, 5 HEPES, pH 7.4 with NaOH. The SAN was identified as 
the narrow band of tissue located on the inner wall of the right atrium, medial to the crista 
terminalis and between the superior and inferior vena cava. Two incisions were made to 
the superficial side of the superior and inferior vena cava, followed by a longer cut along 
the outer atrial wall, to expose the SAN region. SAN-containing tissue was excised into a 
modified Tyrode’s solution containing (in mM): 140 NaCl, 5.4 KCl, 1.2 KH2PO4, 0.2 
CaCl2, 50 taurine, 18.5 glucose, 5 HEPES, 0.1% BSA, pH 6.9 with NaOH, with elastase 
(0.3 mg/mL; Worthington Biochemical Corp., Lakewood, NJ) and collagenase II (0.21 
mg/mL; Worthington). SAN tissue was digested at 37°C for 30 min and then washed 
three times in a solution containing (in mM): 100 L-glutamic acid/potassium salt, 10 L-
aspartic acid/potassium salt, 25 KCl, 10 KH2PO4, 2 MgSO4, 20 taurine, 5 creatine, 0.5 
EGTA, 20 glucose, 5 HEPES, 0.1% BSA, pH 7.2 with KOH. SAN tissue was then 
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triturated in wash solution and plated onto poly-L-lysine coated coverslips. Coverslips 
containing SAN cells were transferred to a perfusion chamber and electrophysiological 
recordings were conducted as described [252, 253]. SAN cells targeted for 
electrophysiological characterization were spindle-shaped, striated, and in most cases, 
exhibited spontaneous beating. Most experiments used a fast-step perfusion system to 
allow for fast application and removal of CCh (within 100 ms) and have been described 
previously [252, 253]. A small subset of experiments was done with gravity-flow 
perfusion of CCh (within 10-20 s). 
Analysis––Statistical analyses were performed using Prism 5 (GraphPad 
Software, Inc.; La Jolla, CA) and SigmaPlot 11 (Systat Software Inc; San Jose, CA). 
Non-linear fitting of dose-response data, Hill co-efficient analysis, and EC50 analysis 
were all done with Prism 5 software using the least squares fitting method. The impact of 
genotype on CCh-induced current responses (steady-state current density and kinetics) 
was evaluated using 1-way (single-saturating concentration study) and 2-way 
(concentration-response study) ANOVA. The impact of genotype on CCh-induced HR 
response was evaluated using two-way (time-response study) ANOVA. Activation and 
deactivation kinetics were determined by fitting regions of current traces with a 1-term 
Boltzmann equation as described previously [252]. Newman-Keuls Multiple Comparison 
(one-way ANOVA) and Bonferroni (two-way ANOVA) post hoc tests were used as 
appropriate. The level of significance was set at P<0.05.  
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Results 
Characterization of Rgs4
–/–
 mice 
  We acquired the Rgs4 mutant strain B6;129P2-Rgs4
tm1Dgen
/J (The Jackson 
Laboratory; Bar Harbor, ME) used previously to implicate RGS4 in the parasympathetic 
regulation of heart rate (HR) [89]. This strain harbors a lacZ-containing insert (LacO-SA-
IRES-lacZ-Neo555G/Kan) that spans part of exons 1 and 2, resulting in the loss of 58 
base pairs of coding sequence (and intervening intronic sequence), predicted to result in a 
frame shift and early truncation of RGS4 (Fig. 5.1A,B). Sequencing of the amplicon 
generated in mutant mice using the supplier’s genotyping conditions confirmed the 
presence of a foreign DNA element positioned between exon 1 and 2 in the Rgs4 gene 
(not shown).  
  We probed the levels of residual RGS4-like mRNAs in tissue samples from the 
heart (SAN and left atria) and brain (hippocampus) from RGS4 mutant mice. We used 
two distinct intron-spanning primer pairs targeting sequence in exons 3-5, which encodes 
the catalytic domain of RGS4, including one pair (“A”) used previously to characterize 
RGS4 expression in B6;129P2-Rgs4
tm1Dgen
/J mice [89]. Residual RGS4 expression levels 
were 10-100-fold lower in tissue samples from B6;129P2-Rgs4
tm1Dgen
/J mice than in 
corresponding wild-type samples (Fig. 5. 1C). 
  RGS4 protein is difficult to detect in cells as it is efficiently degraded via the 
ubiquitin-dependent N-end rule pathway [255, 256]. Indeed, we were unable to detect 
recombinant RGS4 by immunoblotting in HEK cells transfected with RGS4 unless cells 
were pre-treated with the proteasome inhibitor MG132 (not shown). Thus, we used 
MG132 pre-treatment to probe for RGS4 protein in hippocampal cultures from wild-type 
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and B6;129P2-Rgs4
tm1Dgen
/J mice. While RGS4 was observed in MG132-treated wild-
type cultures, no immunoreactive band was seen in cultures from RGS4 mutant mice 
(Fig. 5.1D,E). Collectively, these data indicate that the Rgs4 gene is targeted as described 
B6;129P2-Rgs4
tm1Dgen
/J mice (hereafter referred to as Rgs4
–/–
 mice), yielding a dramatic 
reduction in mRNA levels and no detectable residual RGS4 protein. Rgs4
–/–
 mice were 
bred with Rgs6
–/–
 mice to generate mice lacking both RGS4 and RGS6 (Rgs4
–/–
:Rgs6
–/–
); 
Rgs4
–/–
:Rgs6
–/– 
mice were viable and did not display obvious phenotypic abnormalities. 
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Figure 5.1. Characterization of Rgs4
–/–
 mice. A) Schematic depiction of the Rgs4 gene, 
which consists of 5 exons (rectangles, with corresponding number labels below). The 
translation initiation (ATG) and termination (STOP) codons are shown as forward (►) 
and reverse (◄) flags, respectively. The gray shaded regions in exons 1 and 2 (along with 
intervening intronic sequence) was replaced with the LacZ-containing cassette (LacO-
SA-IRES-LacZ-Neo555G/Kan) to generate B6;129P2-Rgs4
tm1Dgen
/J mice. B) Schematic 
depiction of RGS4 mRNA, with exon boundaries denoted by vertical lines and numbers. 
The gray shaded domain between boxes 1 and 2 corresponds to the 58-bp fragment of 
coding sequence missing in the RGS4 mutant mice. Highlighting across boxes 3-5 shows 
the location of coding sequence for the catalytic (RGS) domain of RGS4. Arrows denote 
the positions and identities of the primer sets (A+/-, B+/-) used for qRT-PCR. C) qRT-
PCR analysis of RGS4 expression in cardiac tissue (SAN and left atria) and hippocampus 
from wild-type and B6;129P2-Rgs4
tm1Dgen
/J mice, using the primer sets depicted in B. 
Expression levels were normalized within samples to GAPDH (levels of which were 
comparable in all tissues examined), and to wild-type samples for each primer set. 
Symbols: *** P<0.001 vs. wild-type (within tissue and primer set by t-test). D) 
Immunoblotting for RGS4 in primary hippocampal cultures (10 DIV) from wild-type and 
B6;129P2-Rgs4
tm1Dgen
/J mice. Cultures were pre-treated with MG132 (50 M) for 6 h 
prior to protein isolation. E) Quantification of RGS4 immunoblotting data (n=3 separate 
experiments). A significant impact of group was observed (F3,11=29.8; P<0.001). 
Symbols: ***P<0.001 vs. wild-type (untreated). 
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Impact of RGS ablation: isolated hearts 
  We first compared the contributions of RGS4 and RGS6 to automaticity and HRV 
using a retrogradely-perfused Langendorff heart preparation. Basal HR in hearts from 
Rgs6
–/–
 mice was significantly lower than measured in wild-type counterparts, consistent 
with published observations [252, 253], while HR in hearts from Rgs4
–/–
 mice was 
normal (Fig. 5.2A). Interestingly, HR measured in hearts from Rgs4
–/–
:Rgs6
–/–
 was also 
normal. Using time- and frequency-based analyses to compare HRV across genotypes 
[253], we observed that HRV was significantly elevated in hearts from Rgs6
–/–
 mice 
(Table 5.1), whereas all HRV measures in Rgs4
–/–
 mice were normal. Similar to the 
effect on HR, concurrent RGS4 ablation rescued in part the HRV abnormalities seen in 
hearts from Rgs6
–/–
 mice. 
  We next evaluated the impact of RGS ablation on the bradycardic effects of the 
cholinergic agonist carbachol (CCh) (Fig. 5.2B). CCh suppressed HR in all genotypes, 
though differences in sensitivity were evident (Fig. 5.2C). The IC50 for CCh-induced 
bradycardia was nearly 10-fold lower in Rgs6
–/–
 hearts (31±6 nM) compared to wild-type 
(219±24 nM). In contrast, CCh sensitivity was normal in hearts from Rgs4
–/–
 mice. The 
dose-response relationship in Rgs4
–/–
 mice was shallower, however, than in other 
genotypes. Finally, the CCh sensitivity of hearts from Rgs4
–/–
:Rgs6
–/–
 mice was 
significantly lower than wild-type and higher than in Rgs6
–/–
 mice, indicating that RGS4 
ablation partially rescued the enhanced CCh sensitivity seen in  Rgs6
–/–
 mice. 
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Figure 5.2. Impact of RGS ablation on HR and CCh-induced bradycardia. A) HR in 
isolated hearts from wild-type (wt) and Rgs
–/–
 mice. A significant effect of genotype on 
HR was observed (F3,94=2.7, P<0.05; n=4-12/genotype). B) Impact of CCh on HR in 
wild-type and Rgs
–/–
 hearts (n=4-8/genotype); data are normalized to baseline HR. A 
significant impact of genotype was observed for normalized HR (F3,101=21.0, P<0.001). 
Hill coefficients for each curve are listed. A significant impact of genotype was observed 
for Hill coefficients (F3,135=3.7, P=0.013). Specifically, Rgs4
–/–
 was significantly 
different from Rgs4
–/–
:Rgs6
–/–
 (*P>0.05). C) IC50 values calculated from dose-response 
curves in B (F3,135=38.1, P<0.001). Symbols: *,***P<0.05 and 0.001, respectively, vs. 
wild-type; 
+++
P<0.001.  
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HRV 
Parameter 
 
Genotype 
 
ANOVA 
wild-type Rgs4
–/–
 Rgs6
–/–
 Rgs4::6
–/–
 
NN range, ms 16.2 ± 1.6 18.2 ± 3.7 30.2 ± 4.8
a
 22.6 ± 7.2 
F3,30=3.0;  
P<0.05 
SDNN, ms 2.70 ± 0.20 3.20 ± 0.43 5.22 ± 0.87
a
 4.06 ± 1.28 
F3,30=3.4; 
 P<0.05 
RMS-SD, ms 1.35 ± 0.28 1.20 ± 0.29 3.90 ± 1.13 2.31 ± 1.30 
F3,30=2.7; 
 P=0.06 
TP, ms
2
 5.2 ± 0.9 8.7 ± 2.2 29.0 ± 8.5
a
 17.5 ± 10.0 
F3,30=3.8; 
 P<0.05 
VLF, ms
2
 4.2 ± 0.8 7.7 ± 1.9 18.2 ± 5.8 11.5 ± 5.5 
F3,30=2.7;  
P=0.06 
LF, ms
2
 0.48 ± 0.17 0.68 ± 0.39 4.50 ± 1.94 3.53 ± 3.25 
F3,30=2.1;  
P=0.12 
LF norm 49.9 ± 3.8 51.7 ± 8.0 48.6 ± 5.4 46.5 ± 5.1 
F3,30=0.1;  
P=0.96 
HF, ms
2
 0.54 ± 0.17 0.32 ± 0.11 6.26 ± 3.49 2.54 ± 2.25 
F3,30=1.7;  
P=0.19 
HF norm 50.1 ± 3.8 48.2 ± 8.0 51.4 ± 5.4 51.2 ± 4.5 
F3,30=0.1; 
 P=0.98 
LF/HF 1.13 ± 0.17 1.82 ± 0.86 1.44 ± 0.54 1.00 ± 0.17 
F3,30=0.4; 
 P=0.75 
 
 
 
 
 
 
 
 
 
 
Table 5.1. HRV analysis of wild-type and Rgs
–/–
 hearts. Baseline HRV analysis of 5-
min recordings from 4-12 mice per genotype (8-16 wk). Abbreviations: NN range, range 
of intervals between successive heart beats; SDNN, standard deviation of NN intervals; 
RMS-SD, square root of the mean squared difference of successive NNs; TP, total power 
(0-10 Hz); VLF, very low frequency (0-0.4 Hz); LF, low frequency (0.4-1.5 Hz); LF 
norm, 100*[LF/(TP-VLF)]; HF, high frequency (1.5-5 Hz); HF norm, 100*[HF/(TP-
VLF)]; LF/HF, ratio of LF to HF. Results of corresponding ANOVAs are indicated in the 
right column; pair-wise comparisons were made using Tukey’s HSD test, when 
appropriate. Symbols: 
a
P<0.05 vs. wild-type. 
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Impact of RGS ablation: M2R-IKACh signaling in SAN cells 
  We next examined the impact of RGS ablation on M2R-IKACh signaling in SAN 
cells (Fig. 5.3). Previous studies have shown that Girk4 gene ablation completely 
eliminated the whole-cell inward currents induced by CCh in SAN cells, confirming the 
IKACh-dependence of the response [248, 253]. No significant genotype-dependent 
differences in peak or steady-state CCh-induced IKACh currents were observed in response 
to a saturating CCh concentration (10 M) (Fig. 5.3A,B), though responses seen in cells 
from Rgs4
–/–
 mice tended to be larger. Similarly, no genotype-dependent difference in 
acute desensitization was found (Fig. 5.3E). Consistent with previous reports [251, 252], 
M2R-IKACh current deactivation rate was profoundly slower in Rgs6
–/–
 SAN cells, and a 
modest but significant slowing of current activation was also seen (Fig. 5.3C,D). In 
alignment with results from the isolated heart study, CCh-induced IKACh currents in Rgs4
–
/–
 cells exhibited normal activation and deactivation kinetics, and concurrent RGS4 
ablation partially rescued M2R-IKACh kinetic deficits seen in Rgs6
–/–
 cells.  
  We also evaluated the sensitivity of M2R-IKACh signaling in SAN cells from wild-
type and Rgs
–/–
 mice. The EC50 values for IKACh activation by CCh in wild-type and Rgs4
–
/– 
SAN cells were indistinguishable (Fig. 5.3F,G). In contrast, the M2R-IKACh signaling 
pathway in SAN cells from Rgs6
–/–
 mice was ~5-fold more sensitive to CCh. The EC50 
measured in Rgs4
–/–
:Rgs6
–/–
 SAN cells was slightly larger than that of Rgs6
–/–
 cells, but 
the difference was not significant. Genotype- and dose-dependent differences in M2R-
IKACh activation and deactivation kinetics were also observed (Fig. 5.3H,I), and these 
differences were consistent with outcomes from the saturating CCh experiments (Fig. 
5.3C,D).  
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Figure 5.3. Impact of RGS ablation on M2R-IKACh signaling in SAN cells. A) IKACh 
currents evoked by CCh (10 M) in SAN cells from wild-type and Rgs–/– mice. Peaks 
were normalized to allow for comparison of deactivation kinetics. Scale bars: 10 s/400 
pA. B) No impact of genotype on peak (F3,36=2.0, P=0.13) or steady-state (F3,36=2.2, 
P=0.10) current densities was observed (n=8-16/genotype). C,D) A significant impact of 
genotype was observed for activation (F3,35=5.0, P<0.01) and deactivation (F3,36=29.1, 
P<0.001) kinetics of the CCh-induced current in wild-type and Rgs
–/–
 SAN cells. E) 
There was no impact of genotype on the acute desensitization of the CCh-induced IKACh 
current (F3,36=1.3, P=0.29). F) Concentration-response curves for CCh-induced IKACh 
activation (steady-state current amplitudes normalized to response measured with 10 M 
CCh) in wild-type and Rgs
–/–
 mice (n=6-8 per group). Hill coefficients for each curve are 
listed. No significant impact of genotype was observed for Hill coefficients (F3,151=0.4, 
P=0.8). G) EC50 values calculated from concentration-response curves shown in F 
(F3,151=24.8, P<0.0001). H,I) Activation and deactivation kinetics of the CCh-induced 
currents in wild-type and Rgs
–/–
 SAN cells. An interaction of genotype and dose was 
observed for activation kinetics (F6,95=7.4, P<0.001) but not deactivation kinetics 
(F6,95=1.5, P=0.18). However, a significant impact of group on deactivation kinetics was 
observed for both genotype (F3,95=66.2, P<0.001) and concentration (F2,95=15.3, 
P<0.001), so within-concentration comparisons were performed by one-way ANOVA. 
Symbols: *,***P<0.05 and 0.001, respectively, vs. wild-type; 
+++
P<0.001. 
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Influence of another R7 RGS protein 
  The partial rescue of RGS6-dependent phenotypes seen with concurrent ablation 
of RGS4 suggested that another cardiac RGS protein(s) is present that can modulate 
parasympathetic signaling when RGS4 is absent. To test this hypothesis, and to explore 
the possibility that adaptations secondary to constitutive RGS4 ablation played a role in 
these phenomena, we employed a pharmacologic strategy involving CCG-63802, a 
compound that inhibits RGS4 (and likely other RGS and non-RGS proteins) by forming a 
covalent adduct to cysteine residues [257, 258]. With CCG-63802 (50 M) included in 
the pipette solution, M2R-IKACh deactivation rate was significantly accelerated in SAN 
cells from Rgs6
–/–
 mice, similar to the effect of concurrent genetic ablation of RGS4 and 
RGS6 (Fig. 5.4A,B). There was no effect of CCG-63802 on activation kinetics, and while 
peak and steady-state current responses tended to be larger than in control cells, this 
difference was not significant (Fig. 5.4C-E). 
  As RGS6 belongs to the R7 sub-family of RGS proteins (which consists of RGS6, 
RGS7, RGS9, and RGS11 [132]), we next asked whether the unusual influence of genetic 
ablation of RGS4 or acute CCG-63802 application on M2R-IKACh signaling seen in SAN 
cells from Rgs6
–/–
 mice was attributable to another R7 RGS family member. We 
exploited the observation that all four R7 RGS proteins are undetectable in G5–/– mice 
[238]. Consistent with the involvement of multiple R7 RGS proteins, CCh-induced IKACh 
current deactivation was significantly longer in G5–/– SAN cells than in Rgs6–/– SAN 
cells (t13=2.30, P<0.05). Moreover, while CCG-63802 accelerated M2R-IKACh 
deactivation rate in Rgs6
–/–
 SAN cells, it had no such effect in SAN cells from G5–/– 
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mice (Fig. 5.4A,B). The differential impact of RGS4 inhibition (genetic or 
pharmacologic) on M2R-IKACh signaling in SAN cells from Rgs6
–/–
 and G5–/– mice 
argues that RGS4 suppresses the influence of another R7 RGS family member when 
RGS6 is absent.  
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Figure 5.4. Influence of another R7 RGS protein revealed by Rgs4 ablation. A) IKACh 
currents evoked by CCh (10 M) in Rgs6–/– and Gβ5–/– SAN cells treated with vehicle or 
CCG-63802 (50 M, delivered via the pipette). Peak currents were normalized for 
comparison. B) Activation kinetics of the CCh-induced current in Rgs6
–/–
 (t14=0.1, P=0.9) 
or G5–/– (t8=0.2, P=1.0) SAN cells. C) Deactivation kinetics of the CCh-induced current 
in Rgs6
–/–
 (t18=3.0, P<0.01) or G5
–/–
 (t6=0.3, P=0.8) SAN cells. D) Peak IKACh current 
densities in Rgs6
–/–
 (t15=1.7, P=0.1) or G5
–/–
 (t9=0.4, P=0.7) SAN cells. E) Steady-state 
IKACh current densities in Rgs6
–/–
 (t16=1.1, P=0.3) or G5
–/–
 (t8=0.2, P=0.8) SAN cells. 
Note that only within-genotype comparisons were made. n=4-12/genotype. Symbols: 
***P<0.001 vs. vehicle for each genotype. 
  
        Rgs regulation of cardiac muscarinic signaling 
  134 
Discussion 
Our findings extend the previously-reported roles for RGS6 in the 
parasympathetic regulation of HR and M2R-IKACh signaling in SAN cells [251-253]. 
RGS6 ablation correlates with decreased HR (in vivo and ex vivo), increased HRV, 
enhanced sensitivity to the negative chronotropic effects of CCh, and multiple effects on 
M2R-IKACh signaling in SAN cells that should collectively enhance the influence of this 
signaling pathway on cardiac output. Under equivalent conditions, no similar impact of 
RGS4 ablation was observed. 
To the contrary, we did observe that the ablation of RGS4 seemed to enhance 
slightly M2R-IKACh signaling in SAN cells rather than disrupt it. While these effects were 
not statistically significant, the loss of RGS4 (by either genetic or pharmacologic 
manipulation) tended to correlate with larger peak CCh-induced responses, higher EC50 
value for CCh-induced IKACh activation, and exhibited faster activation and deactivation 
kinetics. In addition, isolated heart experiments from Rgs4
–/–
 mice revealed a shallower 
CCh dose-response curve compared to wild-type despite that the IC50 was the same for 
both genotypes. Collectively, these observations suggest that RGS4 can impact 
parasympathetic regulation of HR and underlying signaling pathways, albeit in manner 
distinct from that proposed previously. Furthermore, the mild effect observed with RGS4 
ablation appears to be exacerbated with the concurrent ablation of RGS6, leading to the 
partial rescue of the prominent phenotypes linked to RGS6 ablation in both single cell 
and isolated heart assays. 
The lack of negative influence of RGS4 on parasympathetic signaling was 
unexpected in light of a previous report involving the same mice [89]. While some of the 
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cardiac phenotypes in Rgs4
–/–
 mice reported previously could be due to an influence of 
RGS4 in the central nervous system (e.g., the enhanced negative chronotropic effect of 
CCh seen in conscious Rgs4
–/–
 mice), there are few differences between studies with 
respect to the design of the isolated heart experiments. In this context, it is worth noting 
that we also examined the influence of RGS4 ablation on CCh-induced bradycardia under 
conditions of sympathetic (isoproterenol) stimulation. While the previous study reported 
that CCh-induced bradycardia was more pronounced in isoproterenol-treated hearts from 
Rgs4
–/–
 mice as compared to wild-type controls [89], we observed no genotype-dependent 
difference in this assay (Fig. 5.5A-C). Interestingly, baseline HR of retrogradely-perfused 
hearts was slower (300-350 bpm) in our hands than in the previous study (>400 bpm). 
This may be due to the difference in the perfusion protocol used in the ex vivo heart 
studies, which involved constant pressure (our study) or constant flow (previous study). 
Moreover, while the CCh sensitivity of hearts from Rgs4
–/–
 mice was apparently similar 
in both studies, hearts from wild-type mice appeared to be slightly more sensitive to 
CCh-induced bradycardia in our study. 
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Figure 5.5. Rgs4 ablation in isoproterenol-stimulated hearts. A) HR in isolated hearts 
from wild-type (wt) and Rgs4
–/–
 mice stimulated with isoproterenol. HR from 
isoproterenol-treated wild-type and Rgs4
–/–
 hearts were not significantly different 
(t4=0.14, P=0.9). B) Impact of CCh on HR in wild-type and Rgs4
–/–
 hearts 
(n=3/genotype); data are normalized to baseline HR. There was no significant impact of 
genotype observed for normalized HR (F2,37=2.4, P=0.1). Hill coefficients for each curve 
are listed and were not significantly different (t37=1.8, P=0.09). C) IC50 values calculated 
from dose-response curves in B were not significant (t37=1.6, P=0.12).  
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With respect to the measurement of M2R-IKACh signaling in SAN cells, there were 
also few study design-related differences that might explain the divergent outcomes. We 
used a rapid solution-exchange system to apply and remove CCh to/from SAN cells. 
Accordingly, the rates of current activation and deactivation were ~100-fold faster in our 
study. Rapid solution exchange (complete solution exchange in <100 ms) ensures that the 
time-course of IKACh activation and deactivation is controlled by G protein cycling rather 
than gradually changing levels of agonist and/or the potentially confounding influence of 
signaling pathway desensitization. This difference in experimental design, however, is 
unlikely to explain the discrepancy between studies. Indeed, using a slower gravity-flow 
perfusion approach to deliver and remove CCh, we found no difference in CCh-induced 
IKACh current densities, desensitization, or kinetics in SAN cells from wild-type and Rgs4
–
/–
 mice (Fig. 5.6A-D). 
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Figure 5.6. M2R-IKACh signaling evaluated by slow perfusion of CCh. Summary data 
of IKACh currents evoked by CCh (10 M) in wild-type and Rgs4
–/– 
SAN cells, taken from 
experiments in which CCh was allowed to slowly fill the recording chamber by gravity 
flow, and was washed out of the chamber by gravity flow of CCh-free bath solution. 
While responses in SAN cells from Rgs4
–/–
 mice showed slightly faster kinetics and 
larger current densities, there were no significant genotype-dependent differences in any 
of the following parameters: A) Activation rate (t8=0.4, P=0.7) and B) deactivation rate 
(t7=0.7, P=0.5), C) Peak (t8=0.9, P=0.4) or steady-state (t7=1.5, P=0.2) CCh-induced 
current densities, or D) Acute desensitization of the CCh-induced IKACh current (t8=0.2, 
P=0.8; n=4-6/genotype). 
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While we did not observe a marked influence of RGS4 on the parasympathetic 
regulation of HR or M2R-IKACh signaling in SAN cells, our data suggest that RGS4 could 
influence such signaling under certain circumstances. Indeed, while the sensitivity of the 
isolated heart to CCh-induced bradycardia was normal in Rgs4
–/–
 mice, the slope of curve 
was shallower. Moreover, M2R-IKACh current densities tended to be higher with inhibition 
of RGS4. While the mechanisms underlying these observations are unclear, RGS4 can 
serve as a GAP for Gq [259-261], which should enhance the activity of PLCβ and 
increase the levels of phosphoinositol-4,5-bisphosphate (PIP2), a required co-factor for 
GIRK channel gating [57, 217]. As RGS4 is up-regulated in the failing human heart 
[262], a more robust influence of RGS4 on parasympathetic HR regulation and related 
signaling might be expected in this setting.  
Studies with embryonic stem cell-derived cardiomyocytes expressing RGS-
insensitive G proteins implicated Gi2 and Go in M2R-dependent signaling [233]. 
RGS6/Gβ5 strictly acts on members of the Gαi/o family [242], while RGS4 can serve as a 
GAP for Go and Gi1, Gi2, Gi3, and Gq [131, 263, 264]. Since RGS4 can regulate M2R-
GIRK signaling mediated by Gi2 and Go in expression systems [265, 266], some 
compartmentalization mechanism in SAN cells must facilitate the interaction between 
RGS6/Gβ5 and M2R-IKACh and/or preclude the interaction between RGS4 and M2R-
GIRK. Macromolecular complex formation may play a role in this process, as RGS/Gβ5 
can interact directly with cardiac and neuronal GIRK channels [146, 252]. In contrast, 
while RGS4 can interact with receptor-GIRK complexes [199, 266], the association 
appears to be driven by an interaction between RGS4 and the receptor. 
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Our data suggest that another member of the R7 RGS protein family, whose 
influence on M2R-IKACh signaling is masked by RGS4 in the absence of RGS6, can 
partially compensate for the loss of RGS6. RGS7 and/or RGS9 may be the compensatory 
factor(s), as expression of both RGS proteins has been detected in the heart [262, 267]. 
The presence of another R7 RGS protein would explain the comparably larger impact of 
G5 ablation on IKACh deactivation kinetics in SAN cells than is seen in SAN cells from 
Rgs6
–/–
 mice. It remains unclear how RGS4 masks its influence on M2R-IKACh activity. It 
is possible that RGS4 is expressed at levels sufficiently higher than the compensatory R7 
RGS protein(s) in SAN cells, which allows it to out-compete residual RGS/G5 
complexes for binding to receptor and/or channel. 
Enhanced parasympathetic input to the heart facilitates the induction of atrial 
fibrillation (AF), while decreased parasympathetic influence (and decreased IKACh) 
confers resistance to atrial fibrillation [249]. A mutation in the human GIRK4/KCNJ5 
gene that yields reduced surface expression of IKACh has been linked to long QT 
syndrome [178, 180]. Furthermore, loss-of-function mutations in RGS6 that increase 
IKACh function result in elevated HRV and increased susceptibility to AF induction [253].  
These observations suggest directly that certain arrhythmias may be effectively treated or 
prevented by decreasing (AF) or enhancing (long QT syndrome) M2R-IKACh signaling. 
While direct-acting IKACh agonists and antagonists may eventually prove useful in these 
settings, data presented herein argue that RGS6/G5 should be considered as a novel 
target for the treatment or prevention of arrhythmias.  
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General summary and significance 
GIRK channels are involved in the control and maintenance of cellular 
excitability in the brain through regulating synaptic transmission and in the heart by 
modulating heart rate [50, 51]. Alterations or disruptions to GIRK signaling processes 
may contribute to a number of cardiac and CNS disorders, including arrhythmia, 
epilepsy, depression, anxiety, schizophrenia, and drug addiction [57]. GIRK channels are 
one set of downstream effectors in inhibitory Gi/o protein signaling cascades, which are 
activated by a plethora of GPCRs. GPCRs are popular drug targets, but often have 
adverse or unwanted affects as they activate G proteins that have several downstream 
effectors. This has created a need for pharmacotherapies that directly target individual 
downstream effectors to elicit a desired effect. One such effector, GIRK channels, 
represents an important target for pharmacotherapeutic treatment of cardiac and 
neurological disorders.  
Findings in this dissertation contribute to current understandings of GIRK channel 
structure and function within the CNS and modulation in the heart.  Within the CNS, we 
identify key GIRK1 residues that are necessary for receptor-induced channel activation 
and characterize a new drug class that selectively targets these channels. Further, we 
demonstrate that the novel GIRK agonist, ML297, has an anxiolytic effect in mice, 
suggesting that it may be a potential therapeutic in the treatment of anxiety-related 
disorders. This work also demonstrates that RGS6, and not RGS4, regulates M2R-IKACh 
signaling and is the key modulator of parasympathetic activity of the heart, making it a 
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potential therapeutic target in the treatment of cardiac disorders, such as arrhythmias, 
long-QT syndrome, and fibrillation.  
 There were a few challenges associated with the work presented here. First, the 
constitutive knockdown of genes can often result in compensatory mechanisms that can 
sometimes mask the full effect of a complete loss-of-function of a gene of interest. 
Second, preferred knockout lines, such as a double knockout of Gβ5−/− and Rgs4−/−, were 
not viable, leading us to pursue pharmacological approaches instead. Third, hippocampal 
and sinoatrial node cell culture models employed throughout this work are a 
heterogeneous mix of cell types, creating potential confounds when using assays that 
analyze entire cell populations such as immunoblotting techniques. Finally, the study of 
heteromeric channels in a reconstituted system produces certain qualitative and 
quantitative confounds. For example, we are unable to strictly control the order and 
stoichiometry of GIRK subunits in a given heteromeric channel. Furthermore, it is 
impossible to control how much of the transfected material forms GIRK1/GIRK2 
heteromers versus GIRK2 homomers, which is particularly problematic when studying 
heteromers of GIRK2 mutant and wild-type GIRK2. Despite these confounds, it is 
important to study the native GIRK1/GIRK2 heteromer because it displays fundamentally 
different channel properties compared to a native GIRK2 homomer or engineered GIRK1 
homomer.   
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Key functional domains in GIRK1  
Our initial studies sought to expand upon previous published deletion and chimera 
work within the context of a GIRK1-containing heteromeric channel by identifying a 
specific amino acid residue or residues that would account for the robust currents 
associated with GIRK1-containing heteromers. Previous work demonstrated the necessity 
of both GIRK1 core and distal C-terminal regions in the facilitation of M2R-induced 
signaling via GIRK1-containing heteromeric channels [110]. Our work has also been 
studied at the level of receptor-facilitated GIRK activation. Consistent with previous 
findings, we also observed that the GIRK1 distal C-terminus was dependent on the 
presence of the GIRK1 core region. Further, we have linked GIRK1 residues F137, 
A142, Y150, and Q404 to the robust GABABR-induced activity associated with GIRK1-
containing heteromeric channels. 
 
GIRK1 C-terminus and residue Q404 
Q404, a residue within the distal C-terminal domain, was found to significantly 
influence the magnitude of basal and GPCR-dependent GIRK currents. When compared 
to GIRK1, GIRK1 Q404A demonstrated a 30% reduction in GABABR-induced current. 
This reduction could be linked to altered channel gating, Gβγ sensitivity, or an inherent 
property of the channel, as there is neither a difference in expression between GIRK1 and 
GIRK1 Q404A nor a difference in GIRK2A surface expression when coexpressed with 
either GIRK1 or GIRK1 Q404A. Most likely, this residue strengthens the channel–Gβγ 
interaction. However, it is also possible that Q404 strengthens the allosteric coupling that 
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translates Gβγ binding to an increase in channel gating. Future experiments should be 
aimed at defining the physical interactions between Gβγ and GIRK1 Q404, with the 
expectation that the Q404A mutant would display significantly less co-
immunoprecipitation with Gβγ compared to wild-type GIRK1 if it is responsible for 
facilitating the physical protein-protein interaction. 
We demonstrated that the CT/GIRK2 heteromer has small basal and receptor-
induced currents similar to that of a GIRK2 homomer. On the contrary, previous work in 
oocytes suggests that the distal C-terminus of GIRK1 (359-501) is responsible for 
elevated basal and M2R-induced channel activity associated with GIRK1, while GIRK1 
residues 190-501 also elevate receptor-induced channel activity [112, 113]. A number of 
experimental differences may contribute to the disparity of GIRK1 C-terminal 
functionality between CT chimera data and previously reported work. First, the chimera 
containing GIRK4 (1-365) and GIRK1 (359-501) was evaluated as a homomeric channel 
[113]. Heteromeric overlapping of GIRK1 NT with GIRK2 CT and vice versa may play a 
large role in how the channel passes current [268, 269]. Second, the intracellular milieu, 
e.g., endogenous proteins, can be distinctly different across expression systems and 
potentially altering signaling cascades in oocytes that are not present in HEK cells.  For 
example, these cell types have since been identified to contain an endogenous GIRK-like 
subunit: GIRK5 [270]. Finally, previous studies only explored the distal region and 
excluded the first 10 amino acids of the C-terminus, suggesting the possibility of a site in 
the proximal GIRK1 C-terminus inhibiting channel activity [112, 113]. Any one or more 
  146 
of these experimental differences may contribute to the lack of GIRK1-like function seen 
with our CT/GIRK2 heteromeric channel.  
Basal activity of GIRK1-containing channels is significantly greater than that of 
non-GIRK1-containing counterparts, and substantial basal activity of GIRK channels is 
seen in neurons [52, 158, 213, 271-273]. While structures that enhance single-channel 
properties such as conductance and mean open time should increase basal (and GPCR-
induced) activity, the most significant determinants identified in our study were the 
domains between 180-328 and 409-462, as deletion of the latter domain reduced basal 
activity by 50% while sparing GABABR-dependent signaling. While further refinement 
of these domains is necessary, it is tempting to speculate that the different affinities 
observed for GIRK1 (higher) and GIRK2 (lower) for PIP2, which binds between residues 
61-81, 183-189, and 219-229 of GIRK1 [111, 274], contributes to this phenomenon. 
Interestingly, a specific interaction between the unique distal C-terminus of GIRK1 and 
Gαi3 has been shown to reduce basal activity and increase Gβγ activity in GIRK1 F137S 
homomeric channels, while GIRK2 homomeric channels were independent of Gαi3 
modulation [275]. Although this regulation of GIRK1 was not studied in a wild-type 
GIRK1/GIRK2 heteromeric context, it does provide insight into potential functions of the 
GIRK1 distal C-terminus. For example, it is possible that binding Gαi3 enhances coupling 
of the GIRK1/GIRK2 heteromer to the GPCR over that of a GIRK2 homomer, giving rise 
to augmented GPCR-induced channel activity in GIRK1-containing heteromeric 
channels.  
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The difference in affinity of GIRK1 and GIRK2 for PIP2 is an interesting 
phenomenon for which a mechanism of action has yet to be discovered. Similar to other 
residues found in this study, there is likely a residue or small domain unique to GIRK1 
that is responsible for the increased affinity and resulting increased sensitivity of GIRK1 
to PIP2. In order to find this domain, future experiments should employ a similar 
mutagenic strategy and the voltage-sensing phosphatase (Dr-VSP) described in Chapter 
5. Mutants would be tested for their GABABR-induced activity both prior to and during 
the activation of Dr-VSP. If indeed a GIRK1 structure is responsible, the loss of 
GABABR-induced activity through GIRK2 during Dr-VSP activation would be partially 
rescued by inserting GIRK1 residues. 
 
GIRK1 core domain and residues F137, A142, Y150 
Previous work first identified GIRK1 F137 as a key determinant in the slow 
voltage-dependent activation kinetics typical of GIRK1-containing channels [225]. Later 
work showed GIRK1 F137 as an enhancer of basal and GPCR-dependent currents carried 
by the GIRK1/GIRK4 heteromer [114]. Likewise, GIRK2 (S148F) was the only single 
point mutant tested in our study to significantly enhance GABABR-induced current when 
expressed with GIRK2. The phenylalanine substitution at this position introduces an 
aromatic side chain into the space between the pore and inner helices. While the precise 
impact of this substitution on the selectivity filter and/or the inner (M1) and pore helices 
is unknown, it is clear that manipulations at this site influence a wide spectrum of GIRK 
channel properties. Indeed, substitution of the serine residue in GIRK2 (S148) and 
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GIRK4 (S143) for threonine yields homomeric channels exhibiting significantly higher 
activity than their wild-type counterparts [215, 276]. Further, the GIRK1 (F137S) mutant 
expresses on the cell surface and makes functional homomeric channels, despite the lack 
of an ER export signal that normally precludes trafficking of GIRK1 to cell surface [68], 
indicating that single channel properties are not dramatically affected, even across 
GIRK1/GIRK2 vs. GIRK2 and that influence of GIRK1 on heteromers is in enhancing 
open probability (gating).  
The current understanding is that GIRK channels possess two gates: the inner 
helix gate and the G loop gate [93]. The former consists of the inner helices of the 
transmembrane spanning domains [277, 278], while the latter is formed by the G loop at 
the top of the cytoplasmic domain [103, 105]. Recent crystal structures of the GIRK2 
homomer demonstrate that Gβγ only opens the G loop in the absence of PIP2, but the 
presence of PIP2 causes the inner helix gate to couple to the G loop gate so that both open 
upon Gβγ activation [93]. These gates are highly conserved across GIRK subunits, yet 
there are discrete differences in amino acids surrounding these regions that suggest 
potential changes to the molecular structure of these gates when comparing GIRK1 and 
GIRK2. For example, there has been some indication from previous work that GIRK1 is 
more sensitive to PIP2 than GIRK2 [111]; whereas Na
+
 enhances the open state of GIRK2 
homomeric channels but GIRK1 subunits are Na
+
 insensitive [98]. The pore residues of 
GIRK1 (F137, A142, and Y150) explored in this work will most likely cause slight 
changes and movements to the molecular architecture of the pore loop and selectivity 
filter. Perhaps these GIRK1 pore residues better facilitate the coactivation of these 
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heteromeric channels by PIP2 and Gβγ. It is, however, unclear how GIRK1 Q404A fits 
into this picture because the distal C-terminus of GIRK1 has yet to be crystallized. It is 
possible that it facilitates (directly or indirectly) a higher level of PIP2 binding or an 
interaction with Gαi/o-GTP to facilitate GPCR coupling.  
 
Summary   
  Using electrophysiological and biochemical approaches, we sought to better 
understand how GIRK1 potentiates basal and receptor-dependent activity of the 
prototypical neuronal GIRK channel, GIRK1/GIRK2.  We established that GIRK1 does 
not enhance the surface trafficking of GIRK2-containing channels, arguing that GIRK1 
confers unique functionality to heteromeric GIRK channels.  Indeed, we identified four 
amino acids in GIRK1 that promote enhanced basal and/or GABABR-GIRK signaling.  
One residue (Q404) is found in the unique, unresolved C-terminal domain of GIRK1, 
within a region that has been linked to high affinity interactions between the GIRK1 C-
terminus and G [214, 268].  The other three amino acids (F137, A142, Y150) are 
located near the K
+
 selectivity filter, where they work together to enhance channel mean 
open time and single channel conductance. Through this work, we have provided new 
structural insights of subunit-dependent differences that GIRK1 contributes to basal and 
GABABR-facilitated GIRK channel activity.  
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Mechanisms of ML297 activation and selectivity  
Recently, a novel family of small molecule modulators of GIRK channels was 
discovered using a high-throughput screen [169]. Preliminary functional characterization 
of the prototypical agonist ML297, which relied heavily on an indirect thallium flux 
assay, suggested that it selectively activated GIRK1-containing channels in a G protein-
independent manner, however the exact mechanism of action remained unclear. Using a 
combination of mutagenesis, thallium flux screening, and electrophysiology, we 
successfully determined that two GIRK1 residues are responsible for the selectivity of 
ML297: F137 and D173. Further experiments demonstrated that ML297-induced GIRK 
channel activation is dependent upon PIP2 and has fundamental differences compared to 
the canonical receptor-induced activation of GIRK channels. Importantly, we 
demonstrated that ML297 has anxiolytic properties in wild-type mice that were absent 
upon constitutive knockout of Girk1. 
 
Mechanism of ML297 activation 
One focus of this work was to determine the mechanism that underlies the ML297 
activation of GIRK channels. We investigated the dependence of ML297 on the presence 
of PIP2 and found that PIP2 is required to maximally activate GIRK channels. This 
finding was expected given that PIP2 is necessary for complete activation of the channel 
by endogenous Gβγ, intracellular Na+, and ethanol [92, 97, 166]. Activation of GIRK 
channels via Gβγ, ethanol, or ML297, all hinge on the presence of membrane-bound 
PIP2. Yet, it appears that ML297 agonism is structurally distinct, as previously known 
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channel activators do not exhibit a strong GIRK1-dependence. Binding sites for PIP2, 
Gβγ, and ethanol are mostly conserved across all GIRK subunits. The hydrophobic 
alcohol binding pocket is made up of the N-terminus (GIRK2 residue Y56) and the βL-
βM sheet (GIRK2 residues L340, Y347) from one subunit and the βD-βE sheet (GIRK2 
residues I242, P254, L254) from the adjacent subunit [167]. Ethanol, like ML297, can 
activate GIRK channels in the presence of PTX, indicating that GPCR-mediated 
activation of Gi/o proteins is not involved in either compounds mechanism of action [162, 
169]. Further, ethanol activation of GIRK channels was shown to be insensitive to 
alterations in cellular levels of Gβγ, indicating that it does not require channel-bound Gβγ 
to activate GIRK current [166].  
  While it has been established that ML297 can activate GIRK channels in the 
presence of PTX [169], it is still unclear if ML297 is completely independent of G 
protein signaling. PTX acts on Gαi/o by locking it in the inactive GDP-bound state 
through ADP-ribosylation [36, 39]. It is unclear as to whether the ADP-ribosylation of 
Gαi/o occludes the Gβγ binding site leaving it free to interact with downstream targets or 
still allows it to sequester Gβγ. Further, G proteins other than Gi/o are unaffected by PTX 
and are still able to release Gβγ. Therefore, more experiments need to be done to assess 
the dependence of ML297 on free Gβγ. This would be done by looking at reconstituted 
GABABR-GIRK1/GIRK2 signaling in HEK cells in the presence and absence of co-
transfected phosducin, a protein that scavenges free Gβγ. In this paradigm, baclofen-
induced GIRK currents through the GABAB receptor would be reduced by the presence 
of phosducin. If ML297 acts independently of Gβγ, then the presence of phosducin would 
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not affect ML297-induced GIRK currents. Understanding the dependence or 
independence of ML297 on the presence of Gβγ is important to further elucidating the 
mechanism of ML297 activation of GIRK channels. 
   
Mechanism of ML297 selectivity and the GIRK1/GIRK2 heteromeric channel 
  The most attractive feature of ML297 is that it is highly selective for GIRK1-
containing channels, while having no effect on GIRK2 homomers. We sought to identify 
the structural determinants in GIRK1 that make it an effective target of ML297. Work in 
Chapter 3 clearly demonstrates that ML297 is dependent upon two residues unique to the 
GIRK1 subunit, F137 and D173. F137 is located in the pore-helix and D173 is located in 
the M2 domain. As previously demonstrated in Chapter 2, GIRK1 residue F137 is a 
critical determinant of robust basal- and GABABR-induced GIRK channel activity. 
Previous mutagenic studies have shown this residue to play a role in kinetics of 
activation, GIRK1 surface trafficking, and enhancement of GIRK current [68, 114, 225]. 
In the context of the P chimera discussed in Chapter 2, D173 enhanced GABABR-
induced GIRK current when compared to GIRK2 residue N184. Interestingly, GIRK1 
residue D173 has been previously identified as is a critical determinant for the inward 
rectification of K
+
 channels.  Removing the negative charged aspartate residue and 
replacing it with an uncharged glutamine weakened the inward-rectification properties 
associated with GIRK1 [225]. This aspartic residue is conserved across several other Kir 
channels, but is not in GIRK2, GIRK3, or GIRK4. D173 has been implicated as an 
interaction site for Mg
2+
, polyamines, and cation blockade. In mutating a homologous 
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residue in IRK1 (Kir2.1) (D172N), blockade by Cs
+
 and Rb
+
 were abolished [279]. 
Having an aspartate residue at this position is associated with strong rectification and a 
high affinity for blockade by Mg
2+
 and polyamines [280, 281]. By mutating this aspartate 
residue to asparagine (D to N), the channel affinity for Mg
2+
 and polyamines and strong 
rectification are both diminished [60, 282, 283]. GIRK activation by ML297 is dependent 
upon the presence of an aspartate at this position (GIRK1 D173) but our experiments also 
show that ML297 weakens inward rectification. This relationship suggests a direct 
interaction of ML297 with the channel and perhaps residue D173 itself, and that, through 
binding of ML297, the position of D173 is altered to cause a weakened rectification 
profile.  
  The work presented in this dissertation falls short of identifying the physical 
binding site of ML297 on GIRK channels. There are two binding theories that would be 
supported by the data shown here. The first is that ML297 could directly interact with 
GIRK1 residues F137 and D173. The fact that the mutation of either of these residues in 
GIRK1 disrupts activation by ML297 supports this theory but more experiments are 
needed. There is an alternate possibility that ML297 can bind GIRK1/GIRK2 channels or 
GIRK2 homomers and that F137 and D173 are simply required for enhanced channel 
activity. It is possible that ML297 could bind GIRK2 homomeric channels without 
activating them. Perhaps ML297 binds in a manner that mimics activation by Gβγ, 
similar to Na
+
 and short chain alcohols [93, 106, 167]. However, ML297 differs from 
these compounds in its complete dependence on the presence of GIRK1.  
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The mechanism of GIRK activation by ML297 is further complicated by the 
ability of ML297 to switch its function depending on the composition of the GIRK 
channel. ML297 has no effect on GIRK2 homomeric channels, is an effective agonist on 
GIRK1/GIRK2 and GIRK2
S148F/N184D
/GIRK2 heteromeric channels, and, surprisingly, 
acts as an antagonist on GIRK2
S148F/N184D
 homomers or GIRK2
S148F/N184D 
coexpressed 
with GIRK1 (data not shown). These results suggest that the organization of the GIRK 
channel pore is an extremely important determinant of ML297 activity. Similarly, other 
studies have observed differences in channel activity between heteromeric and 
homomeric pore conformations of GIRK channels [284]. Further, set configurations and 
stoichiometry of GIRK1/GIRK4 heterotetramers have been proposed [65, 285, 286]. 
Also, several groups suggest that a heteromeric GIRK1/GIRK4 pore is necessary for high 
K
+
 selectivity and robust channel activity [48, 69, 209, 284]. While some consider 
studying heteromeric channels as a caveat, it would seem that a heteromeric GIRK 
channel, and particularly a heteromeric pore, can be fundamentally different from a 
homomeric GIRK channel.  
 
Therapeutic potential of ML297  
The drug metabolism and pharmacokinetic (DMPK) properties of ML297 were 
characterized previously [169]. ML297 was found to have one inactive metabolite 
“ML397-M1” after being metabolized by cytochrome P450. In vitro assays found that 
ML297 has modest solubility, plasma protein binding, and hepatic clearance. In vivo 
assays found that ML297 is able to cross the blood brain barrier in mice with a 
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brain:plasma ratio of 0.2 at 30 minutes post I.P. injection of 60 mg/kg ML297. Despite 
the relatively short half-life and only modest brain penetration of ML297, a positive 
effect of ML297 was observed in two models of epilepsy [169]. In both models of 
epilepsy, ML297 treatment was found to be as, if not more, effective than sodium 
valproate, an antiepileptic compound in clinical use. In a maximal electroshock epilepsy 
model, 60 mg/kg ML297 resulted in a significant increase in the latency of seizure onset. 
In the chemically-induced epilepsy model (PTZ-treatment), pretreatment with 60 mg/kg 
ML297 resulted in a significant level of prevention of both convulsions and death [169].  
The full therapeutic potential associated with inhibiting or enhancing GIRK 
signaling will likely not be achieved without regional and/or GIRK subunit-selective 
manipulation because they are so widely expressed. In Chapter 3, we demonstrate the 
therapeutic potential that results from the selectivity of ML297. ML297, by activating 
GIRK1/2 channels, is able to elicit an anxiolytic phenotype without developing a 
conditioned place preference, meaning that ML297 achieves selective anxiolytic efficacy 
without a significant rewarding liability in mice. There is a need for anxiolytics with 
fewer side effects, rapid onset, with no abuse potential or motor dysfunction, and ML297 
poses to be a good therapeutic candidate. Given the importance of GIRK signaling to the 
proper function of the heart and brain, ML297 and derivatives represent the most 
promising class of pharmacologic tools currently available to study GIRK-dependent 
signaling. Their availability will transform this field, allowing us to break the species 
barrier and begin examining in rigorous detail the therapeutic potential of GIRK 
manipulation in more clinically-relevant settings. 
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RGS influence on parasympathetic heart rate regulation 
  Activation of the parasympathetic branch of the autonomic nervous system 
decreases heart rate via the neurotransmitter acetylcholine. Acetylcholine stimulates M2 
muscarinic receptors (M2R) on sinoatrial nodal cells and atrial myocytes, leading to the G 
protein-dependent activation of the potassium channel IKACh [51, 69]. Temporal 
regulation of the M2R-IKACh signaling cascade can impact heart rate [205, 206]. In 
Chapter 4, we found that the RGS6/Gβ5 protein complex is an essential modulator of 
M2R-IKACh signaling in cardiac myocytes and sinoatrial node cells. Furthermore, 
inactivation of the Rgs6 gene in mice results in a mild bradycardia and an enhanced effect 
of drug-induced parasympathetic stimulation. Thus, RGS6/Gβ5 may contribute to, or 
represent a novel therapeutic target for, pathological conditions characterized by 
abnormal regulation of cardiac output. 
  At the same time the work in Chapter 4 was published, another study about the 
role of RGS6 in parasympathetic regulation was also published [251]. Both studies 
demonstrated high levels of RGS6 expressed in atrial tissue via immunoblotting, 
particularly compared to RGS4 levels, which were higher in the brain than in the heart. 
Using immunohistochemistry, RGS6 was demonstrated to be specifically expressed in 
the SAN and AVN regions [251]. In our study we observed a slight but significant 
decrease in resting HR in Rgs6
−/− 
mice compared to wild-type mice as well as enhanced 
bradycardia during carbachol administration in Rgs6
−/− 
mice. Other work also observed 
enhanced carbachol induced bradycardia in Rgs6
−/− 
mice [251]. Furthermore, an 
exaggerated CCh-induced inhibition of spontaneous action potential firing in SAN cells 
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isolated from Rgs6
−/− 
mice was observed [251]. Both studies identify RGS6 as a key 
modulator of the M2R-IKACh cascade and, subsequently, of the parasympathetic regulation 
of heart rate.  
  An interesting finding of this study was that R7BP is not expressed in atrial tissue 
of wild-type mice. In the CNS, both Gβ5 and R7BP are necessary for the functionality of 
the R7 RGS family, including RGS6 [135-138]. While we demonstrated that the presence 
of Gβ5 is necessary for the stability and function of atrial RGS6, we don’t observe any 
deficits in RGS6 expression in the absence of R7BP. In the CNS, R7BP anchors RGS6 to 
the membrane so that it can interact with Gi/o protein signaling complexes. The 
mechanism by which RGS6 is anchored to the membrane in cardiomyocytes is still 
unknown. We demonstrated that RGS6/Gβ5 has a protein-protein interaction with 
GIRK4, but this interaction is likely through Gβ5 and not the DEP/DHEX domain of 
RGS6. It is possible that there is a different anchoring protein expressed in 
cardiomyocytes that fills the role of R7BP. Another possibility is that the RGS6/Gβ5 
complex is regulating the M2R-IKACh cascade from the cytosol and not the membrane. 
One approach to answering this question would be to perform a proteomic screen of 
RGS6/Gβ5 binding partners. Another approach would be to look at the intracellular 
localization of RGS6/Gβ5 with a live cell imaging assay. 
  A study in 2008 identified RGS4 as a regulator of parasympathetic M2R-IKACh 
signaling and heart rate, very similar to our findings for RGS6 [89]. It was demonstrated, 
albeit indirectly, that RGS4 is expressed in the SAN [89]. Rgs4
−/−  
mice displayed both 
significantly reduced resting heart rate and significantly enhanced CCh-induced 
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inhibition of spontaneous action potential firing compared to wild-type mice [89]. 
Further, Rgs4
−/−
 SAN cells had significantly slower activation and deactivation kinetics 
of CCh-induced IKACh activity [89]. Our original hypothesis concerning this work was 
that RGS4 and RGS6/Gβ5 were acting in parallel to regulate M2R-IKACh signaling. 
However, we failed to see an upregulation of RGS4 in the atrial tissue taken from Rgs6
−/−
 
mice, which we would expect to see if RGS4 were to exert a compensatory effect in these 
knockout animals. The goal of our next study (Chapter 5) was aimed at testing this 
hypothesis.  
  The work in Chapter 5 sought to clarify the molecular basis of the 
parasympathetic regulation of heart rate, dysregulation of which underlies multiple forms 
of arrhythmia and sudden cardiac death. Both RGS4 and RGS6 have been implicated in 
the temporal regulation of M2R-IKACh signaling and in the parasympathetic regulation of 
heart rate. We found that RGS4 does not make a significant contribution to the 
parasympathetic regulation of HR or related signaling in the SAN, under recording 
conditions where a prominent impact of RGS6 is observed. Interestingly, concurrent 
ablation of Rgs4 rescued, in part, many of the phenotypes observed in Rgs6
–/– 
mice. It 
appears that another member of the R7 RGS protein subfamily is present in SAN cells 
and can modulate muscarinic signaling, but its influence is masked by RGS6 and RGS4. 
This is an intriguing form of molecular compensation that may suggest an efficacious 
form of pharmacotherapy (i.e., RGS4 antagonism) that could be used to treat disorders 
linked to loss-of-function Rgs6 mutations.   
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In reconstituted expression systems, RGS4 has been shown to regulate GIRK 
channel kinetics [145, 287]. RGS4 was demonstrated to have GAP activity on members 
of both Gαi/o and Gαq protein families [145, 259, 262]. Furthermore, RGS4 has been 
shown to be upregulated in myocardial tissue taken from failing human hearts [262]. In 
that study, they found that the upregulation of RGS4 corresponded to a reduction in Gαq 
protein signaling. In our study, Rgs4 ablation trended in faster kinetics and larger GIRK 
responses through M2 activation. It is possible that RGS4 is acting on Gαq in the SAN in 
our study. If this is the case, the loss of RGS4 would result in less regulation of excitatory 
G protein signaling. GIRK signaling has been shown to be enhanced by excitation 
through feedback mechanisms, particularly by increases in intracellular Na
+
 [73, 93, 97-
101]. Taken together, RGS4 may be acting on Gαq to regulate excitatory sympathetic 
inputs in the SAN. 
 Another explanation as to why we did not observe an effect of Rgs4 ablation is 
that different signaling cascades might be compartmentalized within the atria, perhaps 
even within the SAN. Both adenosine and acetylcholine have been demonstrated to signal 
through IKACh in atrial myocytes [288]. In Chapter 4, we demonstrate that Rgs6 ablation 
causes enhanced CCh-induced bradycardia but there was no enhancement of adenosine-
induced bradycardia. This would suggest that while RGS6 is the key regulator of M2R-
IKACh signaling, the same may not be true for adenosine receptor-IKACh signaling. Perhaps 
the roles of RGS4 and RGS6 within the heart depend on the identity of GPCR upstream 
of the IKACh channel. Further, both signaling cascades may not be present in the SAN. 
While we’ve demonstrated robust M2R-IKACh activity in SAN cells by applying both CCh 
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and ACh, we have not observed an IKACh response in SAN cells to maximal doses of 
adenosine (data not shown). In order to get at this question, comparisons of 
electrophysiology responses to CCh and adenosine are needed from both SAN cells and 
atrial cardiomyocytes. These experiments could be done in cells taken from wild-type, 
Rgs4
–/–
, and Rgs6
–/– 
mice to further explore the compartmentalization of RGS proteins by 
cell population and GPCR identity. 
 
Future Directions 
Crystallization of the GIRK1/GIRK2 heteromer 
Many of the questions that remain unanswered in Chapters 2 and 3 point to the 
need to resolve the structure of the GIRK1/GIRK2 heteromeric channel. First, the 
functionality and structure of the distal C-terminus region unique to GIRK1 are still 
unknown. Some studies suggest that it may participate in binding Gβγ or even Gαi/o 
subunits [275, 289, 290]. Second, the shape and configuration of the GIRK1/GIRK2 
heteromeric pore has yet to be resolved and compared with the GIRK2 homomeric pore. 
Third, GIRK1 residue Q404 alters the sensitivity of GIRK channels for Gβγ but the 
underlying mechanism remains unknown. Resolving the GIRK1/GIRK2 heteromer in the 
absence and presence of Gβγ would give insight into whether Q404 alters the structural 
conformation of the channel’s cytosolic regions or if this residue is directly involved with 
a stronger physical interaction with Gβγ. Finally, the location of the physical binding site 
of ML297 and how the channel rearranges in the presence of ML297 needs to be 
elucidated to further understand the mechanism of action of this new drug class. 
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Unfortunately, crystallizing a natively formed heteromer is not possible, as a subset of 
formed-channel would be GIRK2 homomers, giving a non-uniform organization of 
protein. To fix this issue a concatamer of GIRK1 and GIRK2 fused together could be 
used instead. When expressed, this concatamer would form a dimer with another 
concatamer forcing uniform expression of GIRK1/GIRK2 heteromeric protein. This 
protein would be crystallized by itself, in the presence of PIP2 and Gβγ, and in the 
presence of ML297. Point mutations of GIRK1, such as Q404A, could be made on the 
concatamer and crystallized as well. This set of crystal structures would give much 
needed insight into the unresolved questions from Chapters 2 and 3.  
   
 Mechanism of selectivity for GIRK2- and GIRK4-containing channels 
  An interesting observation in the characterization of ML297 is that, while it has a 
robust effect on GIRK1/GIRK2 heteromeric channels, it induces less current from 
GIRK1/GIRK4 heteromeric channels. Some drugs from this new class demonstrate even 
more preference for GIRK2 over GIRK4 than ML297, while others are able to activate 
GIRK1/GIRK2 and GIRK1/GIRK4 equally. VU0466553 is completely selective for 
GIRK1/GIRK2 channels, and actually antagonizes GIRK1/GIRK4 channels (data not 
shown). As this drug class undergoes development, it would have enormous therapeutic 
potential if drugs completely selective in their activation of either GIRK1/GIRK2 or 
GIRK1/GIRK4 could be designed or identified in a high-throughput screen. 
GIRK1/GIRK4 channels make up the IKACh channel in the heart and, as discussed 
previously, play a role in the modulation of heart rate. A targeted GIRK1/GIRK4 agonist, 
  162 
with no activity on GIRK1/GIRK2 channels, could be used to treat arrhythmias without 
having adverse effects on cognitive functions. Alternately, a completely GIRK1/GIRK2 
selective drug could be used in the treatment of anxiety, epilepsy, and perhaps pain, 
without the concern of adverse effects on cardiac function.  
  In order to test compounds for their selectivity between GIRK2- and GIRK4-
containing channels, we would first apply them in electrophysiology experiments in 
different cell types. By taking advantage of the endogenous expression of different 
heteromeric GIRK channels in hippocampal neurons (GIRK1/GIRK2) and sinoatrial 
node cells (GIRK1/GIRK4), we would apply these compounds to both types and see if 
they are able to evoke a response in one and not the other. In doing so, this assay would 
assess their selectivity for GIRK1/GIRK2 and GIRK1/GIRK4. Behavioral tests, such as 
motor activity, elevated plus maze, stress-induced hyperthermia, and physiological tests, 
including ECG telemetry and ex vivo perfused-heart rate measurements (also referred to 
as Langendorff perfusion), would be further used to look at the efficacy and selectivity of 
compounds that show promise in the electrophysiology assays.  
  The other side of this project would be to identify the structural determinant(s) in 
GIRK2 and GIRK4 that cause this difference in selective activation by this new drug 
class. Out of all the GIRK channels, GIRK2A and GIRK4 are the most similar in 
sequence and structure but differ in their distribution [50, 70, 291]. Using a chimeric 
approach, similar to the approach used in Chapter 2, and the high-throughput thallium 
flux assay, we would be able to test different regions for their role in this mechanism of 
selectivity. Once a region (or regions) was isolated, site-directed mutagenesis would 
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allow us to pinpoint the exact residues responsible for this difference. In discovering the 
structural determinant(s) of selectivity between GIRK2 and GIRK4, we may also gain 
insight into the physical binding site of compounds in this new drug class.  
By understanding the mechanism of selectivity between GIRK2- and GIRK4-
containing channels, we would have new potential therapeutic compounds that could 
selectively treat cardiac and CNS diseases. GIRK1/GIRK2 selective agonists and 
antagonists would allow for new pharmacotherapies against anxiety, epilepsy, 
neuropathic pain, depression, addiction, schizophrenia, and Down’s syndrome [57, 170]. 
GIRK1/GIRK4 selective agonists and antagonists could offer new pharmacotherapies for 
cardiac arrhythmias, hyperaldosteronism, and obesity [170]. Together, this new drug 
class will have an important impact on how GIRK channels are studied and will greatly 
change how many excitatory diseases are treated.  
  
  164 
 
 
 
 
 
 
 
 
 
REFERENCES 
  
  165 
1. Schlyer, S. and R. Horuk, I want a new drug: G-protein-coupled receptors in 
drug development. Drug discovery today, 2006. 11(11-12): p. 481-93. 
2. Oldham, W.M. and H.E. Hamm, Heterotrimeric G protein activation by G-
protein-coupled receptors. Nature reviews. Molecular cell biology, 2008. 9(1): p. 
60-71. 
3. Schmidt, C.J., et al., Specificity of G protein beta and gamma subunit 
interactions. The Journal of biological chemistry, 1992. 267(20): p. 13807-10. 
4. Downes, G.B. and N. Gautam, The G protein subunit gene families. Genomics, 
1999. 62(3): p. 544-52. 
5. Hermans, E., Biochemical and pharmacological control of the multiplicity of 
coupling at G-protein-coupled receptors. Pharmacology & therapeutics, 2003. 
99(1): p. 25-44. 
6. Senogles, S.E., et al., Specificity of receptor-G protein interactions. 
Discrimination of Gi subtypes by the D2 dopamine receptor in a reconstituted 
system. The Journal of biological chemistry, 1990. 265(8): p. 4507-14. 
7. Simon, M.I., M.P. Strathmann, and N. Gautam, Diversity of G proteins in signal 
transduction. Science, 1991. 252(5007): p. 802-8. 
8. Trumpp-Kallmeyer, S., et al., Modeling of G-protein-coupled receptors: 
application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian 
opsin receptors. Journal of medicinal chemistry, 1992. 35(19): p. 3448-62. 
9. Hearing, M.C., A.N. Zink, and K. Wickman, Cocaine-induced adaptations in 
metabotropic inhibitory signaling in the mesocorticolimbic system. Reviews in the 
neurosciences, 2012. 23(4): p. 325-51. 
10. Lambright, D.G., et al., Structural determinants for activation of the alpha-
subunit of a heterotrimeric G protein. Nature, 1994. 369(6482): p. 621-8. 
11. Coleman, D.E., et al., Structures of active conformations of Gi alpha 1 and the 
mechanism of GTP hydrolysis. Science, 1994. 265(5177): p. 1405-12. 
12. Mixon, M.B., et al., Tertiary and quaternary structural changes in Gi alpha 1 
induced by GTP hydrolysis. Science, 1995. 270(5238): p. 954-60. 
13. Smotrys, J.E. and M.E. Linder, Palmitoylation of intracellular signaling proteins: 
regulation and function. Annual review of biochemistry, 2004. 73: p. 559-87. 
14. Chen, C.A. and D.R. Manning, Regulation of G proteins by covalent modification. 
Oncogene, 2001. 20(13): p. 1643-52. 
15. Sondek, J., et al., Crystal structure of a G-protein beta gamma dimer at 2.1A 
resolution. Nature, 1996. 379(6563): p. 369-74. 
16. Wall, M.A., et al., The structure of the G protein heterotrimer Gi alpha 1 beta 1 
gamma 2. Cell, 1995. 83(6): p. 1047-58. 
17. Zhang, F.L. and P.J. Casey, Protein prenylation: molecular mechanisms and 
functional consequences. Annual review of biochemistry, 1996. 65: p. 241-69. 
18. Bjarnadottir, T.K., et al., Comprehensive repertoire and phylogenetic analysis of 
the G protein-coupled receptors in human and mouse. Genomics, 2006. 88(3): p. 
263-73. 
  166 
19. Fredriksson, R., et al., The G-protein-coupled receptors in the human genome 
form five main families. Phylogenetic analysis, paralogon groups, and 
fingerprints. Molecular pharmacology, 2003. 63(6): p. 1256-72. 
20. Kristiansen, K., Molecular mechanisms of ligand binding, signaling, and 
regulation within the superfamily of G-protein-coupled receptors: molecular 
modeling and mutagenesis approaches to receptor structure and function. 
Pharmacology & therapeutics, 2004. 103(1): p. 21-80. 
21. Javitch, J.A., The ants go marching two by two: oligomeric structure of G-
protein-coupled receptors. Molecular pharmacology, 2004. 66(5): p. 1077-82. 
22. Milligan, G., G protein-coupled receptor dimerization: function and ligand 
pharmacology. Molecular pharmacology, 2004. 66(1): p. 1-7. 
23. Baneres, J.L. and J. Parello, Structure-based analysis of GPCR function: evidence 
for a novel pentameric assembly between the dimeric leukotriene B4 receptor 
BLT1 and the G-protein. Journal of molecular biology, 2003. 329(4): p. 815-29. 
24. Pin, J.P., T. Galvez, and L. Prezeau, Evolution, structure, and activation 
mechanism of family 3/C G-protein-coupled receptors. Pharmacology & 
therapeutics, 2003. 98(3): p. 325-54. 
25. George, S.R., B.F. O'Dowd, and S.P. Lee, G-protein-coupled receptor 
oligomerization and its potential for drug discovery. Nature reviews. Drug 
discovery, 2002. 1(10): p. 808-20. 
26. Brinkerhoff, C.J., J.R. Traynor, and J.J. Linderman, Collision coupling, crosstalk, 
and compartmentalization in G-protein coupled receptor systems: can a single 
model explain disparate results? Journal of theoretical biology, 2008. 255(3): p. 
278-86. 
27. Challiss, R.A. and J. Wess, Receptors: GPCR-G protein preassembly? Nature 
chemical biology, 2011. 7(10): p. 657-8. 
28. Gales, C., et al., Probing the activation-promoted structural rearrangements in 
preassembled receptor-G protein complexes. Nature structural & molecular 
biology, 2006. 13(9): p. 778-86. 
29. Alves, I.D., et al., Phosphatidylethanolamine enhances rhodopsin photoactivation 
and transducin binding in a solid supported lipid bilayer as determined using 
plasmon-waveguide resonance spectroscopy. Biophysical journal, 2005. 88(1): p. 
198-210. 
30. Alves, I.D., et al., Direct observation of G-protein binding to the human delta-
opioid receptor using plasmon-waveguide resonance spectroscopy. The Journal 
of biological chemistry, 2003. 278(49): p. 48890-7. 
31. Qin, K., et al., Inactive-state preassembly of G(q)-coupled receptors and G(q) 
heterotrimers. Nature chemical biology, 2011. 7(10): p. 740-7. 
32. Nobles, M., A. Benians, and A. Tinker, Heterotrimeric G proteins precouple with 
G protein-coupled receptors in living cells. Proceedings of the National Academy 
of Sciences of the United States of America, 2005. 102(51): p. 18706-11. 
33. Hall, R.A., R.T. Premont, and R.J. Lefkowitz, Heptahelical receptor signaling: 
beyond the G protein paradigm. The Journal of cell biology, 1999. 145(5): p. 927-
32. 
  167 
34. Wickman, K. and D.E. Clapham, Ion channel regulation by G proteins. 
Physiological reviews, 1995. 75(4): p. 865-85. 
35. Burns, D.L., et al., Biochemical properties of pertussis toxin. The Tokai journal of 
experimental and clinical medicine, 1988. 13 Suppl: p. 181-5. 
36. Burns, D.L., Subunit structure and enzymic activity of pertussis toxin. 
Microbiological sciences, 1988. 5(9): p. 285-7. 
37. Katada, T. and M. Ui, ADP ribosylation of the specific membrane protein of C6 
cells by islet-activating protein associated with modification of adenylate cyclase 
activity. The Journal of biological chemistry, 1982. 257(12): p. 7210-6. 
38. Kurose, H., et al., Specific uncoupling by islet-activating protein, pertussis toxin, 
of negative signal transduction via alpha-adrenergic, cholinergic, and opiate 
receptors in neuroblastoma x glioma hybrid cells. The Journal of biological 
chemistry, 1983. 258(8): p. 4870-5. 
39. Mangmool, S. and H. Kurose, G(i/o) protein-dependent and -independent actions 
of Pertussis Toxin (PTX). Toxins, 2011. 3(7): p. 884-99. 
40. Carter, B.D. and F. Medzihradsky, Go mediates the coupling of the mu opioid 
receptor to adenylyl cyclase in cloned neural cells and brain. Proceedings of the 
National Academy of Sciences of the United States of America, 1993. 90(9): p. 
4062-6. 
41. Wittpoth, C., et al., Regions on adenylyl cyclase that are necessary for inhibition 
of activity by beta gamma and G(ialpha) subunits of heterotrimeric G proteins. 
Proceedings of the National Academy of Sciences of the United States of 
America, 1999. 96(17): p. 9551-6. 
42. Johnson, D.A., et al., Dynamics of cAMP-dependent protein kinase. Chemical 
reviews, 2001. 101(8): p. 2243-70. 
43. Chen, H. and N.A. Lambert, Inhibition of dendritic calcium influx by activation of 
G-protein-coupled receptors in the hippocampus. Journal of neurophysiology, 
1997. 78(6): p. 3484-8. 
44. Jeong, S.W. and S.R. Ikeda, Effect of G protein heterotrimer composition on 
coupling of neurotransmitter receptors to N-type Ca(2+) channel modulation in 
sympathetic neurons. Proceedings of the National Academy of Sciences of the 
United States of America, 2000. 97(2): p. 907-12. 
45. Herlitze, S., et al., Modulation of Ca2+ channels by G-protein beta gamma 
subunits. Nature, 1996. 380(6571): p. 258-62. 
46. Wickman, K.D., et al., Recombinant G-protein beta gamma-subunits activate the 
muscarinic-gated atrial potassium channel. Nature, 1994. 368(6468): p. 255-7. 
47. Reuveny, E., et al., Activation of the cloned muscarinic potassium channel by G 
protein beta gamma subunits. Nature, 1994. 370(6485): p. 143-6. 
48. Krapivinsky, G., et al., G beta gamma binds directly to the G protein-gated K+ 
channel, IKACh. The Journal of biological chemistry, 1995. 270(49): p. 29059-62. 
49. Inanobe, A., et al., G beta gamma directly binds to the carboxyl terminus of the G 
protein-gated muscarinic K+ channel, GIRK1. Biochemical and biophysical 
research communications, 1995. 212(3): p. 1022-8. 
  168 
50. Karschin, C., et al., IRK(1-3) and GIRK(1-4) inwardly rectifying K+ channel 
mRNAs are differentially expressed in the adult rat brain. The Journal of 
neuroscience : the official journal of the Society for Neuroscience, 1996. 16(11): 
p. 3559-70. 
51. Wickman, K., et al., Structure, G protein activation, and functional relevance of 
the cardiac G protein-gated K+ channel, IKACh. Annals of the New York 
Academy of Sciences, 1999. 868: p. 386-98. 
52. Luscher, C., et al., G protein-coupled inwardly rectifying K+ channels (GIRKs) 
mediate postsynaptic but not presynaptic transmitter actions in hippocampal 
neurons. Neuron, 1997. 19(3): p. 687-95. 
53. Lacey, M.G., N.B. Mercuri, and R.A. North, Dopamine acts on D2 receptors to 
increase potassium conductance in neurones of the rat substantia nigra zona 
compacta. The Journal of physiology, 1987. 392: p. 397-416. 
54. Newberry, N.R. and R.A. Nicoll, Comparison of the action of baclofen with 
gamma-aminobutyric acid on rat hippocampal pyramidal cells in vitro. The 
Journal of physiology, 1985. 360: p. 161-85. 
55. Dutar, P., H.M. Vu, and D.J. Perkel, Pharmacological characterization of an 
unusual mGluR-evoked neuronal hyperpolarization mediated by activation of 
GIRK channels. Neuropharmacology, 1999. 38(4): p. 467-75. 
56. Sun, Q.Q., J.R. Huguenard, and D.A. Prince, Somatostatin inhibits thalamic 
network oscillations in vitro: actions on the GABAergic neurons of the reticular 
nucleus. The Journal of neuroscience : the official journal of the Society for 
Neuroscience, 2002. 22(13): p. 5374-86. 
57. Luscher, C. and P.A. Slesinger, Emerging roles for G protein-gated inwardly 
rectifying potassium (GIRK) channels in health and disease. Nature reviews. 
Neuroscience, 2010. 11(5): p. 301-15. 
58. Nichols, C.G. and A.N. Lopatin, Inward rectifier potassium channels. Annual 
review of physiology, 1997. 59: p. 171-91. 
59. Fakler, B., et al., Strong voltage-dependent inward rectification of inward 
rectifier K+ channels is caused by intracellular spermine. Cell, 1995. 80(1): p. 
149-54. 
60. Lopatin, A.N., E.N. Makhina, and C.G. Nichols, Potassium channel block by 
cytoplasmic polyamines as the mechanism of intrinsic rectification. Nature, 1994. 
372(6504): p. 366-9. 
61. Yamada, M. and Y. Kurachi, Spermine gates inward-rectifying muscarinic but not 
ATP-sensitive K+ channels in rabbit atrial myocytes. Intracellular substance-
mediated mechanism of inward rectification. The Journal of biological chemistry, 
1995. 270(16): p. 9289-94. 
62. Yamada, M., A. Inanobe, and Y. Kurachi, G protein regulation of potassium ion 
channels. Pharmacological reviews, 1998. 50(4): p. 723-60. 
63. Liao, Y.J., Y.N. Jan, and L.Y. Jan, Heteromultimerization of G-protein-gated 
inwardly rectifying K+ channel proteins GIRK1 and GIRK2 and their altered 
expression in weaver brain. The Journal of neuroscience : the official journal of 
the Society for Neuroscience, 1996. 16(22): p. 7137-50. 
  169 
64. Jelacic, T.M., et al., Functional and biochemical evidence for G-protein-gated 
inwardly rectifying K+ (GIRK) channels composed of GIRK2 and GIRK3. The 
Journal of biological chemistry, 2000. 275(46): p. 36211-6. 
65. Tucker, S.J., M. Pessia, and J.P. Adelman, Muscarine-gated K+ channel: subunit 
stoichiometry and structural domains essential for G protein stimulation. The 
American journal of physiology, 1996. 271(1 Pt 2): p. H379-85. 
66. Kofuji, P., N. Davidson, and H.A. Lester, Evidence that neuronal G-protein-gated 
inwardly rectifying K+ channels are activated by G beta gamma subunits and 
function as heteromultimers. Proceedings of the National Academy of Sciences of 
the United States of America, 1995. 92(14): p. 6542-6. 
67. Dascal, N., Signalling via the G protein-activated K+ channels. Cellular 
signalling, 1997. 9(8): p. 551-73. 
68. Ma, D., et al., Diverse trafficking patterns due to multiple traffic motifs in G 
protein-activated inwardly rectifying potassium channels from brain and heart. 
Neuron, 2002. 33(5): p. 715-29. 
69. Krapivinsky, G., et al., The G-protein-gated atrial K+ channel IKACh is a 
heteromultimer of two inwardly rectifying K(+)-channel proteins. Nature, 1995. 
374(6518): p. 135-41. 
70. Jelacic, T.M., S.M. Sims, and D.E. Clapham, Functional expression and 
characterization of G-protein-gated inwardly rectifying K+ channels containing 
GIRK3. The Journal of membrane biology, 1999. 169(2): p. 123-9. 
71. Wischmeyer, E., et al., Subunit interactions in the assembly of neuronal Kir3.0 
inwardly rectifying K+ channels. Molecular and cellular neurosciences, 1997. 
9(3): p. 194-206. 
72. Lesage, F., et al., Cloning provides evidence for a family of inward rectifier and 
G-protein coupled K+ channels in the brain. FEBS letters, 1994. 353(1): p. 37-
42. 
73. Lesage, F., et al., Molecular properties of neuronal G-protein-activated inwardly 
rectifying K+ channels. The Journal of biological chemistry, 1995. 270(48): p. 
28660-7. 
74. Isomoto, S., et al., A novel ubiquitously distributed isoform of GIRK2 (GIRK2B) 
enhances GIRK1 expression of the G-protein-gated K+ current in Xenopus 
oocytes. Biochemical and biophysical research communications, 1996. 218(1): p. 
286-91. 
75. Nehring, R.B., et al., Neuronal inwardly rectifying K(+) channels differentially 
couple to PDZ proteins of the PSD-95/SAP90 family. The Journal of neuroscience 
: the official journal of the Society for Neuroscience, 2000. 20(1): p. 156-62. 
76. Inanobe, A., et al., Molecular cloning and characterization of a novel splicing 
variant of the Kir3.2 subunit predominantly expressed in mouse testis. The 
Journal of physiology, 1999. 521 Pt 1: p. 19-30. 
77. Nelson, C.S., J.L. Marino, and C.N. Allen, Cloning and characterization of Kir3.1 
(GIRK1) C-terminal alternative splice variants. Brain research. Molecular brain 
research, 1997. 46(1-2): p. 185-96. 
  170 
78. Steinecker, B., C. Rosker, and W. Schreibmayer, The GIRK1 brain variant 
GIRK1d and its functional impact on heteromultimeric GIRK channels. Journal of 
receptor and signal transduction research, 2007. 27(5-6): p. 369-82. 
79. Wagner, V., et al., Cloning and characterisation of GIRK1 variants resulting from 
alternative RNA editing of the KCNJ3 gene transcript in a human breast cancer 
cell line. Journal of cellular biochemistry, 2010. 110(3): p. 598-608. 
80. Wickman, K., et al., Brain localization and behavioral impact of the G-protein-
gated K+ channel subunit GIRK4. The Journal of neuroscience : the official 
journal of the Society for Neuroscience, 2000. 20(15): p. 5608-15. 
81. Perry, C.A., et al., Predisposition to late-onset obesity in GIRK4 knockout mice. 
Proceedings of the National Academy of Sciences of the United States of 
America, 2008. 105(23): p. 8148-53. 
82. Koyrakh, L., et al., Molecular and cellular diversity of neuronal G-protein-gated 
potassium channels. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 2005. 25(49): p. 11468-78. 
83. Slesinger, P.A., et al., Defective gamma-aminobutyric acid type B receptor-
activated inwardly rectifying K+ currents in cerebellar granule cells isolated 
from weaver and Girk2 null mutant mice. Proceedings of the National Academy 
of Sciences of the United States of America, 1997. 94(22): p. 12210-7. 
84. Torrecilla, M., et al., G-protein-gated potassium channels containing Kir3.2 and 
Kir3.3 subunits mediate the acute inhibitory effects of opioids on locus ceruleus 
neurons. The Journal of neuroscience : the official journal of the Society for 
Neuroscience, 2002. 22(11): p. 4328-34. 
85. Cruz, H.G., et al., Absence and rescue of morphine withdrawal in GIRK/Kir3 
knock-out mice. The Journal of neuroscience : the official journal of the Society 
for Neuroscience, 2008. 28(15): p. 4069-77. 
86. Labouebe, G., et al., RGS2 modulates coupling between GABAB receptors and 
GIRK channels in dopamine neurons of the ventral tegmental area. Nature 
neuroscience, 2007. 10(12): p. 1559-68. 
87. Cruz, H.G., et al., Bi-directional effects of GABA(B) receptor agonists on the 
mesolimbic dopamine system. Nature neuroscience, 2004. 7(2): p. 153-9. 
88. Inanobe, A., et al., Characterization of G-protein-gated K+ channels composed of 
Kir3.2 subunits in dopaminergic neurons of the substantia nigra. The Journal of 
neuroscience : the official journal of the Society for Neuroscience, 1999. 19(3): p. 
1006-17. 
89. Cifelli, C., et al., RGS4 regulates parasympathetic signaling and heart rate 
control in the sinoatrial node. Circulation research, 2008. 103(5): p. 527-35. 
90. Iwanir, S. and E. Reuveny, Adrenaline-induced hyperpolarization of mouse 
pancreatic islet cells is mediated by G protein-gated inwardly rectifying 
potassium (GIRK) channels. Pflugers Archiv : European journal of physiology, 
2008. 456(6): p. 1097-108. 
91. Yi, Y.J., et al., Sperm GIRK2-containing K+ inward rectifying channels 
participate in sperm capacitation and fertilization. Systems biology in 
reproductive medicine, 2011. 57(6): p. 296-308. 
  171 
92. Huang, C.L., S. Feng, and D.W. Hilgemann, Direct activation of inward rectifier 
potassium channels by PIP2 and its stabilization by Gbetagamma. Nature, 1998. 
391(6669): p. 803-6. 
93. Whorton, M.R. and R. MacKinnon, Crystal structure of the mammalian GIRK2 
K+ channel and gating regulation by G proteins, PIP2, and sodium. Cell, 2011. 
147(1): p. 199-208. 
94. Suh, B.C. and B. Hille, PIP2 is a necessary cofactor for ion channel function: 
how and why? Annual review of biophysics, 2008. 37: p. 175-95. 
95. Somlyo, A.P. and A.V. Somlyo, Signal transduction and regulation in smooth 
muscle. Nature, 1994. 372(6503): p. 231-6. 
96. Lopes, C.M., et al., Alterations in conserved Kir channel-PIP2 interactions 
underlie channelopathies. Neuron, 2002. 34(6): p. 933-44. 
97. Zhang, H., et al., Activation of inwardly rectifying K+ channels by distinct 
PtdIns(4,5)P2 interactions. Nature cell biology, 1999. 1(3): p. 183-8. 
98. Ho, I.H. and R.D. Murrell-Lagnado, Molecular determinants for sodium-
dependent activation of G protein-gated K+ channels. The Journal of biological 
chemistry, 1999. 274(13): p. 8639-48. 
99. Ho, I.H. and R.D. Murrell-Lagnado, Molecular mechanism for sodium-dependent 
activation of G protein-gated K+ channels. The Journal of physiology, 1999. 520 
Pt 3: p. 645-51. 
100. Sui, J.L., K.W. Chan, and D.E. Logothetis, Na+ activation of the muscarinic K+ 
channel by a G-protein-independent mechanism. The Journal of general 
physiology, 1996. 108(5): p. 381-91. 
101. Sui, J.L., J. Petit-Jacques, and D.E. Logothetis, Activation of the atrial KACh 
channel by the betagamma subunits of G proteins or intracellular Na+ ions 
depends on the presence of phosphatidylinositol phosphates. Proceedings of the 
National Academy of Sciences of the United States of America, 1998. 95(3): p. 
1307-12. 
102. Nishida, M. and R. MacKinnon, Structural basis of inward rectification: 
cytoplasmic pore of the G protein-gated inward rectifier GIRK1 at 1.8 A 
resolution. Cell, 2002. 111(7): p. 957-65. 
103. Pegan, S., et al., Cytoplasmic domain structures of Kir2.1 and Kir3.1 show sites 
for modulating gating and rectification. Nature neuroscience, 2005. 8(3): p. 279-
87. 
104. Inanobe, A., et al., Structural diversity in the cytoplasmic region of G protein-
gated inward rectifier K+ channels. Channels, 2007. 1(1): p. 39-45. 
105. Nishida, M., et al., Crystal structure of a Kir3.1-prokaryotic Kir channel chimera. 
The EMBO journal, 2007. 26(17): p. 4005-15. 
106. Whorton, M.R. and R. MacKinnon, X-ray structure of the mammalian GIRK2-
betagamma G-protein complex. Nature, 2013. 498(7453): p. 190-7. 
107. Lunn, M.L., et al., A unique sorting nexin regulates trafficking of potassium 
channels via a PDZ domain interaction. Nature neuroscience, 2007. 10(10): p. 
1249-59. 
  172 
108. Hibino, H., et al., Anchoring proteins confer G protein sensitivity to an inward-
rectifier K(+) channel through the GK domain. The EMBO journal, 2000. 19(1): 
p. 78-83. 
109. Leaney, J.L., Contribution of Kir3.1, Kir3.2A and Kir3.2C subunits to native G 
protein-gated inwardly rectifying potassium currents in cultured hippocampal 
neurons. The European journal of neuroscience, 2003. 18(8): p. 2110-8. 
110. Slesinger, P.A., et al., Identification of structural elements involved in G protein 
gating of the GIRK1 potassium channel. Neuron, 1995. 15(5): p. 1145-56. 
111. Thomas, A.M., et al., Differential phosphoinositide binding to components of the 
G protein-gated K+ channel. The Journal of membrane biology, 2006. 211(1): p. 
43-53. 
112. Stevens, E.B., et al., Identification of regions that regulate the expression and 
activity of G protein-gated inward rectifier K+ channels in Xenopus oocytes. The 
Journal of physiology, 1997. 503 ( Pt 3): p. 547-62. 
113. Chan, K.W., et al., Specific regions of heteromeric subunits involved in 
enhancement of G protein-gated K+ channel activity. The Journal of biological 
chemistry, 1997. 272(10): p. 6548-55. 
114. Chan, K.W., et al., Control of channel activity through a unique amino acid 
residue of a G protein-gated inwardly rectifying K+ channel subunit. Proceedings 
of the National Academy of Sciences of the United States of America, 1996. 
93(24): p. 14193-8. 
115. Kunkel, M.T. and E.G. Peralta, Identification of domains conferring G protein 
regulation on inward rectifier potassium channels. Cell, 1995. 83(3): p. 443-9. 
116. Conklin, B.R. and H.R. Bourne, Structural elements of G alpha subunits that 
interact with G beta gamma, receptors, and effectors. Cell, 1993. 73(4): p. 631-
41. 
117. Doupnik, C.A., et al., Time resolved kinetics of direct G beta 1 gamma 2 
interactions with the carboxyl terminus of Kir3.4 inward rectifier K+ channel 
subunits. Neuropharmacology, 1996. 35(7): p. 923-31. 
118. Benians, A., J.L. Leaney, and A. Tinker, Agonist unbinding from receptor dictates 
the nature of deactivation kinetics of G protein-gated K+ channels. Proceedings 
of the National Academy of Sciences of the United States of America, 2003. 
100(10): p. 6239-44. 
119. Blumer, J.B., et al., AGS proteins: receptor-independent activators of G-protein 
signaling. Trends in pharmacological sciences, 2005. 26(9): p. 470-6. 
120. Cismowski, M.J., et al., Activation of heterotrimeric G-protein signaling by a ras-
related protein. Implications for signal integration. The Journal of biological 
chemistry, 2000. 275(31): p. 23421-4. 
121. Peterson, Y.K., et al., Stabilization of the GDP-bound conformation of Gialpha by 
a peptide derived from the G-protein regulatory motif of AGS3. The Journal of 
biological chemistry, 2000. 275(43): p. 33193-6. 
122. Ghosh, M., et al., Receptor- and nucleotide exchange-independent mechanisms 
for promoting G protein subunit dissociation. The Journal of biological chemistry, 
2003. 278(37): p. 34747-50. 
  173 
123. Siderovski, D.P., S.P. Heximer, and D.R. Forsdyke, A human gene encoding a 
putative basic helix-loop-helix phosphoprotein whose mRNA increases rapidly in 
cycloheximide-treated blood mononuclear cells. DNA and cell biology, 1994. 
13(2): p. 125-47. 
124. Berman, D.M., T.M. Wilkie, and A.G. Gilman, GAIP and RGS4 are GTPase-
activating proteins for the Gi subfamily of G protein alpha subunits. Cell, 1996. 
86(3): p. 445-52. 
125. Ross, E.M. and T.M. Wilkie, GTPase-activating proteins for heterotrimeric G 
proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annual 
review of biochemistry, 2000. 69: p. 795-827. 
126. Popov, S., et al., The regulators of G protein signaling (RGS) domains of RGS4, 
RGS10, and GAIP retain GTPase activating protein activity in vitro. Proceedings 
of the National Academy of Sciences of the United States of America, 1997. 
94(14): p. 7216-20. 
127. Zeng, W., et al., The N-terminal domain of RGS4 confers receptor-selective 
inhibition of G protein signaling. The Journal of biological chemistry, 1998. 
273(52): p. 34687-90. 
128. Sjogren, B., L.L. Blazer, and R.R. Neubig, Regulators of G protein signaling 
proteins as targets for drug discovery. Progress in molecular biology and 
translational science, 2010. 91: p. 81-119. 
129. Hepler, J.R., Emerging roles for RGS proteins in cell signalling. Trends in 
pharmacological sciences, 1999. 20(9): p. 376-82. 
130. Bernstein, L.S., et al., RGS4 binds to membranes through an amphipathic alpha -
helix. The Journal of biological chemistry, 2000. 275(24): p. 18520-6. 
131. Watson, N., et al., RGS family members: GTPase-activating proteins for 
heterotrimeric G-protein alpha-subunits. Nature, 1996. 383(6596): p. 172-5. 
132. Anderson, G.R., E. Posokhova, and K.A. Martemyanov, The R7 RGS protein 
family: multi-subunit regulators of neuronal G protein signaling. Cell 
biochemistry and biophysics, 2009. 54(1-3): p. 33-46. 
133. Cabrera, J.L., et al., Identification of the Gbeta5-RGS7 protein complex in the 
retina. Biochemical and biophysical research communications, 1998. 249(3): p. 
898-902. 
134. Makino, E.R., et al., The GTPase activating factor for transducin in rod 
photoreceptors is the complex between RGS9 and type 5 G protein beta subunit. 
Proceedings of the National Academy of Sciences of the United States of 
America, 1999. 96(5): p. 1947-52. 
135. Snow, B.E., et al., Fidelity of G protein beta-subunit association by the G protein 
gamma-subunit-like domains of RGS6, RGS7, and RGS11. Proceedings of the 
National Academy of Sciences of the United States of America, 1999. 96(11): p. 
6489-94. 
136. Witherow, D.S., et al., Complexes of the G protein subunit gbeta 5 with the 
regulators of G protein signaling RGS7 and RGS9. Characterization in native 
tissues and in transfected cells. The Journal of biological chemistry, 2000. 
275(32): p. 24872-80. 
  174 
137. Anderson, G.R., et al., Expression and localization of RGS9-2/G 5/R7BP complex 
in vivo is set by dynamic control of its constitutive degradation by cellular 
cysteine proteases. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 2007. 27(51): p. 14117-27. 
138. Drenan, R.M., et al., R7BP augments the function of RGS7*Gbeta5 complexes by 
a plasma membrane-targeting mechanism. The Journal of biological chemistry, 
2006. 281(38): p. 28222-31. 
139. Stanfield, P.R., S. Nakajima, and Y. Nakajima, Constitutively active and G-
protein coupled inward rectifier K+ channels: Kir2.0 and Kir3.0. Reviews of 
physiology, biochemistry and pharmacology, 2002. 145: p. 47-179. 
140. Doupnik, C.A., et al., RGS proteins reconstitute the rapid gating kinetics of 
gbetagamma-activated inwardly rectifying K+ channels. Proceedings of the 
National Academy of Sciences of the United States of America, 1997. 94(19): p. 
10461-6. 
141. Saitoh, O., et al., RGS8 accelerates G-protein-mediated modulation of K+ 
currents. Nature, 1997. 390(6659): p. 525-9. 
142. Herlitze, S., J.P. Ruppersberg, and M.D. Mark, New roles for RGS2, 5 and 8 on 
the ratio-dependent modulation of recombinant GIRK channels expressed in 
Xenopus oocytes. The Journal of physiology, 1999. 517 ( Pt 2): p. 341-52. 
143. Chuang, H.H., et al., Evidence that the nucleotide exchange and hydrolysis cycle 
of G proteins causes acute desensitization of G-protein gated inward rectifier K+ 
channels. Proceedings of the National Academy of Sciences of the United States 
of America, 1998. 95(20): p. 11727-32. 
144. Ulens, C., P. Daenens, and J. Tytgat, Changes in GIRK1/GIRK2 deactivation 
kinetics and basal activity in the presence and absence of RGS4. Life sciences, 
2000. 67(19): p. 2305-17. 
145. Fujita, S., et al., A regulator of G protein signalling (RGS) protein confers 
agonist-dependent relaxation gating to a G protein-gated K+ channel. The 
Journal of physiology, 2000. 526 Pt 2: p. 341-7. 
146. Xie, K., et al., Gbeta5 recruits R7 RGS proteins to GIRK channels to regulate the 
timing of neuronal inhibitory signaling. Nature neuroscience, 2010. 13(6): p. 661-
3. 
147. Ransom, C.B. and H. Sontheimer, Biophysical and pharmacological 
characterization of inwardly rectifying K+ currents in rat spinal cord astrocytes. 
Journal of neurophysiology, 1995. 73(1): p. 333-46. 
148. Kurachi, Y., T. Nakajima, and T. Sugimoto, Quinidine inhibition of the muscarine 
receptor-activated K+ channel current in atrial cells of guinea pig. Naunyn-
Schmiedeberg's archives of pharmacology, 1987. 335(2): p. 216-8. 
149. Nakajima, T., et al., Anti-cholinergic effects of quinidine, disopyramide, and 
procainamide in isolated atrial myocytes: mediation by different molecular 
mechanisms. Circulation research, 1989. 64(2): p. 297-303. 
150. Katayama, J., T. Yakushiji, and N. Akaike, Characterization of the K+ current 
mediated by 5-HT1A receptor in the acutely dissociated rat dorsal raphe neurons. 
Brain research, 1997. 745(1-2): p. 283-92. 
  175 
151. Krishna, S. and N.J. White, Pharmacokinetics of quinine, chloroquine and 
amodiaquine. Clinical implications. Clinical pharmacokinetics, 1996. 30(4): p. 
263-99. 
152. Patel, U. and B.B. Pavri, Short QT syndrome: a review. Cardiology in review, 
2009. 17(6): p. 300-3. 
153. Jin, W. and Z. Lu, A novel high-affinity inhibitor for inward-rectifier K+ 
channels. Biochemistry, 1998. 37(38): p. 13291-9. 
154. Jin, W., et al., Mechanisms of inward-rectifier K+ channel inhibition by tertiapin-
Q. Biochemistry, 1999. 38(43): p. 14294-301. 
155. Kanjhan, R., et al., Tertiapin-Q blocks recombinant and native large conductance 
K+ channels in a use-dependent manner. The Journal of pharmacology and 
experimental therapeutics, 2005. 314(3): p. 1353-61. 
156. Jin, W. and Z. Lu, Synthesis of a stable form of tertiapin: a high-affinity inhibitor 
for inward-rectifier K+ channels. Biochemistry, 1999. 38(43): p. 14286-93. 
157. Tabata, T., et al., GABAergic activation of an inwardly rectifying K+ current in 
mouse cerebellar Purkinje cells. The Journal of physiology, 2005. 563(Pt 2): p. 
443-57. 
158. Chen, X. and D. Johnston, Constitutively active G-protein-gated inwardly 
rectifying K+ channels in dendrites of hippocampal CA1 pyramidal neurons. The 
Journal of neuroscience : the official journal of the Society for Neuroscience, 
2005. 25(15): p. 3787-92. 
159. Matsuda, T., et al., Blockade by NIP-142, an antiarrhythmic agent, of carbachol-
induced atrial action potential shortening and GIRK1/4 channel. Journal of 
pharmacological sciences, 2006. 101(4): p. 303-10. 
160. Hashimoto, N., T. Yamashita, and N. Tsuruzoe, Characterization of in vivo and in 
vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, 
NIP-151: a comparison with an IKr-blocker dofetilide. Journal of cardiovascular 
pharmacology, 2008. 51(2): p. 162-9. 
161. Machida, T., et al., Effects of a highly selective acetylcholine-activated K+ 
channel blocker on experimental atrial fibrillation. Circulation. Arrhythmia and 
electrophysiology, 2011. 4(1): p. 94-102. 
162. Kobayashi, T., et al., Ethanol opens G-protein-activated inwardly rectifying K+ 
channels. Nature neuroscience, 1999. 2(12): p. 1091-7. 
163. Lewohl, J.M., et al., G-protein-coupled inwardly rectifying potassium channels 
are targets of alcohol action. Nature neuroscience, 1999. 2(12): p. 1084-90. 
164. Yow, T.T., et al., Naringin directly activates inwardly rectifying potassium 
channels at an overlapping binding site to tertiapin-Q. British journal of 
pharmacology, 2011. 163(5): p. 1017-33. 
165. Weigl, L.G. and W. Schreibmayer, G protein-gated inwardly rectifying potassium 
channels are targets for volatile anesthetics. Molecular pharmacology, 2001. 
60(2): p. 282-9. 
166. Bodhinathan, K. and P.A. Slesinger, Molecular mechanism underlying ethanol 
activation of G-protein-gated inwardly rectifying potassium channels. 
  176 
Proceedings of the National Academy of Sciences of the United States of 
America, 2013. 110(45): p. 18309-14. 
167. Aryal, P., et al., A discrete alcohol pocket involved in GIRK channel activation. 
Nature neuroscience, 2009. 12(8): p. 988-95. 
168. Ramos-Hunter, S.J., et al., Discovery and SAR of a novel series of GIRK1/2 and 
GIRK1/4 activators. Bioorganic & medicinal chemistry letters, 2013. 23(18): p. 
5195-8. 
169. Kaufmann, K., et al., ML297 (VU0456810), the first potent and selective activator 
of the GIRK potassium channel, displays antiepileptic properties in mice. ACS 
chemical neuroscience, 2013. 4(9): p. 1278-86. 
170. Lujan, R., et al., New insights into the therapeutic potential of Girk channels. 
Trends in neurosciences, 2014. 37(1): p. 20-9. 
171. Nishizawa, D., et al., Association between KCNJ6 (GIRK2) gene polymorphisms 
and postoperative analgesic requirements after major abdominal surgery. PloS 
one, 2009. 4(9): p. e7060. 
172. Lotsch, J., et al., A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid 
effects on analgesia and addiction but not on pupil size. Pharmacogenetics and 
genomics, 2010. 20(5): p. 291-7. 
173. Clarke, T.K., et al., KCNJ6 is associated with adult alcohol dependence and 
involved in gene x early life stress interactions in adolescent alcohol drinking. 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology, 2011. 36(6): p. 1142-8. 
174. Reeves, R.H., et al., A mouse model for Down syndrome exhibits learning and 
behaviour deficits. Nature genetics, 1995. 11(2): p. 177-84. 
175. Sago, H., et al., Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, 
exhibits learning and behavioral abnormalities. Proceedings of the National 
Academy of Sciences of the United States of America, 1998. 95(11): p. 6256-61. 
176. Cooper, A., et al., Trisomy of the G protein-coupled K+ channel gene, Kcnj6, 
affects reward mechanisms, cognitive functions, and synaptic plasticity in mice. 
Proceedings of the National Academy of Sciences of the United States of 
America, 2012. 109(7): p. 2642-7. 
177. Yamada, K., et al., Association study of the KCNJ3 gene as a susceptibility 
candidate for schizophrenia in the Chinese population. Human genetics, 2012. 
131(3): p. 443-51. 
178. Yang, Y., et al., Identification of a Kir3.4 mutation in congenital long QT 
syndrome. American journal of human genetics, 2010. 86(6): p. 872-80. 
179. Jabbari, J., et al., Common polymorphisms in KCNJ5 [corrected] are associated 
with early-onset lone atrial fibrillation in Caucasians. Cardiology, 2011. 118(2): 
p. 116-20. 
180. Wang, F., et al., The phenotype characteristics of type 13 long QT syndrome with 
mutation in KCNJ5 (Kir3.4-G387R). Heart rhythm : the official journal of the 
Heart Rhythm Society, 2013. 10(10): p. 1500-6. 
  177 
181. Scholl, U.I. and R.P. Lifton, New insights into aldosterone-producing adenomas 
and hereditary aldosteronism: mutations in the K+ channel KCNJ5. Current 
opinion in nephrology and hypertension, 2013. 22(2): p. 141-7. 
182. Mulatero, P., et al., Role of KCNJ5 in familial and sporadic primary 
aldosteronism. Nature reviews. Endocrinology, 2013. 9(2): p. 104-12. 
183. Burt, D.R. and G.L. Kamatchi, GABAA receptor subtypes: from pharmacology to 
molecular biology. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology, 1991. 5(14): p. 2916-23. 
184. Bormann, J., Electrophysiology of GABAA and GABAB receptor subtypes. Trends 
in neurosciences, 1988. 11(3): p. 112-6. 
185. Jones, K.A., et al., GABA(B) receptors function as a heteromeric assembly of the 
subunits GABA(B)R1 and GABA(B)R2. Nature, 1998. 396(6712): p. 674-9. 
186. Kaupmann, K., et al., GABA(B)-receptor subtypes assemble into functional 
heteromeric complexes. Nature, 1998. 396(6712): p. 683-7. 
187. Kuner, R., et al., Role of heteromer formation in GABAB receptor function. 
Science, 1999. 283(5398): p. 74-7. 
188. White, J.H., et al., Heterodimerization is required for the formation of a 
functional GABA(B) receptor. Nature, 1998. 396(6712): p. 679-82. 
189. Malitschek, B., et al., The N-terminal domain of gamma-aminobutyric Acid(B) 
receptors is sufficient to specify agonist and antagonist binding. Molecular 
pharmacology, 1999. 56(2): p. 448-54. 
190. Margeta-Mitrovic, M., Y.N. Jan, and L.Y. Jan, A trafficking checkpoint controls 
GABA(B) receptor heterodimerization. Neuron, 2000. 27(1): p. 97-106. 
191. Galvez, T., et al., Allosteric interactions between GB1 and GB2 subunits are 
required for optimal GABA(B) receptor function. The EMBO journal, 2001. 
20(9): p. 2152-9. 
192. Kammerer, R.A., et al., Heterodimerization of a functional GABAB receptor is 
mediated by parallel coiled-coil alpha-helices. Biochemistry, 1999. 38(40): p. 
13263-9. 
193. Calver, A.R., et al., The C-terminal domains of the GABA(b) receptor subunits 
mediate intracellular trafficking but are not required for receptor signaling. The 
Journal of neuroscience : the official journal of the Society for Neuroscience, 
2001. 21(4): p. 1203-10. 
194. Premkumar, L.S. and P.W. Gage, Potassium channels activated by GABAB 
agonists and serotonin in cultured hippocampal neurons. Journal of 
neurophysiology, 1994. 71(6): p. 2570-5. 
195. Kulik, A., et al., Compartment-dependent colocalization of Kir3.2-containing K+ 
channels and GABAB receptors in hippocampal pyramidal cells. The Journal of 
neuroscience : the official journal of the Society for Neuroscience, 2006. 26(16): 
p. 4289-97. 
196. Wallenstein, G.V., Simulation of GABAB-receptor-mediated K+ current in 
thalamocortical relay neurons: tonic firing, bursting, and oscillations. Biological 
cybernetics, 1994. 71(3): p. 271-80. 
  178 
197. Lacey, M.G., N.B. Mercuri, and R.A. North, On the potassium conductance 
increase activated by GABAB and dopamine D2 receptors in rat substantia nigra 
neurones. The Journal of physiology, 1988. 401: p. 437-53. 
198. Osmanovic, S.S. and S.A. Shefner, Baclofen increases the potassium conductance 
of rat locus coeruleus neurons recorded in brain slices. Brain research, 1988. 
438(1-2): p. 124-36. 
199. Fowler, C.E., et al., Evidence for association of GABA(B) receptors with Kir3 
channels and regulators of G protein signalling (RGS4) proteins. The Journal of 
physiology, 2007. 580(Pt 1): p. 51-65. 
200. Ciruela, F., et al., Evidence for oligomerization between GABAB receptors and 
GIRK channels containing the GIRK1 and GIRK3 subunits. The European journal 
of neuroscience, 2010. 32(8): p. 1265-77. 
201. Fajardo-Serrano, A., et al., Association of Rgs7/Gbeta5 complexes with Girk 
channels and GABAB receptors in hippocampal CA1 pyramidal neurons. 
Hippocampus, 2013. 23(12): p. 1231-45. 
202. Bonner, T.I., The molecular basis of muscarinic receptor diversity. Trends in 
neurosciences, 1989. 12(4): p. 148-51. 
203. Ikegaya, T., et al., Interaction of atrial muscarinic receptors with three kinds of 
GTP-binding proteins. Journal of molecular and cellular cardiology, 1990. 22(3): 
p. 343-51. 
204. Li, D., H. Sun, and P. Levesque, Antiarrhythmic drug therapy for atrial 
fibrillation: focus on atrial selectivity and safety. Cardiovascular & hematological 
agents in medicinal chemistry, 2009. 7(1): p. 64-75. 
205. Wickman, K., et al., Abnormal heart rate regulation in GIRK4 knockout mice. 
Neuron, 1998. 20(1): p. 103-14. 
206. Sakmann, B., A. Noma, and W. Trautwein, Acetylcholine activation of single 
muscarinic K+ channels in isolated pacemaker cells of the mammalian heart. 
Nature, 1983. 303(5914): p. 250-3. 
207. Neubig, R.R., And the winner is ... RGS4! Circulation research, 2008. 103(5): p. 
444-6. 
208. Signorini, S., et al., Normal cerebellar development but susceptibility to seizures 
in mice lacking G protein-coupled, inwardly rectifying K+ channel GIRK2. 
Proceedings of the National Academy of Sciences of the United States of 
America, 1997. 94(3): p. 923-7. 
209. Duprat, F., et al., Heterologous multimeric assembly is essential for K+ channel 
activity of neuronal and cardiac G-protein-activated inward rectifiers. 
Biochemical and biophysical research communications, 1995. 212(2): p. 657-63. 
210. Bettahi, I., et al., Contribution of the Kir3.1 subunit to the muscarinic-gated atrial 
potassium channel IKACh. The Journal of biological chemistry, 2002. 277(50): p. 
48282-8. 
211. Arora, D., et al., Acute cocaine exposure weakens GABA(B) receptor-dependent 
G-protein-gated inwardly rectifying K+ signaling in dopamine neurons of the 
ventral tegmental area. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 2011. 31(34): p. 12251-7. 
  179 
212. Mirkovic, K. and K. Wickman, Identification and characterization of alternative 
splice variants of the mouse Trek2/Kcnk10 gene. Neuroscience, 2011. 194: p. 11-
8. 
213. Wiser, O., et al., Modulation of basal and receptor-induced GIRK potassium 
channel activity and neuronal excitability by the mammalian PINS homolog LGN. 
Neuron, 2006. 50(4): p. 561-73. 
214. Huang, C.L., Y.N. Jan, and L.Y. Jan, Binding of the G protein betagamma subunit 
to multiple regions of G protein-gated inward-rectifying K+ channels. FEBS 
letters, 1997. 405(3): p. 291-8. 
215. Rogalski, S.L., et al., TrkB activation by brain-derived neurotrophic factor 
inhibits the G protein-gated inward rectifier Kir3 by tyrosine phosphorylation of 
the channel. The Journal of biological chemistry, 2000. 275(33): p. 25082-8. 
216. Rubinstein, M., et al., Galphai3 primes the G protein-activated K+ channels for 
activation by coexpressed Gbetagamma in intact Xenopus oocytes. The Journal of 
physiology, 2007. 581(Pt 1): p. 17-32. 
217. Hibino, H., et al., Inwardly rectifying potassium channels: their structure, 
function, and physiological roles. Physiological reviews, 2010. 90(1): p. 291-366. 
218. Yamakura, T., J.M. Lewohl, and R.A. Harris, Differential effects of general 
anesthetics on G protein-coupled inwardly rectifying and other potassium 
channels. Anesthesiology, 2001. 95(1): p. 144-53. 
219. Kobayashi, T. and K. Ikeda, G protein-activated inwardly rectifying potassium 
channels as potential therapeutic targets. Current pharmaceutical design, 2006. 
12(34): p. 4513-23. 
220. Wydeven, N., et al., Structural elements in the Girk1 subunit that potentiate G 
protein-gated potassium channel activity. Proceedings of the National Academy 
of Sciences of the United States of America, 2012. 109(52): p. 21492-7. 
221. Okamura, Y., Y. Murata, and H. Iwasaki, Voltage-sensing phosphatase: actions 
and potentials. The Journal of physiology, 2009. 587(Pt 3): p. 513-20. 
222. Van der Heyden, J.A., T.J. Zethof, and B. Olivier, Stress-induced hyperthermia in 
singly housed mice. Physiology & behavior, 1997. 62(3): p. 463-70. 
223. Blednov, Y.A., et al., GIRK2 deficient mice. Evidence for hyperactivity and 
reduced anxiety. Physiology & behavior, 2001. 74(1-2): p. 109-17. 
224. Pravetoni, M. and K. Wickman, Behavioral characterization of mice lacking 
GIRK/Kir3 channel subunits. Genes, brain, and behavior, 2008. 7(5): p. 523-31. 
225. Kofuji, P., et al., A unique P-region residue is required for slow voltage-
dependent gating of a G protein-activated inward rectifier K+ channel expressed 
in Xenopus oocytes. The Journal of physiology, 1996. 490 ( Pt 3): p. 633-45. 
226. Wen, W., et al., Discovery of 'molecular switches' within a GIRK activator 
scaffold that afford selective GIRK inhibitors. Bioorganic & medicinal chemistry 
letters, 2013. 23(16): p. 4562-6. 
227. Arora, D., et al., Altered neurotransmission in the mesolimbic reward system of 
Girk mice. Journal of neurochemistry, 2010. 114(5): p. 1487-97. 
228. Hearing, M., et al., Repeated cocaine weakens GABA(B)-Girk signaling in layer 
5/6 pyramidal neurons in the prelimbic cortex. Neuron, 2013. 80(1): p. 159-70. 
  180 
229. Hill, K.G., et al., Reduced ethanol-induced conditioned taste aversion and 
conditioned place preference in GIRK2 null mutant mice. Psychopharmacology, 
2003. 169(1): p. 108-14. 
230. Mirshahi, T., T. Jin, and D.E. Logothetis, G beta gamma and KACh: old story, 
new insights. Science's STKE : signal transduction knowledge environment, 2003. 
2003(194): p. PE32. 
231. Hollinger, S. and J.R. Hepler, Cellular regulation of RGS proteins: modulators 
and integrators of G protein signaling. Pharmacological reviews, 2002. 54(3): p. 
527-59. 
232. Fu, Y., et al., Endogenous RGS proteins modulate SA and AV nodal functions in 
isolated heart: implications for sick sinus syndrome and AV block. American 
journal of physiology. Heart and circulatory physiology, 2007. 292(5): p. H2532-
9. 
233. Fu, Y., et al., Endogenous RGS proteins and Galpha subtypes differentially 
control muscarinic and adenosine-mediated chronotropic effects. Circulation 
research, 2006. 98(5): p. 659-66. 
234. Martemyanov, K.A. and V.Y. Arshavsky, Noncatalytic domains of RGS9-1.Gbeta 
5L play a decisive role in establishing its substrate specificity. The Journal of 
biological chemistry, 2002. 277(36): p. 32843-8. 
235. Martemyanov, K.A., et al., R7BP, a novel neuronal protein interacting with RGS 
proteins of the R7 family. The Journal of biological chemistry, 2005. 280(7): p. 
5133-6. 
236. Martemyanov, K.A., J.A. Hopp, and V.Y. Arshavsky, Specificity of G protein-
RGS protein recognition is regulated by affinity adapters. Neuron, 2003. 38(6): p. 
857-62. 
237. Kennedy, M.E., J. Nemec, and D.E. Clapham, Localization and interaction of 
epitope-tagged GIRK1 and CIR inward rectifier K+ channel subunits. 
Neuropharmacology, 1996. 35(7): p. 831-9. 
238. Chen, C.K., et al., Instability of GGL domain-containing RGS proteins in mice 
lacking the G protein beta-subunit Gbeta5. Proceedings of the National Academy 
of Sciences of the United States of America, 2003. 100(11): p. 6604-9. 
239. Koyrakh, L., et al., The heart rate decrease caused by acute FTY720 
administration is mediated by the G protein-gated potassium channel I. American 
journal of transplantation : official journal of the American Society of 
Transplantation and the American Society of Transplant Surgeons, 2005. 5(3): p. 
529-36. 
240. McGrath, M.F. and A.J. de Bold, Transcriptional analysis of the mammalian 
heart with special reference to its endocrine function. BMC genomics, 2009. 10: 
p. 254. 
241. Doupnik, C.A., T. Xu, and J.M. Shinaman, Profile of RGS expression in single rat 
atrial myocytes. Biochimica et biophysica acta, 2001. 1522(2): p. 97-107. 
242. Hooks, S.B., et al., RGS6, RGS7, RGS9, and RGS11 stimulate GTPase activity of 
Gi family G-proteins with differential selectivity and maximal activity. The 
Journal of biological chemistry, 2003. 278(12): p. 10087-93. 
  181 
243. Mangoni, M.E. and J. Nargeot, Genesis and regulation of the heart automaticity. 
Physiological reviews, 2008. 88(3): p. 919-82. 
244. DiFrancesco, D., The role of the funny current in pacemaker activity. Circulation 
research, 2010. 106(3): p. 434-46. 
245. Dobrzynski, H., M.R. Boyett, and R.H. Anderson, New insights into pacemaker 
activity: promoting understanding of sick sinus syndrome. Circulation, 2007. 
115(14): p. 1921-32. 
246. Vaseghi, M. and K. Shivkumar, The role of the autonomic nervous system in 
sudden cardiac death. Progress in cardiovascular diseases, 2008. 50(6): p. 404-19. 
247. Kovoor, P., et al., Evaluation of the role of I(KACh) in atrial fibrillation using a 
mouse knockout model. Journal of the American College of Cardiology, 2001. 
37(8): p. 2136-43. 
248. Mesirca, P., et al., The G-protein-gated K+ channel, IKACh, is required for 
regulation of pacemaker activity and recovery of resting heart rate after 
sympathetic stimulation. The Journal of general physiology, 2013. 142(2): p. 113-
26. 
249. Mighiu, A.S. and S.P. Heximer, Controlling Parasympathetic Regulation of Heart 
Rate: A Gatekeeper Role for RGS Proteins in the Sinoatrial Node. Frontiers in 
physiology, 2012. 3: p. 204. 
250. Stewart, A., J. Huang, and R.A. Fisher, RGS Proteins in Heart: Brakes on the 
Vagus. Frontiers in physiology, 2012. 3: p. 95. 
251. Yang, J., et al., RGS6, a modulator of parasympathetic activation in heart. 
Circulation research, 2010. 107(11): p. 1345-9. 
252. Posokhova, E., et al., RGS6/Gbeta5 complex accelerates IKACh gating kinetics in 
atrial myocytes and modulates parasympathetic regulation of heart rate. 
Circulation research, 2010. 107(11): p. 1350-4. 
253. Posokhova, E., et al., Essential role of the m2R-RGS6-IKACh pathway in 
controlling intrinsic heart rate variability. PloS one, 2013. 8(10): p. e76973. 
254. Vasan, R.S., et al., Genome-wide association of echocardiographic dimensions, 
brachial artery endothelial function and treadmill exercise responses in the 
Framingham Heart Study. BMC medical genetics, 2007. 8 Suppl 1: p. S2. 
255. Davydov, I.V. and A. Varshavsky, RGS4 is arginylated and degraded by the N-
end rule pathway in vitro. The Journal of biological chemistry, 2000. 275(30): p. 
22931-41. 
256. Lee, M.J., et al., RGS4 and RGS5 are in vivo substrates of the N-end rule 
pathway. Proceedings of the National Academy of Sciences of the United States 
of America, 2005. 102(42): p. 15030-5. 
257. Blazer, L.L., et al., Reversible, allosteric small-molecule inhibitors of regulator of 
G protein signaling proteins. Molecular pharmacology, 2010. 78(3): p. 524-33. 
258. Vashisth, H., et al., Conformational dynamics of a regulator of G-protein 
signaling protein reveals a mechanism of allosteric inhibition by a small 
molecule. ACS chemical biology, 2013. 8(12): p. 2778-84. 
  182 
259. Huang, C., et al., Attenuation of Gi- and Gq-mediated signaling by expression of 
RGS4 or GAIP in mammalian cells. Proceedings of the National Academy of 
Sciences of the United States of America, 1997. 94(12): p. 6159-63. 
260. Yan, Y., P.P. Chi, and H.R. Bourne, RGS4 inhibits Gq-mediated activation of 
mitogen-activated protein kinase and phosphoinositide synthesis. The Journal of 
biological chemistry, 1997. 272(18): p. 11924-7. 
261. Hepler, J.R., et al., RGS4 and GAIP are GTPase-activating proteins for Gq alpha 
and block activation of phospholipase C beta by gamma-thio-GTP-Gq alpha. 
Proceedings of the National Academy of Sciences of the United States of 
America, 1997. 94(2): p. 428-32. 
262. Mittmann, C., et al., Expression of ten RGS proteins in human myocardium: 
functional characterization of an upregulation of RGS4 in heart failure. 
Cardiovascular research, 2002. 55(4): p. 778-86. 
263. Lan, K.L., et al., A point mutation in Galphao and Galphai1 blocks interaction 
with regulator of G protein signaling proteins. The Journal of biological 
chemistry, 1998. 273(21): p. 12794-7. 
264. Heximer, S.P., et al., RGS2/G0S8 is a selective inhibitor of Gqalpha function. 
Proceedings of the National Academy of Sciences of the United States of 
America, 1997. 94(26): p. 14389-93. 
265. Zhang, Q., M.A. Pacheco, and C.A. Doupnik, Gating properties of GIRK 
channels activated by Galpha(o)- and Galpha(i)-coupled muscarinic m2 
receptors in Xenopus oocytes: the role of receptor precoupling in RGS 
modulation. The Journal of physiology, 2002. 545(Pt 2): p. 355-73. 
266. Jaen, C. and C.A. Doupnik, RGS3 and RGS4 differentially associate with G 
protein-coupled receptor-Kir3 channel signaling complexes revealing two modes 
of RGS modulation. Precoupling and collision coupling. The Journal of biological 
chemistry, 2006. 281(45): p. 34549-60. 
267. Kardestuncer, T., et al., Cardiac myocytes express mRNA for ten RGS proteins: 
changes in RGS mRNA expression in ventricular myocytes and cultured atria. 
FEBS letters, 1998. 438(3): p. 285-8. 
268. Huang, C.L., et al., Evidence that direct binding of G beta gamma to the GIRK1 G 
protein-gated inwardly rectifying K+ channel is important for channel activation. 
Neuron, 1995. 15(5): p. 1133-43. 
269. Sarac, R., et al., Mutation of critical GIRK subunit residues disrupts N- and C-
termini association and channel function. The Journal of neuroscience : the 
official journal of the Society for Neuroscience, 2005. 25(7): p. 1836-46. 
270. Luchian, T. and W. Schreibmayer, Ion permeation through a G-protein activated 
(GIRK1/GIRK5) inwardly rectifying potassium channel. Biochimica et biophysica 
acta, 1998. 1368(2): p. 167-70. 
271. Velimirovic, B.M., et al., Opposing mechanisms of regulation of a G-protein-
coupled inward rectifier K+ channel in rat brain neurons. Proceedings of the 
National Academy of Sciences of the United States of America, 1995. 92(5): p. 
1590-4. 
  183 
272. Bajic, D., et al., Two different inward rectifier K+ channels are effectors for 
transmitter-induced slow excitation in brain neurons. Proceedings of the National 
Academy of Sciences of the United States of America, 2002. 99(22): p. 14494-9. 
273. Koike-Tani, M., et al., Signal transduction pathway for the substance P-induced 
inhibition of rat Kir3 (GIRK) channel. The Journal of physiology, 2005. 564(Pt 
2): p. 489-500. 
274. Stansfeld, P.J., et al., PIP(2)-binding site in Kir channels: definition by multiscale 
biomolecular simulations. Biochemistry, 2009. 48(46): p. 10926-33. 
275. Rubinstein, M., et al., Divergent regulation of GIRK1 and GIRK2 subunits of the 
neuronal G protein gated K+ channel by GalphaiGDP and Gbetagamma. The 
Journal of physiology, 2009. 587(Pt 14): p. 3473-91. 
276. Vivaudou, M., et al., Probing the G-protein regulation of GIRK1 and GIRK4, the 
two subunits of the KACh channel, using functional homomeric mutants. The 
Journal of biological chemistry, 1997. 272(50): p. 31553-60. 
277. Doyle, D.A., et al., The structure of the potassium channel: molecular basis of K+ 
conduction and selectivity. Science, 1998. 280(5360): p. 69-77. 
278. Jiang, Y., et al., The open pore conformation of potassium channels. Nature, 
2002. 417(6888): p. 523-6. 
279. Abrams, C.J., et al., The role of a single aspartate residue in ionic selectivity and 
block of a murine inward rectifier K+ channel Kir2.1. The Journal of physiology, 
1996. 493 ( Pt 3): p. 643-9. 
280. Lu, Z. and R. MacKinnon, Electrostatic tuning of Mg2+ affinity in an inward-
rectifier K+ channel. Nature, 1994. 371(6494): p. 243-6. 
281. Ficker, E., et al., Spermine and spermidine as gating molecules for inward 
rectifier K+ channels. Science, 1994. 266(5187): p. 1068-72. 
282. Stanfield, P.R., et al., A single aspartate residue is involved in both intrinsic 
gating and blockage by Mg2+ of the inward rectifier, IRK1. The Journal of 
physiology, 1994. 478 ( Pt 1): p. 1-6. 
283. Yang, J., Y.N. Jan, and L.Y. Jan, Control of rectification and permeation by 
residues in two distinct domains in an inward rectifier K+ channel. Neuron, 1995. 
14(5): p. 1047-54. 
284. Silverman, S.K., H.A. Lester, and D.A. Dougherty, Asymmetrical contributions of 
subunit pore regions to ion selectivity in an inward rectifier K+ channel. 
Biophysical journal, 1998. 75(3): p. 1330-9. 
285. Silverman, S.K., H.A. Lester, and D.A. Dougherty, Subunit stoichiometry of a 
heteromultimeric G protein-coupled inward-rectifier K+ channel. The Journal of 
biological chemistry, 1996. 271(48): p. 30524-8. 
286. Riven, I., et al., Conformational rearrangements associated with the gating of the 
G protein-coupled potassium channel revealed by FRET microscopy. Neuron, 
2003. 38(2): p. 225-35. 
287. Inanobe, A., et al., Interaction between the RGS domain of RGS4 with G protein 
alpha subunits mediates the voltage-dependent relaxation of the G protein-gated 
potassium channel. The Journal of physiology, 2001. 535(Pt 1): p. 133-43. 
  184 
288. Lomax, A.E., R.A. Rose, and W.R. Giles, Electrophysiological evidence for a 
gradient of G protein-gated K+ current in adult mouse atria. British journal of 
pharmacology, 2003. 140(3): p. 576-84. 
289. Ivanina, T., et al., Mapping the Gbetagamma-binding sites in GIRK1 and GIRK2 
subunits of the G protein-activated K+ channel. The Journal of biological 
chemistry, 2003. 278(31): p. 29174-83. 
290. Ivanina, T., et al., Galphai1 and Galphai3 differentially interact with, and 
regulate, the G protein-activated K+ channel. The Journal of biological 
chemistry, 2004. 279(17): p. 17260-8. 
291. Wickman, K., W.T. Pu, and D.E. Clapham, Structural characterization of the 
mouse Girk genes. Gene, 2002. 284(1-2): p. 241-50. 
 
 
 
 
